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LIST OF SYMBOLS AND ABBREVIATIONS
The use of symbols and abbreviations in this thesis follows the recommendations of
the European Respiratory Society (1). The following out-line defines the key
symbols and abbreviations used throughout the thesis.
Lung Volumes and Forced Expiration
FVC Forced vital capacity, the volume of gas which is exhaled during forced 
expiration starting from a position of full inspiration and ending at complete 
expiration.
FEVj Forced expiratory volume in one second', the volume of gas exhaled in the 
first second of the FVC manoeuvre.
FRC Functional residual capacity : the volume of gas present in the lung and 
airways at the average end-expiratory level.
RV Residual volume: the volume of gas remaining in the lung at the end of a 
full expiration.
TLC Total lung capacity : the volume of gas in the lung at the end of full 
inspiration.
Diffusion
TLco Pulmonary transfer factor fo r carbon monoxide (CO) - also called
pulmonary diffusing capacity: the rate of carbon monoxide uptake from 
alveolar gas to pulmonary capillary blood; expressed in mmol.min VkPa'1
Kco Transfer coefficient - also referred to as Tl/Va: TLCo per unit alveolar 
volume (Va); expressed in mmol.min 1.kPa‘1L‘1.
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Dm Diffusing capacity o f the alveolar-capillary membrane; expressed
in mmol.minVkPa"1.
Vc Pulmonary capillary blood volume available for gas exchange
(also expressed as Qc).
0 Reaction rate o f CO with oxyhaemoglobin.
1/TLco Reciprocal o f TLco; the total resistance to CO transfer from the
alveolar spaces to pulmonary capillary blood.
1/Dm Resistance o f the alveolar-capillary membrane.
1/0 Vc Resistance of the total mass of erythrocytes in the pulmonary capillary 
blood “intra-capillary resistance
Exercise and Gas Exchange
V ’0 2  Oxygen (O2) consumption, expressed in ml.min \
V*C0 2  Carbon dioxide (CO2) production’, expressed in ml.min’1.
V ’e  Expiratory minute ventilation (L.min \).
VyV 'coi Ventilatory equivalent for CO2 - also called the ventilatory response.
P(A-^Pi Alveolar-arterial O2 gradient in kPa.
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SUMMARY
A number of studies have shown a consistent reduction in pulmonary transfer factor 
(TLco) after heart transplantation despite improvement in lung volumes and cardio­
pulmonary haemodynamics. The mechanism and causes of this decline have not 
been determined and the clinical significance of TLco reduction in heart transplant 
recipients is unknown. The aims of the studies comprising this thesis were to 
describe prospectively the longitudinal changes in TLco after heart transplantation, 
determine the mechanisms and causes of its decline and to evaluate the effect of 
TLco reduction on gas exchange and exercise performance.
During 2.5 years of follow-up, pulmonary function tests including the single breath 
TLco were performed in 81 patients before and at specific intervals after heart 
transplantation. Fifty seven of these had results before and at least once after 
transplantation, 61 had 4 serial post-transplant assessments and 37 had both pre- 
transplant and 4 post-transplant assessments. Results were compared with data 
from 28 normal subjects. Before transplantation there was a mild restrictive 
ventilatory defect with reduction in both TLco (72.1% of predicted) and TLco per 
unit alveolar volume; Kco (90.1% of predicted). At 6 weeks after transplantation, 
there was a further reduction in all lung function parameters with greater reductions 
in TLco and Kco (declined by 18% and 26% of predicted, respectively). However, 
lung volumes and flow rates increased in the subsequent measurements, to exceed 
their pre-transplant values at about one year after transplantation. In contrast, TLco
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and Kco did not change after the initial decline up to three years after 
transplantation.
TLco and its components (the diffusing capacity of the alveolar-capillary 
membrane, Dm and the pulmonary capillary blood volume, Vc) were measured in 
75 heart transplant recipients using the Roughton and Forster method. The 
procedure of estimating TLco components was used after performing several 
validation studies which showed that the applied technique yielded reproducible 
estimation of TLco components with values comparable to previous reports. 
Results were compared with data from 38 heart transplant candidates and 26 
normal subjects. The % predicted TLco and Vc were significantly lower in 
recipients (56.9% and 52.8%) compared to candidates (69.9% and 80.2%) which 
were themselves significantly lower than normal (97.7% and 102.3%). Dm was 
similarly reduced in recipients (77.7%) and candidates (81.4%) compared to normal 
controls (100.1%). Correction for haemoglobin increased TLco in recipients to 
63.5% of predicted, but this was still significantly lower than that of candidates 
(71.1%). In recipients, the intra-capillary resistance (1/0Vc) formed 60% of 1/TLco 
compared to 50% in candidates and normal subjects. In 9 patients assessed before 
and at 6 weeks after heart transplantation, the changes in TLco, Dm and Vc were 
similar to those of 7 patients with mitral stenosis assessed before and at 6 weeks 
after mitral valve replacement.
The potential responsible factors for TLco decline were analysed in 57 heart 
transplant recipients. The change in TLco adjusted for haemoglobin was inversely 
correlated with the pre-transplant TLco (r = -0.55) and mean pulmonary capillary
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wedge pressure (r = -0.27). There was no relationship between the change in TLco 
and any of the other variables which included pre-transplant static and dynamic lung 
volumes, pre-transplant cardiac status as assessed by the duration and severity of 
symptoms and by left ventricular ejection fraction, cardio-pulmonary bypass time, 
post-transplant pulmonary complications, cytomegalovirus infection, cardiac 
allograft rejection and cyclosporin blood levels. The potential role of cardio­
pulmonary bypass was further evaluated by comparing the results in heart 
transplant patients with those of 15 patients who had lung function tests before and 
at 6 weeks after coronary artery bypass graft (CABG). There was a significant 
reduction in lung volumes, flow rates, TLco and Kco after CABG. However, the 
decline in TLco and Kco was less marked in CABG patients than in recipients and it 
was entirely explained by post-operative anaemia (corrected TLCo was 84.3% 
before surgery and 87.9% afterwards).
The relationship between haemoglobin-corrected TLco and exercise performance 
after heart transplantation was determined in 53 recipients. Results were compared 
with data from 53 heart transplant candidates and 28 normal subjects. Maximal 
symptom-limited oxygen uptake (V02) was higher in recipients than in candidates 
(39.8% and 46.0% of predicted respectively, p<0.05), but it was substantially lower 
than that of normal controls (92.9% of predicted, p<0.001). The ventilatory and 
gas exchange responses (Fe/FCo2, Vd/Vt , and 7)^A-a>02) at maximum exercise were 
significantly improved in recipients compared to candidates, but were still 
abnormal. In recipients, TLco was correlated positively with V02 (r = 0.60) and 
inversely with ventilatory and gas exchange responses; V^/Vcm (r = -0.43), Vd/Vt
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(r = -0.29) and P(A-a),02 (r = -0.38), but there was no relationship between TLCo 
and any of these variables in the other 2 groups.
In conclusion, the studies comprising this thesis have demonstrated that TLco 
decline is very common after heart transplantation and is present by 6 weeks with 
no further changes up to three years after transplantation. This decline was shown 
to be due to an increase in the intra-capillary resistance caused by a combination of 
anaemia and reduced Vc. After correcting for haemoglobin concentration, pre­
transplant TLco and mean pulmonary capillary wedge pressure were identified as 
the only factors which predicted TLco decline after heart transplantation. Since 
increases in these two factors reflect elevated pulmonary venous pressure and 
because of the similarity in both TLco and pulmonary haemodynamic changes 
before and after heart transplantation and mitral valve replacement a causal link 
between TLco changes and pulmonary haemodynamics is suggest. The reduction in 
pulmonary vascular pressures may be responsible for Vc reduction and therefore 
TLco decline after heart transplantation. The decline in Vc with persistence of 
reduced Dm after heart transplantation are likely to be markers of persisting 
pulmonary vascular dysfunction caused by pre-transplant chronic pulmonary 
congestion rather than being due to a new damage to the lungs from heart 
transplantation and its associated complications. The relationship between TLco 
and gas exchange abnormalities on exercise is further evidence of pulmonary 
vascular dysfunction which appears to contribute to exercise limitation in heart 
transplant recipients.
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CHAPTER 1 
INTRODUCTION AND AIMS
1.1 Introduction
Gas exchange, the primary function of the lung is carried out by the physical 
process of diffusion between the alveolar spaces and the pulmonary capillary blood 
across the alveolar-capillary membrane. The pulmonary transfer factor for carbon 
monoxide (TLco) is a non-invasive physiological measurement which is used to 
assess the integrity of the alveolar-capillary membrane and the pulmonary capillary 
bed. It is quantitatively defined as the rate of carbon monoxide (CO) uptake into 
the pulmonary capillary blood per unit of driving pressure across the alveolar- 
capillary membrane (2).
TLco is determined by the thickness, physical properties and the surface area of the 
tissue across which the diffusion takes place (3). The effective surface area depends 
on the number and size of functioning alveoli and pulmonary capillaries in contact 
with each other. TLco is also dependent on the rate of reaction of CO with 
haemoglobin in the capillary blood (4). The usual methods used to determine TLco 
do not differentiate between these factors. Since TLco is a measure of conductance 
(flow/pressure), its reciprocal (l/TLCo) represents the resistance to CO transfer 
between the alveolar spaces and haemoglobin in the red blood cells of the 
pulmonary capillary blood. 1/TLco can be partitioned into two major components 
which can be estimated using the Roughton and Forster relationship^). These are: 
the alveolar-capillary membrane resistance (1/D m) and the “intra-capillary”
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resistance (l/0V c), where DM is the diffusing capacity of the alveolar-capillary 
membrane, Vc is the pulmonary capillary blood volume and 0 is the reaction rate 
between CO and haemoglobin. Theta (0) depends on the prevailing alveolar oxygen 
tension and the concentration of haemoglobin in the pulmonary capillary blood. The 
two components of TLco can be estimated by measuring TLco at two different 
inspired oxygen concentrations (5). The relationship between TLCo and its 
components is described by the equation of Roughton and Forster (5);
1/ TLco = 1/Dm + 1/0 Vc
From the relationship between TLco and its components in Roughton and Forster 
model, it is clear that TLco may be normal in diseases which cause abnormal 
changes in both of its components in opposite directions. For example, in heart 
disease with mild to moderate left heart failure, pulmonary venous hypertension 
tends to increase Vc whereas interstitial and alveolar oedema tends to decrease Dm. 
As a result, the overall TLCo, may be normal or only slightly decreased despite 
significant abnormalities in both of its components (2).
The heart and lungs are connected in series by the pulmonary circulation. The 
normal matching of pulmonary blood flow and ventilation in the lungs is essential 
for efficient gas exchange. Because of the interdependence between the heart and 
lung, a dysfunction in one frequently affects the function of the other (6).
Congestive heart failure, the primary indication for heart transplantation, is 
characterised by a restrictive ventilatory defect with small lung volumes and 
reduced lung compliance (7). TLCo is usually normal or only slightly reduced in
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mild to moderate chronic congestive heart failure (8,9), but TLco impairment is 
common in heart transplant candidates with severe chronic heart failure (10,11). 
Lung function abnormalities in patients with heart failure are commonly attributed 
to the well-recognised derangement of the pulmonary circulation and the associated 
lung water imbalance that cause pulmonary congestion and oedema (12). Heart 
transplantation restores pulmonary haemodynamics, lung volumes and airway 
function toward normal (13,14). In contrast, TLco and TLco per unit alveolar 
volume (Kco) have been consistently shown either to deteriorate or remain sub­
normal following heart transplantation (15-21).
The cause of TLco decline following heart transplantation is unknown. Cyclosporin 
pulmonary toxicity (15,16) and cytomegalovirus infection (21) have been proposed 
as possible causes. Other potential causes in the setting of heart transplantation 
include; pre-operative pulmonary dysfunction, sternotomy and cardio-pulmonary 
bypass procedure, pulmonary haemodynamic changes following transplantation, 
post-operative pulmonary complications and cardiac allograft rejection and 
dysfunction.
The mechanism of decline in TLco following heart transplantation is obscure. It has 
been postulated that it may result from a reduction in the Dm component, caused by 
damage to the alveolar-capillary membrane (16). However, the effects of heart 
transplantation on the components of TLco have not been studied.
The reported studies on the TLco changes following heart transplantation are 
limited in being retrospective and based on cross-sectional analysis of patients
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assessed at different intervals after transplantation (15,17-21). They all lack control 
groups for the possible effects of sternotomy, cardio-pulmonary bypass procedure 
and pulmonary venous congestion on lung function. In the only longitudinal study 
(16), the number of patients was small (21 patients), and the post-operative 
assessments were performed yearly for three years. There are, therefore, no 
longitudinal data available on lung function changes within the first year after heart 
transplantation. In addition, the clinical significance of TLco impairment in these 
patients has not been determined.
TLco studies in patients with congenital and valvular heart disease, before and after 
surgery, provide important pointers to the potential causes and possible 
mechanisms of TLco decline following heart transplantation. A detailed account of 
these studies is presented in chapter 3 of this thesis. Patients with congenital heart 
disease and increased pulmonary blood flow associated with mild to moderate 
pulmonary arterial hypertension have a significant increase in TLco due to a 
proportional increase in both of its components (D m and Vc) (22). Surgical 
correction of the malformations in these patients is associated with a reduction in 
TLco, Dm and Vc toward normal (23,24).
Mitral valve surgery is an excellent model for the analysis of the changes in TLco 
after heart transplantation for the following reasons:
1. The effects of mitral valve disease on the lung have been extensively studied both 
before and after surgery and there is a relatively well-defined natural history of 
pulmonary dysfunction in this disorder (25-27).
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2. The changes of TLco and other indices of lung function in chronic heart failure 
(the primary indication for heart transplantation) and in mitral valve disease are very 
similar (28).
3. Pulmonary haemodynamic disturbance is also similar in both mitral valve disease 
and congestive heart failure. Both conditions are associated with low cardiac 
output and raised pulmonary venous pressure and both can lead to secondary 
pulmonary arterial hypertension and high pulmonary vascular resistance as well as 
pulmonary fibrosis (27).
4. Both mitral valve surgery and heart transplantation have been shown to restore 
all pulmonary haemodynamics towards normal early after surgery (13,29).
TLco in mitral valve disease is variable and appears to parallel the functional 
capacity and pulmonary haemodynamics (30). Except in severe cases, it is usually 
normal or only slightly reduced and in a few cases it may be higher than predicted 
(31). Vc is often normal or elevated, but Dm is usually low (32). In advanced cases 
with severe pulmonary hypertension TLco is reduced and this is usually associated 
with a proportional decrease in Dm and Vc (32,33). TLco changes after mitral valve 
surgery are also variable and appear to be related to the preoperative severity of the 
disease and the interval between surgery and lung function assessment and there are 
three patterns:
1. No significant change; this is the most common pattern and has been explained 
by the counterbalanced effects of relieving pulmonary congestion (increased DM), 
and the reduction in pulmonary vascular pressures (reduced Vc) (26,34-36)
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2. Decline; this was reported in studies performed early after surgery, and this 
might be due to the adverse effects of thoracotomy and cardio-pulmonary bypass 
(37,38).
3. Improvement; this is uncommon and mainly found in cases with the lowest TLco 
before surgery (39,40). It might be due to a greater improvement in Dm due to 
relief of pulmonary congestion.
The changes in TLCo following surgery for congenital heart disease and mitral valve 
disease serve to highlight two important points that should be considered in the 
investigation of TLCo changes following heart transplantation:
1. The measurement of TLco components may clarify the mechanisms underlying 
the reported decline in TLco following heart transplantation. The relationship 
between TLco and pulmonary haemodynamics in patients with congenital and 
valvular heart disease suggests an important role for pulmonary haemodynamic 
changes in the decline in TLco following heart transplantation. In heart transplant 
candidates with advanced heart failure, the long-standing pulmonary congestion and 
the associated chronic pulmonary vascular and parenchymal changes would be 
expected to lead to a reduction in both Dm and Vc accounting for the common 
occurrence of TLco impairment (10). The normalisation of pulmonary 
haemodynamics along with the relief of pulmonary oedema following heart 
transplantation, would be expected to decrease Vc and increase Dm, respectively. A 
disproportionate decrease in Vc secondary to the normalisation of pulmonary 
pressures may be an important contributory factor in the observed decline in TLco
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following heart transplantation. In addition, a significant decrease in haemoglobin 
levels after transplantation could lead to reduction in the measured TLco by 
reducing 0 (41).
2. Lung function before transplantation and the time of assessment after 
transplantation may be important. Most of the potential causes of TLco decline in 
the setting of heart transplantation occur within the first few weeks after 
transplantation (42). It is therefore important to define the time course of TLco 
changes following heart transplantation by longitudinal measurements of TLCo and 
other lung function tests before and serially after transplantation at specific 
intervals, including the early post-transplant period.
TLco is a sensitive index of alveolar-capillary membrane integrity (43), and its 
impairment in asymptomatic patients may be due to a sub-clinical injury to the 
pulmonary capillaries, alveolar membrane or both (43). TLco impairment has been 
shown to predict arterial oxygen desaturation and exercise limitation in various lung 
disorders (44). In pulmonary sarcoidosis, isolated TLco impairment in patients with 
normal chest x-rays and no respiratory symptoms is associated with abnormal 
ventilatory and gas exchange responses to exercise (45). It is, therefore, clinically 
important to define the time course of TLCo changes following heart 
transplantation, and to determine the cause of its decline. In addition, the clinical 
significance of TLCo impairment in these patients needs to be evaluated.
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1.2 Aims
The objectives of the studies comprising this thesis were to:
1. Measure prospectively the longitudinal changes in TLCo following heart 
transplantation.
2. Determine the mechanism of TLco impairment in heart transplant recipients in 
terms of the relative contribution of its components.
3. Analyse the factors that could potentially cause TLco reduction following heart 
transplantation
4. Determine the effects of reduced TLCo on exercise capacity and pulmonary gas 
exchange in heart transplant recipients.
1.3 Layout of the thesis
The work of this thesis is presented in 11 chapters grouped in three parts.
Part 1: Consists of three chapters including this introductory chapter. Chapter 2 
reviews the physiological principles underlying TLco measurement and provides a 
brief outline of the various factors affecting it. A review of the limitations and 
clinical applications of TLCo measurements is also included. Chapter 3 is devoted to 
a literature review of lung function in heart disease with particular emphasis on 
TLco changes following cardiac surgery in general and heart transplantation in 
particular.
Part 2: This part presents the general methods used in the studies comprising this 
thesis in three chapters. These include: general design and protocols (chapter 4), 
material and methods of various lung function tests including the broncho-alveolar
lavage study (chapter 5) and validation studies of TLco and its components 
measurements (chapter 6).
Part 3: Consists of the last 5 chapters which investigate TLco changes in heart 
transplant patients. The longitudinal changes in TLco and other lung function tests 
following heart transplantation during a follow-up period of 2.5 years are described 
,v chapter 7. Chapter 8 evaluates the mechanisms of TLco reduction in heart 
transplant recipients in terms of the relative contribution of each of its components 
and chapter 9 investigates the various factors that could theoretically be responsible 
for TLco decline in the setting of heart transplantation. Chapter 10 evaluates the 
significance of reduced TLco in heart transplant recipients in terms of its effects on 
exercise capacity and on pulmonary gas exchange on exertion. Finally, the results of 
the studies comprising this thesis are summarised in chapter 11. The significance 
and contribution of these studies to previous knowledge in the field are discussed. 
The chapter concludes by highlighting the research opportunities in the topic.
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CHAPTER 2 
THE PULMONARY TRANSFER FACTOR: REVIEW OF 
METHODS AND PHYSIOLOGICAL PRINCIPLES
2.1 Fundamentals of gas diffusion in the lungs
In the early years of this century there was a vigorous debate surrounding the 
mechanisms of gas transfer across the alveolar-capillary membrane. Bohr and 
Haldane believed that pulmonary gas transfer occurred by active secretion as well 
as by passive diffusion, whereas the Kroghs and Bancroft argued that gas transfer 
occurred by pure diffusion alone. It is now accepted that gas transfer across the 
alveolar-capillary membrane occurs by passive diffusion according to physical laws
(46).
The factors that determine the diffusion of gases through tissues are described by 
Fick’s law (3). This states that the rate of transfer of a gas (Vg) through a sheet of 
tissue is directly proportional to the surface area of that tissue (A), and the 
difference in the partial pressures of the gas across the two sides of the tissue 
(P1-P2). It is also proportional to a diffusion constant (D), and inversely 
proportional to the tissue thickness (T). Mathematically, Fick’s law is expressed as:
Vg = (AxD/T)/(Pr P2)   1
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For the lung, Pi corresponds to the alveolar partial pressure of the gas (Pa), P2 is 
equivalent to the pulmonary capillary partial pressure of the gas (Pc) and (PA-Pc) is 
the effective driving pressure across the alveolar-capillary membrane. The diffusion 
constant (D) for a gas is directly proportional to its solubility in the diffusion barrier 
and inversely proportional to the square root of the molecular weight of the gas
(47). In a complex structure such as the lung it is not possible to measure 
parameters A, D, or T individually and therefore the value (AxD/T) in equation 1 
was collectively termed the “diffusing capacity of the lung” and was given the 
symbol (DL) with a subscript to denote the gas under consideration. In Europe the 
preferred term is the “Lung transfer factor (TL)”. By substituting TL for (AxD/T), 
equation (1) becomes: Vg = TLg/PA-Pc), and by rearrangement;
TLg = Fg/(PA-Pc)  2
This equation forms the basis for all the physiological methods used to evaluate the 
diffusion characteristics of the lung, and it shows that the value of the lung transfer 
factor for a gas (g) can be readily determined from a knowledge of the rate of the 
gas uptake (Vg) and the partial pressure difference of the gas across the alveolar- 
capillary membrane (PA-Pc).
The lung transfer factor can be measured for oxygen (TL02), carbon monoxide 
(TLco), and nitric oxide (TLno). TL02  is the most relevant physiological 
measurement, but the methods used to derive it are very complex and have very 
poor reproducibility. This is mainly due to the difficulties in estimating the mean 
partial pressure of oxygen in the pulmonary capillaries, and TL0 2  measurements
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have been abandoned (3). TLNo measurement has been recently introduced and its 
clinical application is still being evaluated (48). TLco measurement is the method of 
choice used to evaluate the pulmonary gas transfer factor (3).
Carbon monoxide (CO) has the advantage of being similar to oxygen in its reaction 
with haemoglobin. In addition, it has very high affinity for haemoglobin - about 230 
times that of oxygen (3). As a result, when a small quantity of CO is used, virtually 
all of it is taken up by the haemoglobin of the red blood cells in the pulmonary 
capillaries, and the Peco remains constant and negligible. In the calculations of 
TLco, Peco is assumed to be zero, and equation 2 is therefore simplified to:
TLco =  L c o / P a c o  —------------ 3
where:
• TLco is the lung transfer factor for CO,
•  Vco is the rate of CO uptake and
•  P a c o  is the alveolar CO tension.
The traditional units for TL of any gas are millilitres of gas per minute per 
millimetre of mercury (ml.mm VmmHg'1.). The corresponding international units 
(SI) are millimoles of the gas per minute per kiloPascal (mmol.min'VkPa'1.). The 
relationship between the two systems is given by the following equation (49):
TLco (ml.min \mmHg'1.) = 2.986 x TLco (mmol.min'VkPa'V).
The elimination of the need to estimate Pcco which was first suggested by Bohr and 
applied by Marie Krogh has greatly simplified the physiological methods of
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assessing the diffusion characteristics of the lung and CO tests became the usual 
way of assessing this index of gas exchange (3,47).
2.2 The single-breath transfer factor for carbon monoxide (TLco)
In the process of disproving the theory of active secretion, Marie Krogh described 
the single breath-holding method for the measurement of TLco in 1914 using 
equation 3 (50). In this original method, the subject first exhaled to residual 
volume, then inhaled a test gas containing 1% CO in air to near total lung capacity, 
then exhaled part away, held the breath for six seconds followed by complete 
expiration to residual volume. The alveolar gas was sampled twice during this two- 
stage expiration technique and these samples were used by M. Krogh to estimate 
the alveolar CO concentrations before and after the breath-hold period (46). In this 
original work, M. Krogh used the test in normal subjects and in patients with 
various respiratory diseases: But, this method did not become clinically applicable 
until the 1950s when Forster et al. (51), Ogilvie et al. (52), and others (53) 
developed modifications for its use in clinical practice. The most important 
modification was the addition of helium to the inspired test gas which allowed the 
easy determination of the initial alveolar concentration of CO, as well as the lung 
volume during the breath-holding time (54).
In 1954, Forster and associates introduced the first modification of Krogh's method 
by adding helium to the test gas (51). Helium is an inert gas and does not diffuse 
across the alveolar-capillary membrane, and the change in its concentration before 
and after the breath-holding period was used as a factor for CO dilution in the
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residual volume. This allowed the estimation of the alveolar CO concentration at 
the start of the breath-holding manoeuvre. The technique was therefore, simplified 
to a single alveolar gas collection at the end of breath-holding period.
In 1957, Ogilvie et al. (52) used the modified Krogh single breath technique 
described by Forster to produce a standardised single breath-holding method for the 
clinical measurement of TLco- In this work, many of the factors that affect TLCo 
measurement were presented, and a standardised technique to account for these 
factors was described. TLco values in normal subjects and in patients with various 
respiratory disorders were also presented. In this technique, the subject was asked 
to make a full expiration after which, he made a maximal inspiration of a test gas 
mixture containing 0.3% CO and 21% O2 in nitrogen. The subject then held his 
breath for about ten seconds and then rapidly expired. The first litre of the expired 
gas was discarded and the remainder was collected for analysis. The initial CO 
concentration, before any CO had been transferred across the alveolar-capillary 
membrane was calculated from the dilution of the inspired helium according to the 
following equation:
Initial alveolar [CO] = inspired [CO] X (expired [He] / inspired [He])
From the change in CO concentration in the alveolar sample over the breath- 
holding time, TLco was calculated using Krogh's equation which is based on the 
assumption that the rate of CO uptake across the alveolar-capillary membrane is 
exponential;
TLco = (VA x 60/1 x P a c o )  x  In (initial [CO] / final [CO])
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where:
• Va was the alveolar volume,
• t was the breath-hold time in seconds and
• 60 was used to convert from seconds to minutes.
Ogilvie and associates measured Va separately using either the helium closed circuit 
technique or the nitrogen wash-out method according to the following equation;
Va =  V i + RV
where:
• Vi was the inspired volume and
• RV was the residual volume.
The duration of breath-holding was timed from the start of inspiration to the start 
of the alveolar sample collection.
In 1959 McGrath and Thomson (53) introduced the use of helium dilution 
simultaneously to estimate VA as suggested by Forster (51). The two methods of 
Va estimation give similar values in normal subjects and in patients with interstitial 
lung disease. In patients with chronic airway disease associated with 
maldistribution, the simultaneous method may be unreliable (52).
In 1961, Jones and Meade (55) suggested to inclusion of two thirds of the 
inspiratory time and one half of the alveolar sampling time as parts of the breath- 
holding period. This modification was based on a mathematical model and 
supported experimentally and subsequently recommended by Cotes (56), and by 
both the European Respiratory Society and the American Thoracic Society (41,57).
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2.3 TLco components
The value of TLco derived from equation (3) was originally thought to represent 
the entire process of diffusion from the alveolar spaces to the haemoglobin of the 
red blood cells in the capillary blood. In 1945, Roughton demonstrated that the 
lung transfer for CO was limited not only by the resistance of the alveolar-capillary 
membrane, but also significantly by the relatively slow reaction of CO with 
haemoglobin (4). In 1957, Forster and Roughton further advanced this concept and 
derived a mathematical model to describe the relationship between the determinants 
of the pulmonary transfer factor (5). This model is described by the following 
equation:
1/TLco = 1/Dm+ 1 / 0 x Vc  4
where:
• 1/ TLco is the total resistance to gas transfer for CO between the alveolar gas 
and haemoglobin in the pulmonary capillaries,
•  1/Dm is the  resistance to  gas transfer across the alveolar-capillary membrane,
• If 0xVc is the resistance of the instantaneous total volume of red blood cells in
the pulmonary capillaries “intra-capillary resistance”,
• Vc is the volume of the pulmonary capillary blood in millilitres and
• 9 is the standard rate at which 1 ml of whole blood combines with CO in
millilitres STPD per minute per millimetre of mercury of partial pressure.
In this model, TLCo was called ‘the apparent diffusing capacity” of the entire lung,
and the term  “Dm”  w as called the “true diffusing capacity”  o f  the alveolar-capillary
membrane (58). It was also demonstrated that TLco was inversely proportional to
the prevailing alveolar oxygen partial pressure and that was shown to be due to
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changes in 0. The values of 0 at different oxygen partial pressures were obtained by 
the same investigators from in vitro CO uptake in a suspension of human 
erythrocytes at 37C (59).
The mathematical derivation of equation 4, and the principles underlying the 
estimation of DM and Vc have been fully described by Roughton and Forster (5,58). 
The values of Dm and Vc can be derived by measuring TLco using single breath- 
holding method or any other method, at two different alveolar oxygen tensions and 
using the two corresponding values for 0 to obtain two equations which are then 
solved simultaneously for Dm and Vc. Alternatively, the values of Dm and Vc may 
be obtained graphically by plotting the two values of 1/TLco against the 
corresponding 1/0 as shown in Figure 5.1. The slope of the line equals 1 /Vc and its 
intercept with 1/ TLco axis equals 1/Dm.
In this model, DM and Vc are assumed to be independent of the alveolar oxygen 
tension. It is also assumed that the haemoglobin concentration in the pulmonary 
capillary blood is identical to that of venous blood and the rate of reaction of CO 
with haemoglobin (0) in vitro is identical to that occurring in the pulmonary 
capillary blood (5).
The Roughton and Forster model has been supported by many recent clinical and 
experimental studies, and it has become the standard physiological model which 
describes the transfer of CO and O2 between the alveolar gas and the haemoglobin 
of the red blood cells in the pulmonary capillaries (59). The clinical application of 
this model has contributed to the understanding of the changes in pulmonary gas
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transfer under different physiological and pathological conditions (41). In 
particular, it has been used extensively in clinical research as a non-invasive index 
of pulmonary capillary bed function in health and disease with consistent results 
(2,60).
2.4 Determinants of TLco
From the equations used to calculate the lung transfer factor for CO and its 
components, there are five major determinants. These are: 1) the length of diffusion 
path, 2) the surface area available for diffusion, 3) the characteristics of the 
alveolar-capillary membrane, 4) the driving pressure across the alveolar-capillary 
membrane, and 5) the “diffusion” within the pulmonary capillary blood.
1. Length of diffusion path
Before entering blood, oxygen and other gases such as CO must first cross all the 
tissues interposed between the alveolar spaces and the erythrocytes in the 
pulmonary capillary blood. These tissues are collectively referred to as the alveolar- 
capillary membrane and include: the alveolar surface lining (surfactant), the alveolar 
wall and its basement membrane, the pulmonary capillary wall and its basement 
membrane, and the interstitial space between the alveoli and the capillaries (61). 
Normally, the thickness of the alveolar-capillary membrane is about 0.5 
micrometers, but it can become much thicker when there is pulmonary fibrosis, 
oedema or an inflammatory exudate into the interstitial space (61). Thickened 
alveolar-capillary membrane causes a characteristic reduction in TLco (43). 
However, isolated increase in the thickness of the alveolar-capillary membrane is
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believed to be very rare and indeed some investigators believe that this state does 
not exist in isolation as most pulmonary disorders affect more than one determinant 
of gas exchange (43).
2. Effective surface area
As stated before, the pulmonary gas transfer factor is directly proportional to the 
effective surface area of diffusion. This area is estimated to be about 50-100 m2 in a 
healthy adult at rest (43). The effective surface area is determined by the lung 
volume and by the distribution of alveolar ventilation and pulmonary perfusion. A 
decrease in the number of ventilated alveoli, or the number of patent capillaries, as 
in ventilation-perfusion mismatch, reduces the effective surface area for diffusion 
and can reduce the measured TLCo even when the diffusion distance is normal (62).
3. Characteristics of the alveolar-capillary membrane
The rate of gas transfer across the alveolar-capillary membrane is proportional to 
the solubility of the gas in the pulmonary tissue, but there are no information about 
the influence of this factor on the measured TLCo in either health or disease. It is 
possible that fibrotic lung tissue might resist gas transfer more than normal tissue of 
similar thickness and surface area.
4. Driving pressure across the alveolar-capillary membrane
The effective driving pressure for gas transfer across the alveolar-capillary 
membrane is the difference between the alveolar partial pressure of the gas and its 
partial pressure in the pulmonary capillaries. For carbon monoxide, the pulmonary 
capillary partial pressure is assumed to be zero. In heavy smokers, the pulmonary
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capillary partial pressure for carbon monoxide increases significantly and if it is not 
taken into account, it leads to underestimation TLCo (41,63).
5. “Diffusion" within the pulmonary capillary blood
The diffusion path through plasma is believed to be very short as the diameters of 
erythrocytes and the pulmonary capillaries are similar (about 7 pm each) (59,61). 
The overall “intra-capillary resistance, l/0x Vc” is determined by two factors; 1) the 
total haemoglobin in the pulmonary capillaries which depends on the haematocrit 
and the instantaneous pulmonary capillary blood volume (Vc), and 2) the rate of 
reaction (0) between CO and haemoglobin (5,43). Any factor that reduces the total 
haemoglobin concentration in the pulmonary capillary bed causes a fall in the 
measured TLco (59). In normal subjects, the “intra-capillary resistance” has been 
shown to be equivalent to the resistance caused by the alveolar-capillary membrane 
(5).
Thus, the measured value of TLco may be altered by abnormalities in the 
ventilation-perfusion relationship, in the alveolar-capillary membrane, or in the 
pulmonary capillary blood. Most disorders of gas exchange involve more than one 
of these, sometimes with opposing effects on TLco (43).
2.5 Factors affecting TLco measurement
Several physiological and technical factors have been identified as influencing the 
measurement of TLCo and its components (59). Understanding the effects of these 
factors is not only important for the accurate interpretation of TLco changes, but 
also essential for standardising the methods of TLCo measurement (41). These
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factors include: 1) age, sex, and body size, 2) body position during the 
measurement, 3) lung volume at which TLCo is measured, 4) haemoglobin 
concentration, 5) carboxyhaemoglobin blood level, and cigarette smoking, 6) 
alveolar oxygen tension, 7) exercise and 8) ventilation-perfusion relationship. In 
addition, there are several important technical factors specifically related to the 
single breath-holding method. The influence of these factors on TLCo measurements 
has been extensively evaluated by many investigators (5,52,53,64), and the results 
of these studies form the basis of the recent recommendations of the American 
Thoracic Society and the European Respiratory Society for the standardisation of 
TLco measurements (41,65). The following is an outline of the influence of these 
factors on TLco measurement and interpretation.
1. Age, sex, and body size
TLco increases with growth in children. In adults it decreases with age and is 
proportional to body size. The TLco is less in normal females than in normal males. 
This is believed to be due the difference in body size and the alveolar volume 
between the two sexes (66,67). Body weight appears to have no significant effect 
on TLco. Prediction equations are used to correct for age and height (41).
2. Body position
TLco increases by about 10-20% in the supine compared to sitting position. Dm and 
Vc show similar trends with Vc increasing more than Dm on assuming the supine 
position. These changes are believed to be secondary to the gravitational effect on 
lung volumes and pulmonary ventilation-perfusion distribution (68).
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3. Lung volume
TLco increases with increasing lung volume. This observation lead Marie Krogh to 
consider the TLco per unit lung volume (TLco/VA), which she called the diffusion 
constant (Kc0), to be a more useful index of diffusion because she found it constant 
at various lung volumes (50). Further studies have confirmed that TLco increases 
with increasing lung volumes. However, Kco is not constant; when single breath 
TLco was measured at various lung volumes, Kco decreased as lung volume 
increased until the lung volume reached 80 % of the total lung capacity (TLC) and 
above this Kco became constant (41,69).
The changes in Dm with increasing lung volume parallel that of TLCo, but in normal 
subjects Vc decreases at high lung volumes (70); the expansion of the lungs is 
believed to increase the surface area for diffusion, reduce the thickness of the 
alveolar-capillary membrane, and flatten the pulmonary capillaries and as a result 
TLco and Dm increase, while Vc and Kco decrease with increasing lung volumes 
(41).
4. Haemoglobin concentration
TLco decreases in anaemia and increases in polycythaemia. This is a function of the 
rate CO reaction with haemoglobin which is directly proportional to haemoglobin 
concentration (66). The measured TLco can be normalised for actual haemoglobin 
using standard equations and this is recommended when haemoglobin levels are 
outwith the normal range (41).
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5. Carboxyhaemoglobin (Co-Hb) and cigarette smoking
TLco is inversely proportional to the level of Co-Hb (41,63). Co-Hb reduces the 
measured TLCo by two different mechanisms. Firstly, the increase in the venous 
partial pressure of CO creates a back pressure in the pulmonary capillary blood and 
because the pulmonary capillary CO partial pressure (Pcco) is assumed to be zero, 
the increase in Pcco reduces the effective driving pressure for CO across the 
alveolar-capillary membrane thereby causing a reduction in the measured TLco 
(65). Secondly, Co-Hb reduces the number of the available haemoglobin binding 
sites causing a reduction in the functional haemoglobin concentration (the anaemic 
effect) (71). The magnitude of Co-Hb effect on the measured TLco is about 1% 
decrease in TLco for every 1 % increase in Co-Hb (72). Repeated measurements of 
TLco increase the level Co-Hb, but this is usually not clinically significant (59,63).
TLco is reduced by both acute and chronic cigarette smoking (73), and in heavy 
smokers Co-Hb can reach significant levels and adjustment for this may be 
necessary (41). Cigarette smoking is also associated with accelerated decline in 
TLco even after allowing for the effects of Co-Hb (71). Smoking cessation is 
associated with rapid improvement in TLCo (74). Reference equations that include 
adjustment for Co-Hb and smoking are available (41). The acute effects of smoking 
are best avoided by asking the patients to stop smoking overnight before to being 
tested (63)
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6. Alveolar oxygen tension (PA0 2)
TLco is inversely proportional to Pao2 and this varies with the inspired oxygen 
making standardisation of PAo2 essential (41,75). The European Respiratory Society 
recommended the use of a gas mixture containing 17 to 18% oxygen, because at 
this range PAo2 is nearly constant (41). The American Thoracic Society, on the 
other hand recommended the use of gas mixtures containing 21% oxygen (57,65). 
At other inspired oxygen concentrations, correction to the standard PAo2 should be 
done using Roughton and Forster equation (5).
7. Exercise
TLco, Dm, and Vc increase with exercise. This increase is believed to be due 
increases in the surface area for diffusion and the pulmonary capillary blood volume 
either by the distension of patent vessels, or by the opening of previously closed 
vessels (recruitment) or by both (66).
8. Ventilation-perfusion relationship
All methods of estimating TLco consider the lungs as a homogeneous system with a 
uniform distribution of ventilation and perfusion. However, the normal lungs have 
an uneven distribution of ventilation and perfusion and this usually worsens in 
disease (2,76). The effects of ventilation-perfusion mismatch on the measured TLco 
depends on the method used; it has relatively little effect on TLco measured by 
either single breath-holding or rebreathing techniques, but significantly influence the 
steady-state estimation of TLco especially at rest (77). The discrepancy between 
single breath-holding and steady state TLco in different diseases is believed to be
!
I
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due to the greater effect of ventilation-perfusion mismatch on steady state 
measurements (62).
9. Technical factors specific to single breath-holding method
There are several technical factors specifically related to the single breath-holding 
method which could alter the measured TLCo (78). These include the inspiratory 
and expiratory manoeuvres, the timing and duration of breath-holding, the timing 
and volume of washout and alveolar samples, the variability in the alveolar pressure 
during the breath-holding manoeuvre and the time interval between and the number 
of repeated measurements in a single session (52,55). Standardisation and good 
control of these factors have been shown to decrease the variability of single breath 
TLco (79).
2.6 Comparison between the principal methods of TLco measurement
TLco can be measured using several techniques, but the principal methods in use 
are: a) single breath-holding method, b) steady-state method, and c) rebreathing 
method (79). All of these physiological methods are based on the general equation:
TLco = Vco/Pa c o
Therefore each method involves two basic steps: 1) measuring the rate of CO 
uptake (Leo), and 2) estimating the mean alveolar partial pressure of CO (Paco).
The details of these methods have been well described (2,77,80). The single breath- 
holding technique as described by Ogilvie and associates (52) is the most commonly 
used method, and is the method used in studies comprising this thesis. However,
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some of the previous studies relevant to the work of this thesis were performed 
using other methods, especially steady state and rebreathing methods. The 
following is a brief account of the advantages and disadvantages of the three 
principal methods (2).
1. Single breath-holding method
The advantages of the single breath-holding method are that it is widely available, 
relatively simple to perform, less affected by ventilation-perfusion abnormalities and 
relatively insensitive to CO back pressure in blood. In addition, it is the most 
standardised method and has been computerised and widely studied in normal 
subjects and patients with reproducible results (41). The disadvantages of single 
breath TLco include the criticism that the breath-holding manoeuvre is not a 
physiological state and therefore the obtained TLco values do not reflect the gas 
exchange function during tidal breathing. The requirement to hold their breath for 
about ten seconds may be difficult for some patients with severe breathlessness and 
a vital capacity of at least 1.3 litres is necessary to allow adequate dead space wash 
out and adequate alveolar samples. It is also difficult to apply during exercise (80).
2. Steady state methods
In all steady state methods, the subject breathes a low concentration of carbon 
monoxide (0.1-0.3) for several minutes to reach a steady state of CO exchange. A 
mixed expired gas sample is collected over several more minutes and the rate of CO 
uptake is estimated from the difference between the quantities of the inspired and
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expired CO per unit time. The alveolar partial pressure for CO ( P a ,c o )  is estimated 
using one of the following different ways:
• Filley’s Technique : This method requires an arterial blood sample to measure 
the arterial carbon dioxide tension (Paco2) which is then used to estimate PAco 
using Bohr equation.
• End-tidal CO determination technique : The P a c o  is determined by taking an 
average end-tidal CO tension from the instantaneous analysis of multiple 
breaths. The average end-tidal value is taken to equal the mean PAco-
• Dead space technique: This technique uses an assumed dead space ventilation 
(Vd) and the measured tidal volume (Vt) to derive PAco using the Bohr 
equation.
• Mixed venous Pco2 technique: In this method, the Paco2 is derived indirectly by 
estimating the partial pressure of mixed venous C02 using an equilibrium 
technique. The derived Paco2 is then used to calculate PAco using the Bohr 
equation as in Filley’s technique.
The advantages of steady state-methods include measurement during tidal breathing 
which is physiological and can be applied at rest, during sleep, exercise, and general 
anaesthesia. They also require less equipment, less calculations, and less patient co­
operation. One of the most important limitations of these methods is their 
sensitivity to ventilation-perfusion abnormalities. This is mainly due to the use of 
the Vd/V t ratio, and Paco2 in the calculation of PAco, and small errors in the 
estimation of these parameters can lead to wide variations in the measured TLco-
55
The requirement for arterial blood sample in Filley’s technique is another 
disadvantage. In general, the different steady-state methods for estimating TLCo 
give similar results (81), although values for TLco are consistently less than those 
obtained using single breath-holding method. This is believed to be related to the 
greater lung volume at which the single breath-holding TLco is made (80). In 
normal subjects, there is good agreement between single breath-holding and steady- 
state methods, but in patients the disparity between the two methods can be 
considerable (82).
3. Rebreathing Technique
In this method the subject rebreathes from a bag containing a gas mixture (0.3% 
CO, 10% He, 21% 02 with the remainder being nitrogen) for 30 to 60 seconds at a 
rate of 24 to 30 breaths per minutes. The rapid rebreathing allows continuous 
mixing of the test gas so that the bag gas concentrations can be considered 
equivalent to the alveolar gas concentrations. Gas concentrations are continuously 
monitored during the test using rapidly responding gas analysers. The uptake of CO 
is calculated from the system volume and from the rate of carbon monoxide 
disappearance from the bag. TLco is calculated using the modified Krogh equation, 
except that the alveolar volume is replaced by the system volume which includes 
the alveolar volume and the gas volume in the bag and the apparatus (83).
The advantage of this method is that it can be performed during exercise and in 
patients with vital capacities of less than 1.3 litres. In addition, it is the method least 
affected by ventilation-perfusion abnormalities. However, some patients find it
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difficult to rebreathe rapidly at a fixed rate (80). This method is not recommended 
for routine use (41), but it is considered to be the method of choice when the single 
breath-holding method cannot be used (84).
2.7 Predicted normal values and reproducibility of TLco measurement
The single breath-holding method is the most reproducible technique and it is the 
method of choice (41,57,65). The reported normal intra-individual coefficient of 
variation for single breath TLco is 3.7 % (range; 2.6% - 10.7 %) (79,80). Under 
good control of measurement conditions, the reported coefficients of variation for 
Dm and Vc are 12 % and 7 % respectively (79).
Predicted normal values for TLCo have been derived from many population studies 
and there are many prediction equations for TLco which are corrected for age, 
height, and gender (49,85). Like most other lung function tests, there is a wide 
range of variability in these equations (85). This variability is primarily attributed to 
differences in the techniques and different criteria for population selection (63,80). 
The importance of all the possible technical and physiological factors affecting the 
measurement of TLCo has been emphasised by both the American Thoracic Society 
and the European Respiratory Society in their recommendations for the 
standardisation of TLco measurements (41,57,65). The adherence to these 
recommendations is hoped to improve the reproducibility of TLco measurements 
and reduce the variability between the published results (41,57).
Like most other lung function tests, the normal range of normal TLco is commonly 
defined as the predicted TLco +/- 20% (86). However, this arbitrary definition is
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only valid when the scatter about the regression line of the prediction equation is 
proportional to the value of the predicted index (86). In common with most lung 
function tests in adults, the scatter about the prediction equation for TLco is 
independent of its value (86,87). Therefore, the practice of using a fixed percentage 
of predicted as a lower limit of normal TLco in adult is not recommended 
(41,57,63,65). The recommended approach is to define the lower limit of normal by 
the lower 5th percentile of the reference population (41,63,65,88).
2.8 Clinical applications
The measurement of TLco gives information about the mass of functioning 
pulmonary capillaries in contact with ventilated alveoli and reflects dysfunction of 
gas exchange mechanisms in certain pulmonary vascular and parenchymal diseases. 
TLco measurement has become an established routine test in most respiratory 
laboratories and is used in the screening, monitoring and differential diagnosis of 
many lung disorders (89).
Impaired TLCo is one of the earliest objective indices in extrinsic allergic alveolitis 
(54). It is also used for early detection of pulmonary drug toxicity (e.g. amiodarone 
(90,91)). Serial measurements of TLco have been used to monitor progress and 
response to treatment in many interstitial lung diseases with variable results (54).
Like all other non-invasive lung function tests, TLCo is not diagnostic of any 
disease, but it may be useful in the differential diagnosis. TLco estimation is 
particularly helpful in the differential diagnosis of chronic obstructive pulmonary 
disease; usually being normal and sometimes elevated in asthma, normal in chronic
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bronchitis and reduced in emphysema (63,92). TLco is frequently abnormal in 
pulmonary vascular diseases, but it has very little value in the differential diagnosis 
of these disorders (54). The values of TLco and its components have been shown to 
correlate with severity of pulmonary vascular disease including congenital and 
acquired heart disease (30).
2.9 Limitations of TLCo measurements
From the previous sections, it is clear that TLco tests have important limitations. 
These include lack of specificity, the wide range of normal values and the lack of 
correlation with the severity of disease (80). In addition, the use of different 
methods and different types of equipment along with the lack of standard values 
make it difficult to compare results obtained in different laboratories. The adoption 
of standardised methods is expected to reduce the differences in the TLco values 
obtained in different centres (41,65). The estimation of Dm and Vc requires very 
precise control of measurement conditions as these parameters are very sensitive to 
changes in the breath-holding time and the alveolar pressure during this time which 
must kept constant and close to the atmospheric pressure (79).
In spite of all of its limitations, TLco estimation remains a valuable index of the gas 
exchange function. It is simple, sensitive and non-invasive and may become 
abnormal before dysfunction is reflected by changes in arterial blood gases or by the 
other non-invasive lung function tests (93).
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CHAPTER 3
LUNG FUNCTION IN HEART DISEASE - REVIEW
The lungs are interposed between the right and left sides of the heart and are 
connected to the heart in series by the pulmonary circulation. The matching of 
pulmonary blood flow and ventilation in the lungs is of prime importance to the 
efficiency of gas exchange. Because of the interdependence between the heart and 
lung in both structure and function, compromise in one adversely affects the 
function of the other (6).
The overall process of gas exchange at the alveolar-capillary interface consists of 4 
interdependent processes (28). These processes are: ventilation of the alveoli, 
perfusion of the pulmonary capillaries, matching of ventilation and perfusion, and 
diffusion of oxygen and carbon dioxide across the alveolar-capillary membrane. 
Impairment of all of these processes has been reported in various forms of heart 
disease (6,12,26). The purpose of this section is to review lung function changes in 
heart disease with particular emphasis on the diffusing characteristics of the lung 
before and after various forms of cardiac surgery.
3.1 Mechanisms of pulmonary dysfunction in heart disease
Heart disease disturbs lung function through one or more of the following 
mechanisms (12): 1) increased pulmonary venous pressure, 2) lung compression, 3)
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low cardiac output, 4) altered pulmonary to systemic blood flow ratios, and 5) 
pulmonary complications of heart disease treatment, e.g. drugs and cardiac surgery.
1. Increased pulmonary venous pressure
Pulmonary venous hypertension is the most common cause of altered lung function 
in heart disease (12). Regardless of the cause of left heart failure, the resulting 
increase in left ventricular end-diastolic pressure is transmitted backwards into the 
left atrium and is in turn transmitted to the pulmonary venous system. The effects 
of increased pulmonary venous pressure on lung function are well documented and 
the extent of pulmonary dysfunction appears to depend on the severity and the 
duration of the pulmonary venous hypertension (94-96). The increased pulmonary 
venous pressure causes transudation of fluid out of the capillaries which appears 
first as an increase in the pulmonary lymph flow. Then it accumulates in the 
interstitial space surrounding the peripheral vessels and airways and later in the 
alveolar walls. In severe cases it floods the alveoli (95). Mildly elevated pulmonary 
venous pressure is associated with a corresponding increase in the pulmonary 
arterial pressure to maintain a normal pressure gradient along the pulmonary 
capillaries. With increasing severity, pulmonary artery pressure increases out of 
proportion to the increase in the pulmonary venous pressure indicating the 
development of established active pulmonary hypertension (97). Histological 
studies have shown that severe chronic pulmonary venous hypertension is 
complicated by medial and intimal hyperplasia in the small pulmonary arteries and 
veins and by interstitial fibrosis (30,98,99). These pathological processes are 
reflected by characteristic abnormalities of lung function (30).
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2. Lung compression
Cardiomegaly, pleural effusions, and elevated diaphragm resulting from 
hepatomegaly and ascites are common in congestive heart failure of any cause and 
are believed to contribute to the restrictive ventilatory defect that is commonly 
observed in patients with this condition (12,14).
3. Low cardiac output
Low cardiac output leads to uneven distribution of perfusion and ventilation 
resulting in impairment of pulmonary gas exchange (28). Respiratory muscle fatigue 
is also common in heart failure and has been attributed to low perfusion secondary 
to low cardiac output (100-102).
4. Altered pulmonary blood flow
In congenital heart disease with a left to right shunt, persistent massive pulmonary 
blood flow leads to structural changes in the pulmonary vascular bed which can be 
irreversible resulting in arterial pulmonary hypertension and raised pulmonary 
vascular resistance (27). On the other hand, congenital heart disease with right to 
left shunt is characterised by low pulmonary blood flow, hypoxaemia, and cyanosis 
(103).
5. Pulmonary complications of heart disease treatment
Some of the drugs used in the treatment of heart disease have been shown to cause 
or exacerbate lung disease (12). Beta-adrenergic blockers such as propranolol 
exacerbate bronchoconstriction in patients with asthma and chronic obstructive
62
pulmonary disease (104). Amiodarone-induced pulmonary toxicity has been 
documented clinically and pathologically in patients taking this anti-arrhythmic 
drug, and include pneumonitis, pulmonary fibrosis, and sub-clinical abnormalities of 
lung function (91). Lung function is also altered by cardiac surgery, including heart 
transplantation (10,38).
3.2 The pulmonary circulation in heart disease
As has been noted above, the pulmonary vascular bed is frequently disturbed by 
disorders of cardiac output such as congestive heart failure and congenital heart 
disease. Initially, there are changes in the pulmonary vascular pressures, the 
pulmonary blood flow or both, followed by pathological changes in lung structure 
(30,95). The functional consequences of these change include: abnormal 
ventilation-perfusion relationships (26,94), altered diffusing properties of the lungs 
(31,105) and abnormal lung volumes and mechanics (25). A review of the normal 
structure and function of the human pulmonary circulation is essential for the 
understanding of lung function changes in heart disease. A detailed account of the 
functional anatomy of the pulmonary circulation is beyond the scope of this thesis. 
The following is a brief out-line of the structure and function of the human 
pulmonary circulation both in health and in heart disease (27,61,106,107).
The lungs receive blood from both the bronchial and the pulmonary circulations. 
The bronchial blood flow constitutes a very small portion of the output of left 
ventricle (about 2%) and it supplies parts of the tracheo-bronchial tree with 
systemic arterial blood. The pulmonary blood flow constitutes the entire output of
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the right ventricle and supplies the lungs with mixed venous blood draining the 
tissues of the entire body in order to undergo gas exchange at the alveolar-capillary 
interface. The walls of large pulmonary arteries are thin and consist mainly of 
elastic tissue. The media of the pulmonary arteries is about half as thick as in the 
systemic arteries of corresponding size. At a diameter of about 1000 pm, the 
pulmonary arteries become muscular with a distinct media muscularis. These 
muscular arteries are believed to be the resistance vessels of the pulmonary 
circulation and they branch down to a diameter of 100 pm giving rise to the 
pulmonary arterioles. In contrast to systemic arterioles, pulmonary arterioles have 
no muscular layer. They terminate by supplying the pulmonaiy capillaries which 
arise beyond the terminal bronchioles. The pulmonary capillaries have an average 
luminal diameter of about 7 pm and form a dense network which is enclosed by the 
alveoli to form the functional unit of pulmonary gas exchange. It is estimated that 
there are about 280 billion pulmonary capillaries supplying about 300 million 
alveoli, leading to an estimated surface area for gas exchange between 50 and 100 
m2. The pulmonary capillaries have no smooth muscle or any contractile elements 
surrounding them. The change in their calibre is believed to be achieved by 
mechanical means, such as the changes in the surrounding alveolar pressure, the 
pulmonary arterial and venous pressures and the movement of adjacent structures. 
The pulmonary capillary blood is collected into the pulmonary venules which have 
similar structure to the arterioles and as they increase in size they take up the 
appearance of veins which unite to form the pulmonary veins which eventually 
drain oxygenated blood into the left atrium.
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Because of the structural differences, pulmonary arteries have greater compliance 
and provide less resistance to blood flow than do the systemic arteries. The 
pulmonary vascular resistance (PVR) is about a tenth of the systemic resistance (20 
to 130 and 700 to 1600 dynes.sec.cm'5, respectively). Under normal resting 
conditions, some of the pulmonary capillaries are under-perfused, and as pressure 
rises, they take up more blood (vascular recruitment). With further increases in 
pulmonary vascular pressures the patent capillaries increase their diameter (vascular 
distension). Vascular recruitment and distension act together to reduce the overall 
PVR in the face of increasing blood flow and pressures.
The pulmonary blood flow is equivalent to that of the systemic blood flow (about 
3.5 L.min'Vm^of body surface area at rest). It is estimated that about 250 to 300 
ml/m2 of body surface area is in the pulmonary circulation at any instant, and 60 to 
70 ml.m*2 of this blood is in the pulmonary capillaries. A red blood cell takes about 
4 to 5 seconds to travel through the pulmonary circulation at rest and 0.75 seconds 
of this is spent in the pulmonary capillaries where gas exchange takes place. In 
normal resting conditions gas exchanging reaches equilibrium in about 0.25 
seconds. This gives the gas exchange unit of the lung a large physiological reserve 
at rest.
Chronic left heart failure from any cause can potentially raise the pulmonary artery 
pressure with reactive changes in the pulmonary capillary bed (12). However, most 
of the knowledge concerning the pulmonary consequences of left heart failure has 
come from studies on patients with mitral valve disease, especially those with mitral 
stenosis (27). In mitral stenosis, the rise in left atrial pressure is transmitted to the
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pulmonary veins, capillaries and arteries. Initially the increased pulmonary artery 
pressure is passive, and at this stage, patients usually develop symptoms and signs 
of left heart failure. With long standing mitral stenosis, the pulmonary vascular 
resistance increases along with pathological changes in the vascular and 
parenchymal lung tissue, and patients develop symptoms and signs of right heart 
failure (30,94). Isotope studies have revealed a characteristic early redistribution of 
pulmonary blood flow in mitral stenosis (26,94). Initially there is an abolition of the 
normal pulmonary blood flow gradient from upper to lower lobes with subsequent 
reversal of the normal pattern as the severity of mitral stenosis increases. Mitral 
valve surgery is associated with rapid relief of symptoms and resolution of most of 
the cardio-pulmonary haemodynamic abnormalities (27). Left atrial pressure and 
pulmonary artery pressure fall immediately after surgery and pulmonary congestion 
is also relieved. The cardiac output improves and the PVR decreases to near normal 
(25,29).
Histological studies have demonstrated frequent pulmonary vascular and 
parenchymal abnormalities in patients with mitral valve disease (30,98,99). These 
include medial and intimal thickening of the muscular arteries and arterialisation of 
the veins. In advanced cases, there is marked fibrosis and thickening of the alveolar 
walls and interstitium. The structural changes in patients with increased pulmonary 
blood flow due to congenital heart disease are more severe and are also related to 
the duration and severity of the cardio-pulmonary haemodynamic disturbance. In 
addition to the structural changes seen in patients with chronic pulmonary venous 
hypertension, the pulmonary vasculature of patients with severe pulmonary
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hypertension secondary to congenital heart disease is also characterised by loss of 
smooth muscle cell nuclei and fibrin deposition in the arterial walls (fibrinoid 
necrosis) and by aneurysmal dilatation of the arteries (plexiform lesions) (27,107).
3.3 TLco changes in heart disease
The introduction and development of different forms of corrective surgery for heart 
disease in the late 1950s and early 1960s, was accompanied by a substantial interest 
in the pulmonary consequences of chronic heart disease (27). In this respect, 
particular attention was given to the possible reversibility of lung function 
abnormalities commonly attributed to heart disease, especially those found in 
congenital and valvular heart disease. This resulted in many reports on the 
relationship between the non-invasive measurements of lung function, including 
TLco, and the functional status and pulmonary haemodynamics in patients with 
these disorders both before and after surgery (30). A review of these studies 
provides an insight into the possible mechanisms underlying the reported decline in 
TLco following heart transplantation.
3.3.1 Valvular heart disease
Lung function changes in mitral valve disease have been extensively studied both 
before and after surgery. Severe lung dysfunction is uncommon, but mild to 
moderate abnormalities of various lung function indices have been reported (6,26). 
The most common abnormality is a restrictive ventilatory defect with small lung 
volumes and reduced pulmonary compliance (25,30). Variable degrees of airway 
obstruction and increased bronchial hyper-reactivity have also been reported (108).
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Mitral valve surgery leads to resolution of most of these abnormalities 
(26,108,109).
TLco in mitral valve disease is variable and ranges from higher than predicted 
normal to very low values depending on the haemodynamic and functional severity 
of the disease (30,32,38,110,111). In 1960, Bates and associates (112) using a 
steady state TLco method (TLco,ss) during exercise in 6 patients with mitral 
stenosis showed that Vc was significantly increased with a concomitant reduction in 
Dm, but TLco was within normal limits. Two years later, Flatley et al. (93) reported 
TLco changes in 59 patients with different heart diseases using the single-breath 
method ( T L c o ,s b ) .  There was no significant difference in mean TLco in normal 
subjects and in patients with aortic valve disease, mitral incompetence and 
functional class II mitral stenosis. In contrast, TLco was significantly reduced in 
patients with severe mitral stenosis (New York Heart Association functional classes 
III and IV). Vc was within normal limits in patients with aortic valve disease and 
mitral incompetence, but was elevated in patients with functional class II and III 
mitral stenosis. There was no consistent relationship between the diffusion 
parameters and the pulmonary vascular pressures.
In 1963, Ried et al. (113) reported TLco changes in 53 patients with mitral valve 
disease studied at rest and during exercise using TLco,ss- TLCo was normal both at 
rest and during exercise in patients with normal pulmonary arterial pressure. In 
patients with mild to moderate pulmonary hypertension, TLco was normal at rest, 
but failed to rise normally on exercise. In patients with severe pulmonary 
hypertension, TLCo was reduced at rest and did not rise on exercise. Using the
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same method at rest, McCredie (33) found a significant reduction in mean TLco in 
18 patients with mitral valve disease compared to normal controls (4.34 and 8.34 
mmol. kPa'Vminl. respectively), and this difference was mainly due to a reduction 
in Dm (6.5 and 16.7 mmol.kPa'Vmin'1 respectively). In contrast, there was no 
significant difference in Vc between the 2 groups (Vc was 69.7 ml in patients and
89.6 ml in normal controls). Vc reduction was only found in patients with increased 
PVR.
In 1965, Aber and co-workers (30) reported the changes in T L c o ,sb  in 79 patients 
with predominant mitral stenosis. TLco changes were analysed in relation to the 
degree of functional capacity, the pulmonary haemodynamic disturbance, and the 
pathological lesions in the pulmonary arteries as assessed by lingular biopsies taken 
during mitral valve replacement surgery. Their findings indicated that TLco 
impairment parallels both the functional capacity and the pulmonary vascular 
changes. Mean TLco was less than 60% of predicted in patients with high 
pulmonary vascular resistance and this was associated with considerable thickening 
of the intima of the small peripheral pulmonary arteries.
Two years later, Gazioglu and associates (32) reported the changes in total 
pulmonary blood volume (PB V), TLco and its components in relation to pulmonary 
haemodynamics in 62 patients with mitral valve disease and in 44 patients with 
aortic valve disease using T L co ,sb  in the supine position. In patients with mitral 
valve disease, mean TLco, Dm and Vc were 7.7, 16.7 and 80.1, compared to 11.3, 
22.6, and 96.1 in normal controls, respectively. There was a progressive decline in 
Dm and TLco from functional class II to IV. There was no significant difference
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between the mean values of Vc for functional classes II and III and normal controls 
(84.5, 87.2, and 96.1 ml, respectively). In contrast, Vc was markedly reduced in 
patients in functional class IV (48.1 ml). The diffusing characteristics of the lung in 
aortic valve disease were similar to those of the normal controls irrespective of 
severity.
In 1974, Burgess reported TLco changes in various pulmonary vascular diseases 
(31). In this study, T L co ,sb  and pulmonary haemodynamics were determined in 48 
patients with pulmonary vascular disease associated with either abnormal 
pulmonary vascular pressures, abnormal pulmonary blood flow or both. Patients 
were subdivided into 4 groups based on their pulmonary haemodynamics: 1) in­
flow obstruction (9 patients with isolated pulmonary hypertension), 2) in-flow and 
out-flow obstruction (17 patients with long-standing mitral valve disease), 3) out­
flow obstruction (12 patients with mitral valve disease and heart failure with normal 
pulmonary artery pressure) and 4) increased pulmonary blood flow (10 patients 
with intra-cardiac septal defects). In all groups there was an inverse relationship 
between TLco and the pulmonary vascular resistance (PVR). Patients with mitral 
valve disease and normal PVR had a normal mean TLco (96% of predicted). In 
contrast, TLco was significantly impaired (68%) in those with increased PVR.
In 1978, Jebavy and associates (114) reported the relationship between supine 
TLco,ss and the pulmonary haemodynamics in 12 patients with severe mitral 
stenosis (NYHA functional class IV). Mean TLco was normal both at rest and 
during exercise. In the entire group, there was no correlation between TLco and the 
pulmonary vascular pressures. However, there was a significant positive correlation
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between TLco and mean left atrial pressure up to a value of 22.5 mmHg (r = 0.71). 
With further increases in the left atrial pressure, the correlation between these 2 
variables became negative (r = - 0.44). These findings were later confirmed by 
Yemault and associate (111). In this study, TLco was normal in patients with mitral 
valve disease (MVD) and pulmonary capillary wedge pressure (PCWP) less than 12 
mmHg whereas it was significantly reduced in those with elevated PCWP. The 
results of these 2 studies are consistent with a biphasic relationship between TLco 
and pulmonary vascular pressures and might explain the lack of a consistent linear 
correlation between TLco and the pulmonary haemodynamics in previous studies. It 
was suggested that in mild pulmonary venous hypertension, without any significant 
pulmonary arterial hypertension, there is recruitment and distension of the 
pulmonary capillaries, which increases Vc, and this acts to maintain a normal TLco 
which would otherwise decreases due to reductions in DM caused by pulmonary 
oedema. In advanced cases with severe pulmonary venous hypertension and 
established pulmonary arterial hypertension, there is progressive pulmonary 
vascular and parenchymal fibrosis resulting in progressive destruction and 
narrowing of the pulmonary capillary bed resulting in increased PVR. At this stage, 
Vc starts to decrease along with a progressive decline in Dm causing a reduction in 
the overall TLco (33).
In 1982, Rhodes and co-workers (115) further explored the relationship between 
TLco,s b  and cardio-pulmonary haemodynamics in 25 patients with MVD. Mean 
TLco was reduced (74% of predicted), but mean Kco was normal (93%). TLco was 
negatively correlated with PCWP (r = - 0.44) and PVR (r = - 0.53), and positively
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correlated with the cardiac index (r = 0.46). Kco was also negatively correlated 
with the PCWP (r = - 0.45), but it had no consistent relationship with any of the 
other cardio-pulmonary haemodynamics.
The changes in TLCo and components following mitral valve surgery have been 
reported by many investigators (34-40,105,112,116-118). Earlier studies involved 
patient with various cardio-pulmonary disorders, with only small numbers with 
valvular heart disease (37,112). In the study of Bates and associates (112), TLco 
and its components were measured in one patients with mitral stenosis before and 3 
weeks after valvotomy. At similar levels of exercise Vc decreased from 275 to 85 
ml, whereas DM increased from 6.7 to 10.4 mmol.kPa'Vmin1. These opposite 
changes resulted in a relatively unchanged TLco before and after surgery (6.3 and 
7.1 mmol.kPa^.min*1.). In one patient with mitral incompetence studied by Howatt 
and co-workers (37), TLco values were 6.0, 3.1, 4.3, and 4.8 mmol.kPaVmin1., 
before and at 5 days, 10 days, and 5 months after mitral valve replacements 
respectively.
In 1964, Reid et al. (39) reported TLCo changes in 40 patients with mitral stenosis 
before and at 6 to 9 months after valvotomy. In mild cases with normal pulmonary 
arterial pressure, TLco was normal at rest and during exercise before surgery and 
remained unchanged afterwards. In severe cases with significant pulmonary arterial 
hypertension, TLco was reduced pre-operatively, and failed to increase despite 
improvement in pulmonary haemodynamics, lung volumes, and symptoms after 
surgery. Analysis of the data presented for 6 of these patients who had symptoms 
of chronic bronchitis, revealed that the mean TLco before surgery was reduced both
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at rest and during exercise (4.9 and 6.3 mmol.kPa'1.min'1. respectively) and 
decreased further after surgery (4.0 and 5.1 mmol.kPa'Vmin'1. respectively). 
Whereas TLco declined in 4 out of the 6, it increased in one only. This patients had 
the lowest pre-operative TLco (TLCo was 3.2 and increased to 4.0 mmol.kPa'1. 
min'1. post-operatively).
The effects of valvotomy on TLCo was also reported by McCredie in 1966 (105). 
Eleven patients were studied before and at varying intervals (2 weeks to 18 
months) after surgery. The was no significant difference between the pre- and post­
operative results, but there was a tendency for mean Dm to increase (D m increased 
from 6.7 to 7.1 mmol.kPa'1.min'1.) and for mean TLco and Vc to decrease 
following surgery (TLco decreased from 4.9 to 4.3 mmol.kPa'1.min'1., and Vc from 
84 to 71 ml). Analysis of individual results showed that Vc decreased in 9 patients, 
did not change in one and increased in one. The latter 2 patients had the lowest pre­
operative Vc. There were no consistent changes in the individual results of D m and 
TLco.
In 1970, Singh and associates (34) reported the effects of valvotomy on TLco in a 
larger group of patients. Eighty patients with mitral stenosis were studied a few 
days before and at 3 to 24 months following closed mitral valvotomy. Before 
surgery, mean TLco was reduced (4.8 mmol.kPa'1.min’1.). After surgery, patients 
were subdivided into 3 groups based on the time of post-operative assessment. 
Although, TLco declined in 14 patients at 3 to 5 months and in 43 patients at 6 to 
11 months after surgery, this decline did not reach statistical significance. In the 24 
patients who were assessed at 12 to 24 months after surgery TLco decreased by 1.6
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mmol.kPa'1.min'1., and this was statistically significant. These findings were taken 
to suggest progressive lung damage even after valvotomy.
In 1973, Gazioglu (35) measured TLco and its components in 12 patients with 
mitral valve disease before and at an average of 17 months after surgery. Mean 
TLco and Dm were 8.5 and 17.1 mmol.kPa'1.min'1. before, and 8.5 and 13.4 
mmol.kPa'1.min'1. after surgery. Mean Vc was unchanged by surgery (82 ml before 
and after surgery). Individual TLco changes were mostly in the direction of Vc.
In 1984, the longitudinal changes in TLco following mitral valve surgery were first 
reported by Mustafa and associates (38) in 40 patients with mitral valve disease 
studied before and serially after surgery. Mean pre-operative TLco was 65% of 
predicted and was inversely correlated with PVR (r = - 0.46). Post-operatively 
mean TLCo declined to 56% of predicted at 10 weeks, but progressively improved 
in the subsequent intervals reaching 71% at 25 weeks, 72% at 50 weeks, and 79% 
of predicted at 125 weeks after surgery.
Despite improvement in symptoms, exercise performance, and lung volumes in 50 
patients studied by Rhodes et al. (36) before and 6 months after mitral valve 
surgery, TLco and Kco failed to increase (mean TLco and Kco were respectively 
64% and 86% before and 63% and 84% of predicted after surgery). It was 
suggested that these changes may indicate irreversible damage to the pulmonary 
capillary bed. Alternatively, it was argued that the relief of pulmonary vascular 
engorgement with corresponding decrease in Vc might have masked any expected 
post-operative improvement in Dm resulting from relief of pulmonary oedema.
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In 1987, Ohno and associates (40) showed that TLco changes following mitral 
valve surgery (open mitral valve commissurotomy or mitral valve replacement) 
were related to the pre-operative severity of the disease as judged by the degree of 
pulmonary arterial pressure and the presence of tricuspid valve regurgitation (TR). 
Twenty three patients were studied before and 14 to 20 months after surgery. In 7 
patients with normal pulmonary arterial pressure, pre-operative lung function was 
normal and did show any significant change after surgery (mean TLco was 104% 
and decreased slightly to 95% of predicted). In 11 patients with pulmonary arterial 
hypertension (PAH) without TR, pre-operative TLco was 87% of predicted and 
despite improvement of the mild ventilatory dysfunction following surgery, it 
remained relatively unchanged (85% of predicted). In the 5 patients with PAH and 
TR, the ventilatory dysfunction was more severe and was unchanged by surgery. 
TLco impairment was also more severe (62% of predicted), but increased slightly 
(67% of predicted) after surgery.
In 1990, in attempt to determine the effects of pulmonary haemodynamics on lung 
function without the confounding effect of thoracotomy, Yoshioka and associates 
(116) studied 25 patients with mitral stenosis before and one week after 
percutaneous transvenous mitral commissurotomy (PTMC). Despite marked 
improvement of lung volumes and airway function, mean TLco declined 
significantly from 105% to 96% of predicted. It was suggested that this was 
probably due to the normalisation of the pulmonary vascular pressures which 
occurred immediately after the procedure (mean left atrial pressure decreased from
14.7 to 7.9 mmHg).
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The effect of PTMC on TLco was further evaluated by 2 groups of investigators in 
1994 (117,118). In 46 patients studied by Kim and associates (117), mean TLco 
decreased significantly from 95% of predicted before to 86 % of predicted 10 days 
after the procedure. In a study of 9 patients, Ray and co-workers (118) reported 
that mean TLco was 78% of predicted before PTMC, and did not change following 
the procedure (TLco was 75% of predicted both at 48 hours and at 3 months 
following PTMC). Similarly, Dm was reduced before surgery (56% of predicted) 
and remained unchanged afterwards (59%). In contrast, Vc was elevated before 
(118% of predicted) and decreased significantly to 111% of predicted at 48 hours 
and to 98% at 3 months after the procedure. It was concluded that in patients with 
mitral stenosis associated with moderate PAH, the reduction in TLco is primarily 
due to a reduction in Dm, and that successful PTMC reduces Vc , but does not 
improve Dm implying persistent abnormalities of the pulmonary vascular bed.
In summary, TLco in mitral valve disease is variable and appears to parallel the 
functional capacity and pulmonary haemodynamics. In mild disease, there is a 
tendency to an increase in Vc. At this stage Dm is usually slightly reduced, with an 
overall normal or slightly elevated TLco- With increasing severity, secondary 
pulmonary hypertension develops and the pulmonary vascular resistance increases 
leading to a reduction in Vc, Dm and TLco- The failure to demonstrate a consistent 
relationship between TLco and pulmonary haemodynamics may be due to the 
biphasic nature of this relationship; in mild disease they are positively correlated 
whereas in severe disease the correlation is negative (111,114). The effects of heart 
surgery on TLco are also variable and appear to be influenced by the pre-operative
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severity of the disease and the interval between surgery and TLco measurement. 
Most patients show no significant change in TLCo despite improvements in 
symptoms and lung volumes. However, there is a tendency for TLco to improve 
following surgery in patients with the lowest pre-operative TLCo. The overall effect 
of chronic venous hypertension is therefore a composite of the opposing effects of 
raised pulmonary venous pressure and the increased pulmonary vascular resistance 
together with the pulmonary oedema and fibrosis which reduce Dm- In this context, 
it is clear that TLco may be normal despite significant abnormalities in both of its 
components when they change in opposite directions.
3.3.2 Congenital heart disease
The influence of pulmonary haemodynamics on TLco and its components is further 
supported by studies in patients with congenital heart disease. Congenital heart 
disease with left to right shunts is associated with increased TLco and this has been 
shown to be due to increases in both Dm and Vc (22-24,31,93,110,119,120). In 
1958, Rankin and Callies (22) reported increased TLco in patients with atrial septal 
defects (ASD) or ventricular septal defects (VSD) when the pulmonary arterial 
pressure was normal and this was due to proportionate increases in Dm and Vc. In 
presence of pulmonary hypertension, TLco was reduced due to disproportionate 
decrease in Dm. Auchincloss (110) also reported elevated TLCo in 16 patients with 
increased pulmonary blood flow and this increase was attenuated by the presence of 
pulmonary hypertension (TLCo was 142 and 110% of predicted in the absence and 
presence of pulmonary hypertension respectively).
In 1961 Bedell (119) showed that TLco was significantly correlated with 
pulmonary blood flow (PBF) and was elevated in patients with ASD (165% of 
predicted), but was within normal limits in those with VSD (110% of predicted). In 
the same year, Bucci and associates (23) found that TLco, Dm and Vc were 
significantly elevated in patients with increased PBF (143%, 138%, and 160% of 
predicted respectively). In patients with ASD associated with increased PBF and 
PCWP, Vc was even higher (225% of predicted). It was concluded that the 
increase in Vc in these patients was due to increased PBF augmented by the 
associated increase in PCWP. These findings were subsequently confirmed by 
several investigators (24,31,93,120).
TLco and its components have also been shown to return to normal following 
corrective surgery (23,24). In the study of Bucci and associates (23), 10 patients 
with ASD were assessed before and at least 3 months after surgical closure of their 
lesions. Mean TLco, Dm and Vc declined from 144%, 130%, and 166% to 104%, 
110% and 110% of predicted respectively).
In 1985, Schofield and co-workers (24) studied TLco and other lung function tests 
in 33 patients with ASD before and at an average of one year after surgery. Pre- 
operatively, TLCo was elevated (127% of predicted) and was negatively correlated 
with the pulmonary arterial pressure (r = - 0.52). Despite unchanged ventilatory 
function, TLco returned to normal (100% of predicted) following surgery with the 
greatest decline occurring in those with the highest pre-operative TLco values.
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3.3.3 Coronary artery bypass graft surgery
Cardiac surgery has a complex impact on lung function. The surgical correction of 
different forms of cardiac lesions usually improves most of the lung function 
abnormalities specifically related to these lesions (38). However, new abnormalities 
of lung function after cardiac surgery, including coronary artery bypass graft 
(CABG), have also been reported (121). The cause of these abnormalities is not 
clear, but they have been variously attributed to general anaesthesia (122), the 
mechanical effects of thoracic surgery (123), cardio-pulmonary bypass (CPB) 
procedure (37) and post-operative pulmonary complications including infection and 
drug toxicity (121). Patients undergoing cardiac surgery are subjected to the 
combined effects of all of these factors and it is often difficult to separate the 
individual influence of each factor on lung function. With this in mind, the following 
account is a review of the effects of general anaesthesia, sternotomy, and CPB on 
lung function following CABG.
1. General anaesthesia: General anaesthesia results in approximately 20% 
reduction in the functional residual capacity (124). The cause of this is not fully 
understood, but it is generally believed to be due to the cephalic shift of the 
diaphragm and the decrease in the transverse cross-sectional area of the chest 
which occur immediately after induction of anaesthesia (121,124). Pulmonary 
atelectasis has also been shown to occur immediately after induction (124). The 
overall effects of these changes is to increase the proportion of lung units with low 
ventilation-perfiision ratios (intra-pulmonary shunt) which results in a widened
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alveolar-arterial oxygen gradient (121). It is not clear how long these abnormalities 
persist after general anaesthesia, but they are generally believed to be transient 
(125). The effect of general anaesthesia on TLco is not well documented. In 12 
patients studied by steady state method, before and after halothane anaesthesia, 
Bergman (126) found no significant change in TLco- In contrast, Zebrowski and 
associates (127) using a rebreathing technique reported a significant decline in 
TLco, Dm, and Vc in 9 patients undergoing lower abdominal or lower limb surgery 
under controlled ventilation and halothane anaesthesia. In another study, halothane 
general anaesthesia was shown to cause a reversible decrease in the lung transfer 
factor for oxygen in dogs (128).
2. The surgical procedure: Most cardiac operations are performed through a 
standard median sternotomy. During operation, the sternum is spread open for 
several hours, and during the harvest of the internal mammary artery (IMA), the 
pleural space may be opened. The use of IMA is associated with increased 
incidence of pleural effusions, atelectasis, and greater decrease in lung volumes 
(129-131). In addition, bone scan evidence of rib cage fractures has been 
demonstrated in more than 50% of patients undergoing sternotomy (132). It has 
been suggested that these mechanical changes may contribute to lung function 
deterioration following cardiac surgery (132). However, Bamas et al. (133) showed 
that open heart surgery using median sternotomy does not affect the mechanical 
property of the chest wall and demonstrated that lung dysfunction in this setting is 
largely due to changes in mechanical properties of the lung which^similar to those 
found in pulmonary oedema.
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The effect of sternotomy alone on TLco in humans is not known. In 1959, Schramel 
et al. (134) studied the effect of thoracotomy alone (4 dogs), CPB alone (4 dogs), 
and thoracotomy with CPB (2 dogs) on TLco using the steady-state method. All 
dogs had an immediate decline in TLco and this was of longer duration in animals 
with the combined procedures.
3. The cardio-pulmonary bypass (CPB) procedure: Most heart operations 
require the heart to be immobilised or opened. The goal of total CPB is to divert all 
the venous return to the bypass circuit, so that the bypass machine provides total 
perfusion and gas exchange for the entire body. Detailed discussion of the CPB is 
beyond the scope of this thesis. The following is an outline of the basic components 
and concepts of the CPB (135,136).
Figure 3.1 illustrates a typical CPB circuit (135). The CPB machine consists of 
large diameter plastic tubes, a reservoir, a mechanical pump, a gas exchanger 
(oxygenator), heat exchanger, and an arterial filter. The plastic tubes carry blood 
from the right atrium or the venae cavae to the reservoir, from which it is pumped 
and passed through the oxygenator where oxygen is added and carbon dioxide is 
removed. The blood (perfusate) is then passed through the heat exchanger which 
controls its temperature. The oxygenated blood is then filtered and returned to the 
aorta via plastic tubes connecting the CPB machine to a cannula inserted into the 
proximal aorta. Systemic heparinisation is essential to prevent the activation of the 
coagulation cascade when blood comes in contact with the artificial membranes of 
the bypass machine. After separation of the patient from bypass, heparin effect is 
reversed by protamine. The preparation of the bypass machine requires filling
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(priming) with a fluid (prime). The prime fluid is usually a clear crystalloid solution. 
In addition to systemic cooling, myocardial protection during bypass is achieved by 
cold cardioplegia solution, and topical myocardial cooling using iced saline 
solution.
After heparinisation, CPB is established by cannulation of the ascending aorta and
o
the venae cavae. CPB is initiated with systemic cooling in the range of 25 to 28 C 
with a flow rate of about 1.7 L.m2 body surface area, and a mean systemic pressure 
between 50 to 70 mmHg. Once systemic arterial blood pressure has been 
adequately controlled, ventilation is stopped and the ascending aorta is cross­
clamped. Electromechanical cardiac arrest (asystole) is then achieved by cold
o
cardioplegia solution (St.Thomas at 4 C) infused into the aortic root with topical 
cooling of the heart using iced normal saline. Surgery on the heart is usually 
performed during a single period of aortic cross-clamping (complete bypass).
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Figure 3.1: Schaematic diagram of a typical CPB circuit (from reference 135)
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Adequacy of perfusion and gas exchange while on bypass is assessed by monitoring 
direct arterial blood pressure, haematocrit, arterial blood gases and pH, central and 
peripheral temperature. Separation from bypass is a gradual process and starts with 
systemic rewarming followed by removal of the aortic cross-clamp. This usually 
leads to spontaneous reappearance of sinus rhythm, otherwise defibrillation is used. 
Ventilation is then started and cardiac output is initiated by gradual restriction of 
the venous return to the bypass machine directing blood to the right ventricle. Once 
complete separation from bypass is established, heparin is reversed using protamine 
sulphate.
Pulmonary complications following CPB
The development and continuous refinement of CPB techniques have made cardiac 
surgery for various forms of heart disease one of the most common major surgical 
procedures world-wide (136). However, since the early days of its development, it 
was recognised that CPB is associated with significant complications, including 
pulmonary dysfunction, bleeding tendency, renal and cerebro-vascular 
complications (121,135). These multi-organ complications have been called the 
“post-pump syndrome” (121). Although the advances in various aspects of heart 
surgery, have minimised these complications, they still occur, and in some patients 
contribute significantly to post-operative morbidity and mortality (137). In addition, 
transient sub-clinical physiological disturbance of various body systems is almost 
universal (138). The underlying mechanisms of these disturbances appear to be 
complex and are not completely understood (138). There is increasing evidence
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that these complications result from whole body inflammatory responses to the 
exposure of foreign material in the bypass circuit leading to pan-endothelial damage 
(136,138,139). After exposure of blood to the artificial surfaces of the CPB circuit, 
various inflammatory response are activated tte  including complement, 
coagulation, fibrinolytic and kallikrein cascades. These changes are accompanied by 
impaired platelet function, leucopenia and histological evidence of leucocyte 
sequestration in the capillaries with endothelial cell damage (139,140). In addition, 
a variety of inflammatory mediators has been identified in association with CPB 
including endotoxins, cytokines and reactive oxygen species (139). Despite 
extensive research, the precise role of these mediators and responses remains 
obscure (138).
Pulmonary dysfunction is the most common complication of CPB (121). This 
ranges from sub-clinical abnormalities of lung function to severe respiratory failure 
(121). Almost all patients undergoing CPB experience transient deterioration of 
lung function during the first few days of the operation (135). Lung function 
impairment following CPB is characterised by impaired oxygenation, loss of lung 
volume, and reduced TLco (141-144).
TLco changes following CPB have been reported by several investigators 
(123,141,144-146). In 1963, Ellison and associates (123) measured the steady-state 
TLco in 146 patients undergoing thoracic (81 patients) and non-thoracic (65 
patients) operations. Twenty eight of the thoracic operations were open heart 
surgery requiring CPB. On the first post-operative day, TLco decreased 
significantly in all types of operations and persisted for at least 5 days. In thoracic
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operations, especially those involving CPB, the decline in TLco was more marked 
and took longer to return to its pre-operative values.
The short-term effect of CPB on TLco was also evaluated by Turnbull and co­
workers (145) in 19 patients using the steady-state method. In this study, 
pulmonary dysfunction was maximal on the first post-operative day and gradually 
improved on subsequent measurements. Mean pre-operative TLco was 5.9 
mmol.kPa^.min \  and was 3.1, 4.2, and 4.6 mmol.kPa‘l.min1 on the first, third, and 
seventh post-operative days respectively. These immediate post-operative changes 
in lung function were confirmed by Macnaughton et al. (144). Using the 
rebreathing method, TLco was measured immediately before induction and 2 hours 
after the operation. Haemoglobin corrected TLco declined by 27% and this was 
partly due to simultaneous reduction in lung volumes as Kco decreased by 18% 
only. There was no correlation between any of the lung function parameters and 
pulmonary endothelial permeability, as assessed by a protein accumulation index. It 
was suggested that the decline in lung function following CPB is not mediated by 
increased pulmonary capillary permeability.
The long-term changes in lung function following CABG were assessed by 2 
groups of investigators with similar results (141,146). In 19 patients, Braun et al. 
(141) reported a significant decline in Pa0 2 , lung volumes and TLco at 2 weeks 
after surgery. Although there was a significant improvement at 3 to 4 months, all 
parameters remained significantly lower than their pre-operative values. Mean pre- 
operative TLco was 82% of predicted and was reduced by 28% and 11% at 2 
weeks and 4 months after surgery respectively. There was no significant change in
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Kco at any of the measurements suggesting that the decline in TLco following 
CABG was due to the reduction in lung volumes. In 40 patients studied by Dubios 
and associates (146), mean pre-operative TLco was 100% of predicted and declined 
to 94%, 6 months after surgery (p<0.05). In contrast there was no significant 
change in Kco (104% to 107% of predicted).
In summary, CABG surgery results in immediate deterioration in lung function 
characterised by loss of lung volume, reduction in TLco and widening of the 
alveolar-arterial oxygen gradient. These abnormalities tend to improve with time, 
but remain below their pre-operative values at 4 to 6 months after surgery. The 
changes in TLco and Kco following CABG suggest that TLco impairment in the 
immediate post-operative period is only partly explained by the reduction in lung 
volumes; reversible alveolar-capillary membrane damage may be an additional 
contributory factor. Beyond 2 weeks, TLco impairment appears to be due to the 
loss of lung volume. Since most of these studies did not report the changes in 
haemoglobin and its effects on the measured TLco before and after surgery, it is 
possible that the transient reduction in TLco after CPB may be partly due to 
reductions in haemoglobin concentration which is common after cardiac surgery.
3.3.4 Congestive heart failure
Ischaemic heart disease is the most common cause of congestive heart failure 
(CHF). Other causes include valvular heart disease, systemic hypertension and 
primary myocardial disease. In contrast to valvular heart disease, there are few 
studies on lung function changes in CHF due to other causes. The results of these
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studies indicate that lung function abnormalities are common in CHF and are similar 
to those described in patients with mitral valve disease (28). A restrictive 
ventilatory defect is the most common abnormality, but obstructive ventilatory 
abnormalities are also common especially during acute episodes of left ventricular 
failure (7,147). Bronchial hyperresponsiveness to cholinergic agonists is also well 
documented (148-150). Studies in non-heart transplant candidates (i.e. patients 
with less severe CHF) showed that TLco is usually normal or only slightly reduced 
even during episodes of acute heart failure (7,151,152). In 28 patients admitted 
with acute CHF, the initial mean TLco was within normal limits (91% of predicted) 
and showed no significant change after treatment (99% of predicted). In contrast, 
all indices of lung volumes and airway function were markedly reduced before 
treatment and all improved by greater than 20 % following medical treatment. 
These findings were similar to those of Frand and associates (152) who reported 
mean TLco of 91% of predicted in 6 patients with acute pulmonary oedema due to 
CHF and those of Bedell et al. (151) who found no changes in TLco in 9 patients 
with acute CHF over 2 weeks of treatment despite improvement of lung volumes. It 
was suggested that the increased pulmonary capillary blood volume in acute CHF 
probably compensates for the effects of pulmonary oedema which would be 
expected to reduce TLco (7). It was also suggested that the presence of abnormally 
low TLco in patients with CHF should raise the possibility of co-existing primary 
lung disease such as emphysema or pulmonary vascular disease (7).
In 34 stable patients with mild to moderately severe chronic CHF, Siegel and 
associates (8) showed that mean TLco in the entire group was 73 % of predicted
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and was significantly lower in patients with rales compared to those without (53% 
vs. 83% of predicted). In addition, TLco was found to be strongly correlated with 
the left ventricular ejection fraction (LVEF) in patients with rales ( r = 0.81; 
p<0.001), but not in those without rales. It was concluded that TLco was a useful 
predictor of clinically evident CHF. The presence of rales on auscultation was 
presumed to indicate pulmonary oedema which reduces TLco, and in the absence of 
rales TLco is usually normal.
When the work of this thesis was started, there were no data available on changes 
of TLco components in patients with CHF secondary to ischaemic or dilated 
cardiomyopathy. In 1994, Puri and associates (9) provided the first report on the 
changes of TLco and its components in stable patients with mild to moderately 
severe CHF (NYHA functional classes II and III). In the entire group (38 patients) 
mean TLco was reduced compared to controls (6.8 and 9.7 mmol.kPal.min \  
respectively; p<0.001). TLco impairment was primarily due to a reduction in DM 
(mean Dm was 9.0 in patients and 16.7 mmol.kPaVmin1 in normal controls; 
p<0.001). TLco and Dm were significantly lower in patients in NYHA functional 
class III compared to those in class H. In contrast, mean Vc was not significantly 
different in functional class II patients and normal controls (61 and 66 ml, 
respectively), and was significantly greater than normal controls in functional class 
III patients (95 ml). These finding were similar to those found in patients with 
mitral valve disease (32). In 1995, the same group of investigators (153) showed 
that the reduction in Dm in patients with CHF was significantly correlated with 
maximal exercise oxygen uptake and was inversely correlated with the pulmonary
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vascular resistance. It was concluded that reduction in Dm was the major cause of 
TLco impairment in patients with CHF and it appeared to contribute to exercise 
intolerance. It was also suggested that DM may be a useful marker for the alveolar- 
capillary membrane damage caused by pulmonary hypertension.
3.4 The lungs in heart transplant patients
3.4.1 Background
Heart failure is a serious condition with significant morbidity and high mortality. 
The reported mortality rates in patients with heart failure range from 24 to 35%, 
reaching greater than 50% in patients with NYHA functional class IV (154). 
Although drug therapy with angiotensin converting enzyme (ACE) inhibitors and 
vasodilators has been shown to improve survival in heart failure, patients with 
NYHA class IV and some patients with class III continue to have very poor life- 
expectancy (154). In addition, these patients remain severely limited by dyspnoea 
and fatigue even when on maximal medical therapy (155). For these patients, heart 
transplantation has become the treatment of choice (156).
Since the introduction of cyclosporin immunosuppressive therapy, the reported 
survival rate has reached 80 to 90 % at one year and 60 to 70% at 5 years after 
heart transplantation (154). In addition to increased life expectancy, heart transplant 
recipients report a remarkable improvement in symptoms and functional capacity 
(157). The success of heart transplantation is attributable to the substantial 
improvements in many fields of medicine. These include pre-operative management 
of heart failure, surgical techniques, donor management and organ preservation
techniques, prevention and treatment of rejection and early, aggressive treatment of 
medical complications after transplantation (156). Despite these improvements, 
heart transplant recipients continue to be at risk for a number of complications that 
may limit the overall success of heart transplantation (42). Infectious complications 
are very common, occurring in 40 to 80% of patients and at least 25% of deaths in 
these patients are due to infection (158). Other complications include cardiac 
allograft rejection, accelerated graft atherosclerosis and increased incidence of 
malignancies (42). Pulmonary infections account for more than 50% of all 
infectious complications following heart transplantation (159). Other pulmonary 
complications include atelectasis, oedema, thrombo-embolism, pleural eflusions, 
and malignancy (42,159). Pulmonary complications are particularly common in the 
early post-operative period and contribute significantly to the morbidity and 
mortality in these patients (42,158).
Pulmonary function tests are part of routine assessment of potential heart transplant 
candidates in most centres, and are primarily performed to screen for any significant 
co-existing primary lung disease and to assess the risk for the surgery of heart 
transplantation (160). In addition, studies of lung function before and after 
transplantation provide a unique opportunity to evaluate pulmonary function 
abnormalities specifically related to heart failure (14). The abnormalities of lung 
function that resolve following heart transplantation may reasonably be assumed to 
have been due to the effects of heart failure before transplantation. On the other 
hand, persistent or progressive pulmonary dysfunction following heart 
transplantation may be due to one or more of several possibilities with different
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clinical and therapeutic implications. These include: co-existing primary lung 
disease before transplantation, irreversible pulmonary damage due to long-standing 
heart failure and new lung injury from the procedure of heart transplantation or its 
complications. Lung function measurements before and serially after transplantation 
in conjunction with clinical correlates may help to distinguish between these various 
possibilities.
3.4.2 Cardio-pulmonary haemodynamics
The primary indication for heart transplantation is severe congestive heart failure 
due to ischaemic and dilated cardiomyopathy (156,161). Other indications include 
end-stage valvular heart disease, severe angina, and life threatening arrhythmias not 
responsive to conventional medical or surgical therapy. The majority of these 
patients have mild to moderate pulmonary arterial hypertension secondary to 
chronically elevated end-diastolic left ventricular pressure (161). Heart 
transplantation is associated with an almost immediate improvement in cardio­
pulmonary haemodynamics (13,162). Haemodynamic studies several weeks to 
months after transplantation have reported normalisation of resting cardio­
pulmonary haemodynamics including, the mean pulmonary arterial pressure (PAP), 
mean pulmonary capillary wedge pressure (PCWP), transpulmonary gradient (TPG) 
and the pulmonary vascular resistance (PVR), but thrall remain in the upper limit 
of normal (13,163-165). Bhattia and associates (13) reported the time course of the 
cardio-pulmonary haemodynamic changes in 24 heart transplant recipients. In this 
study, right and left heart filling pressures and pulmonary arterial pressures declined 
rapidly reaching normal levels at about 2 weeks. The pulmonary vascular resistance
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took longer to decrease and was still higher than normal at one year after 
transplantation. During exercise, abnormal increases in PAP, PCWP and PVR have 
been reported by several investigators (165-167). The lack of complete resolution 
of resting pulmonary haemodynamics together with their abnormal responses to 
exercise after heart transplantation has been suggested to indicate incomplete 
reversibility of the pulmonary vascular dysfunction caused by the pre-transplant 
severe chronic heart failure (167).
3.4.3 Lung function
Lung function abnormalities are common in heart transplant candidates, but theyare 
usually mild with a restrictive ventilatory defect being the most common 
abnormality (11,14,16-18). TLco impairment is also common and is usually mild 
(10,11,16-19). Airway obstruction is uncommon (10,14), but has been reported in 
this selected group of patients (11,18). Heart transplantation restores lung volumes 
and airway function towards normal. In 1990, Hosenpud et al. compared the 
spirometric results in 17 patients before and 15 +/- 10 (mean +/- SD) months after 
transplantation (14). Mean values for FVC increased from 3,34 to 3.89 L (p<0.01) 
and FEVi increased from 2.63 to 2.95 L, (p<0.05), but FEVi/FVC did not change. 
These findings were subsequently confirmed by several investigators (16-18,20,21). 
In contrast, TLco and Kco have been consistently shown to deteriorate or remain 
sub-normal following heart transplantation (15-21).
Casan et al. (15) were the first to report the changes in lung function following 
heart transplantation. In their study, lung function tests including TLco,ss were
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measured in 10 patients before and at 6 to 12 months after transplantation. The 
comparison between data before and after transplantation revealed an overall 
improvement of lung function indices except TLco and Kco which deteriorated. 
Mean TLco and Kco declined from 83% and 97% of predicted before 
transplantation to 69% and 73% of predicted after transplantation respectively. The 
decline of Kco was positively correlated with whole blood levels of cyclosporin 
determined within few days of lung function assessment (r = 0.87; p<0.001). It was 
suggested that the decline in TLco and Kco may be due to new pulmonary vascular 
or interstitial damage. In absence of thrombo-embolic disease, graft rejection, and 
pulmonary infection, Casan and associates suggested cyclosporin pulmonary 
toxicity as a possible cause.
In a longitudinal study, Groen and associates (16) reported lung function changes 
before and serially after heart transplantation. In this study, 34 patients were 
followed for at least one year, with 27 of them for 2 years, and 21 for 3 years. 
These patients were selected from 124 transplant recipients. The selection criteria 
were based on the ability to perform pulmonary function tests at the time of follow- 
up, pre-transplant chest radiograph with no abnormalities other than changes of 
heart failure and a normal chest radiograph in the subsequent post-transplant 
intervals. In this selected group, the mean value of pre-transplant Kco was 98% of 
predicted with 33 of the 34 patients having Kco values within the normal predicted 
range. In the first post-operative year, lung volumes and flow rates (TLC, VC, 
FEVi) tended to normalise. In contrast, Kco decreased by a mean of 12% (p<0.01). 
In the following 2 years, Kco tended to improve, but remained below its base line
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pre-operative value (89% and 88 % of predicted in the second and third year after 
transplantation respectively). There was a weak correlation between Kco and the 
mean pulmonary capillary wedge pressure (PCWP), both before and after 
transplantation. Using multiple regression analysis, it was found that the factors 
most strongly related to the percentage of change in Kco in the first year after 
transplantation were the pre-operative Kco, mean cyclosporin blood levels in the 
first post-operative year and the change in diastolic PAP in that year. There was no 
correlation between cyclosporin levels and the pulmonary vascular resistance 
(PVR). It was suggested that the decline in Kco may represent alveolar-capillary 
membrane damage secondary to high levels of cyclosporin.
In 1993, Ohar et al. (19) reported lung function studies in 22 patients before and 3 
to 7 months following heart transplantation. In this study 21 (95%) patients had 
abnormal lung function before transplantation. The mean values for static and 
dynamic lung volumes did not change, but TLco and Kco decreased significantly 
after transplantation. TLco decreased from 68% to 54% of predicted. The values of 
TLco and Kco decreased in 19 (86%), and 18 (82%) patients respectively. There 
was no significant correlation between TLco and the pre-transplant left ventricular 
ejection fraction, mean PAP, PCWP, or PVR. The conclusions of this study were 
that lung function abnormalities were common after heart transplantation and that 
the diffusion abnormalities were not related to indices of cardiac function measured 
before transplantation.
In another selected group of heart transplant patients, Ravenscraft et al. (18) 
reviewed pulmonary function data in 38 patients before and one year after
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transplantation. Mean TLco was sub-normal before transplantation, and 
deteriorated after transplantation (from 82.3% to 76.8% of predicted; p<0.05). 
With improvement in lung volumes, the decline in Kco was more pronounced (from 
106.2% to 85.0% of predicted).
In a retrospective study, Egan and associates (21), analysed lung function data in 
22 patients before and at an average of 14 months after heart transplantation (range 
1 to 42 months). Despite normal cardiac function and in the absence of respiratory 
symptoms, mean percent predicted TLco and Kco declined from pre-operative 
values of 80.0% and 94.1% to 57.8% and 70.6% of predicted respectively. The 
decline in TLco did not show any correlation with cardiac allograft rejection, 
cyclosporin levels, or cardio-pulmonary haemodynamics. The mean percentage 
reduction in TLco in asymptomatic patients with serological evidence of 
cytomegalovirus (CMV) infection was greater than that of those who had no 
evidence of CMV infection (31 vs. 16%; p = 0.06). It was suggested that the 
decline in TLco following heart transplantation may be due sub-clinical lung injury 
caused by CMV infection. In another retrospective study, Niset et al. (17) analysed 
lung function data in 47 patients before and one year after transplantation. In this 
study, the mean % predicted TLco and Kco were impaired before transplantation 
(64% and 75%, respectively), and despite improvement of lung volumes after 
transplantation, TLco remained sub-normal at 67% and Kco decreased to 64% of 
predicted. There were no correlations between TLco and the duration of congestive 
heart failure or the pre-transplant pulmonary haemodynamics.
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The long-term change in lung function following heart transplantation were 
reported by Degre et al. (20) in a study of 100 transplant patients. Before 
transplantation, patients had a significant restrictive ventilatory and mean TLco was 
67% of predicted. The long-term changes following heart transplantation in these 
patients were assessed by cross-sectional analysis of lung function data from one 
month up to 10 years following transplantation. At one month after transplantation, 
lung volumes improved slightly, but the restrictive defect was still present. Lung 
volumes continued to improve and at one year they were normal and remained so in 
the subsequent years. In contrast, TLco declined significantly following 
transplantation with no significant difference between the different post-operative 
interval. At 10 years post-transplantation, mean TLco was 59% and this was 
significantly lower than its pre-transplant value.
The time course of pulmonary function changes following heart transplantation was 
also assessed by Jahnke and associates (168) in 21 heart transplant recipients. 
Patients were selected randomly and divided into 2 groups based on the time 
interval between transplantation and lung function assessment. The short-term 
group (11 patients) was assessed at 12.9 +/ -7.0 months (mean +/-SD), and the 
long-term group (10 patients) was assessed at 53.9 +/- 14.8 months after 
transplantation. In this cross-sectional study mean TLco was reduced in both 
groups, but it was significantly lower in the short-term group compared the long­
term one (70% and 47% of predicted, respectively). It was suggested that the 
difference may be due to a gradual reconstruction of the alveolar-capillary 
membrane secondary to the normalisation of the pulmonary haemodynamics.
PART TWO 
METHODS
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CHAPTER 4 
GENERAL DESIGN AND PROTOCOLS
4.1 Design
A prospective descriptive longitudinal study consisting of one primary study group 
and 3 control groups. The primary group consists of all heart transplant patients 
who were transplanted between January 1992 and March 1996 at the Scottish 
Cardio-pulmonary Transplantation Unit. The control groups include normal 
subjects, coronary artery bypass graft patients and mitral valve replacement 
patients.
4.2 Setting
University Department of Cardiac Surgery and Department of Respiratory 
Medicine, Glasgow Royal Infirmary.
4.3 Study Population
4.3.1 Heart Transplant Patients 
Background
The first heart transplantation in the Scottish Cardio-pulmonary Transplantation 
Unit (SCPTU) was performed in January 1992. Since the start of the 
transplantation programms, the unit has established routine protocols for the 
various aspects of heart transplantation management. All heart transplant patients 
were managed according to the same protocols. Information derived the protocols 
serves to define the clinical characteristics of the patients and are relevant to the
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understanding of the changes in lung function following heart transplantation. 
These include; the pre-operative condition, the heart transplant surgery, 
immunosuppressive therapy, and post-transplant complications such as cardiac 
allograft rejection and pulmonary infection.
Selection criteria
Like any other heart transplant centre, the primary indication for heart 
transplantation is severe heart failure of any cause not amenable to conventional 
medical or surgical therapy. Other indications include severe angina or life 
threatening arrhythmias unresponsive to conventional treatment. Potential 
candidates must have a life expectancy substantially worse than that which would 
be expected after heart transplantation. Table 4.1 lists the primary criteria for heart 
transplant recipients selection in the Scottish Cardio-pulmonary Transplantation 
Unit.
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Table 4.1: The primary criteria for recipients selection in the Scottish Cardio­
pulmonary Transplantation Unit.
Inclusion criteria
• Age; over 10 year and under 65 years.
• Severe symptoms and poor life expectancy.
• High motivation for transplantation.
B. Exclusion criteria
• Raised pulmonary vascular resistance defined as fixed transpulmonary 
gradient greater than 14 mmHg.
• Severe disease which may itself compromise life-expectancy or limit the 
success of transplantation (e.g., malignancy, insulin dependent diabetes with 
significant extra cardiac complications, irreversible renal dysfunction, severe 
liver disease, and active systemic infection.
• Severe obesity, alcohol or drug abuse, and active cigarette smoking.
• Poor prospect of compliance with post-transplant regimes.
• Presence of intra-aortic balloon pump or other mechanical circulatory 
assistance.
Pre-operative Management
Table 4.2 lists the pre-transplant screening tests for heart transplantation 
candidates. Many of these tests are performed by the referring cardiologists. These 
investigations are aimed at identifying patients most likely to benefit from heart 
transplantation and to identify any systemic disease which may limit the success of 
transplantation. If clinical assessment and specialised investigations suggest that the
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patient is indeed a potential candidate for heart transplantation, the patient is put on 
the active waiting list. While on the waiting list, patients are followed up regularly 
and their treatment is optimised.
On acceptance of a donor call, a recipient is chosen and contacted as soon as 
possible. The recipient is admitted to the transplant ward. History, clinical 
examination, and routine pre-operative investigations are performed to identify any 
recent changes in the recipient condition.
Table 4.2: Pre-transplant screening test for heart transplantation candidates
• Chest x-ray and 12-lead electrocardiogram.
• Left ventricular (LV) angiography with LV pressure measurements.
• Nuclear and echocardiographic assessment of LV function.
• Right heart catheterisation
• Pulmonary function and cardio-pulmonary exercise tests.
• Selective coronary angiography in those with angina as the main problem.
• Serum urea, electrolytes and creatinine clearance.
• Liver and thyroid function tests.
• Full blood count and white blood cell differential count.
• Viral antibodies ( including, HIV, hepatitis, and CMV).
• Immunocompatibilty tests.
The heart transplant operation
The timing of operation in the recipient is carefully co-ordinated with that of the 
donor. During the donor heart operation, one litre of St. Thomas cardioplegia
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solution is infused at 4 °C under pressure via an aortic cannula. After excision, the 
donor heart is packed within a plastic bag containing cold saline and placed in a box 
packed with ice for transport.
Anaesthesia and cardio-pulmonary bypass: Once suitability of the donor heart 
has been confirmed, the patient is moved to theatre about one hour before the 
estimated time of the donor heart arrival. A standard anaesthetic regimen similar to 
that for conventional heart surgery is followed. The techniques and dynamics of 
cardio-pulmonary bypass procedure are also very similar to conventional heart 
surgery with 2 notable differences. The first is that systemic cooling is maintained at
25 °C during transplantation instead of the usual 28 to 30 °C in conventional heart 
surgery. The second is that heart transplant recipients are given one litre of warm 
reperfusion solution just before removing the aortic cross clamp. The perfusate 
solution contains glucose, citric acid, buffered amino acids and potassium, and it is 
administered mixed with warm oxygenated blood through the bypass circuit over at 
least 30 minutes.
Operative technique and immediate postoperative management: The technical 
details of heart transplant surgery is beyond the scope of this work. The following 
is a brief outline of the standard heart transplantation procedure as abstracted from 
the unit protocols. The recipient heart is exposed by a standard median sternotomy 
and longitudinal excision of the pericardium taking care not to open the pleural 
spaces. After heparinisation, CPB is established by cannulation of the ascending 
aorta and the venae cavae. Once the donor heart has arrived in theatre, CPB is
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started with cooling to 25 °C. The aorta is cross-clamped and a left ventricular vent 
is inserted and a standard cardiectomy is performed.
After appropriate preparation, the donor heart is anastomosed to the remaining 
cuffs of the left atrium, right atrium, aorta and the pulmonary artery in that order. 
At this stage a left ventricular vent is inserted and the cardioplegia solution is 
infused into the ascending aorta immediately proximal to the cross clamp with 
simultaneous de-airing. The left ventricular vent is turned on and the heart is 
gradually allowed to become reperfused without being distended. Temporary 
epicardial pacing wires are attached to the right atrium and ventricle. When 
normothermia and at least 30 minutes of reperfusion have been attained, the patient 
is slowly weaned from the bypass, maintaining haemodynamic stability by the use of 
isoprenaline, glyceryl trinitrate, and low dose dopamine infusions with or without 
adrenaline. The heart is then decannulated, and protamine is administered. 
Haemostasis is then secured, pericardial and mediastinal drains are inserted and the 
sternal wound is closed. The patient is then transferred to the intensive care unit.
The intensive care management of heart transplant recipients is virtually identical to 
that of patients undergoing conventional open heart surgery. The aim is to monitor 
and maintain haemodynamic stability, prevent infection and to wean from the 
ventilator as quickly as possible. In general, patients are weaned from the ventilator 
within 24 to 48 hours. When stable the patients are transferred to the transplant 
ward where they are nursed and monitored in single cubicles.
104
Follow up
After discharge, patients are routinely followed up at the outpatient clinic according 
to a specific protocol. During each outpatient attendance, all patients have clinical 
assessment, chest x-rays, and blood taken for full blood count, urea and 
electrolytes, liver function tests, and cyclosporin levels. Other investigations are 
performed as indicated in the follow up protocol. Table 3 shows the outpatients 
timetable and lists the routine tests at each visit.
Table 4. 3: Outpatients follow-up timetable and routine investigation
Time Clinic E.M.B*
ECG& 
cardiac scan*
PFTs CPX*
2 -4  weeks twice a week weekly
4 - 6  weeks weekly fortnightly at 4 weeks at 6 weeks
6 -12  weeks fortnightly fortnightly at 12 weeks at 12 weeks
3 - 6  months monthly monthly at 6 months at 6 months at 6 months
6-12 months 3 monthly 3 monthly at 12 month at 12 month at 12 months
1-2 years 6 monthly 6 monthly 6 monthly 6 monthly
> 2 years yearly yearly yearly yearly
* E.M.B = endomyocardial biopsy, resting left and right ventricular ejection 
fractions were determined using Technitium ventriculogarphy and CPX = cardio­
pulmonary exercise
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Immunosuppression
Immunosupression is maintained using triple therapy with steriods, cyclosporin A, 
and azathioprine. Methylprednisolone (500mg intravenously) is routinely given with 
induction anaesthesia and again when on bypass, and additional 3 doses of 125 mg 
are given 8 hourly after the operation. Thereafter, 2.5 mg.kg'1 of oral prednisolone 
is given twice daily until reduced to 0.2 mg.kg'1 daily on day 14 post- 
transplantation. Further reductions in steroids are considered at 3 months after 
transplantation on an individual basis.
The first dose of cyclosporin is given pre-operatively (3 mg.kg'1). Post-operatively, 
cyclosporin is given orally in a dose adjusted to maintain the whole blood trough 
level within a specific target range. The initial target level is 400 to 600 mcg.L'1 
reduced to 400 mcg.L*1 at 1 month, 350 mcg.L'1 at 3 month, 300 mcg.L*1 at 6 
months, 250 mcg.L*1 at 1 year, and 150 to 200 mcg.L*1 at 2 years. Azathioprine is 
given in a dose of 3 mg/kg on induction, followed by 2 mg/kg daily after the 
operation reducing to 1 to 1.5 mg.kg*1 daily.
Cardiac allograft rejection and its management
Surveillance endomyocardial biopsies are routinely performed in all heart 
transplantation patients according to the clinical protocol. Allograft rejection was 
diagnosed on histological grounds and is graded from 0 to 4 with grade 0 being no 
rejection, and grades 1, 2, 3, and 4 denoting mild, focal moderate, difluse 
moderate, and severe rejection respectively. Grades 2 to 4 are routinely treated 
with augmented immunosuppression. Augmented immunosuppression in stable
106
patients consists of a standard high dose steroid taper. Severe and resistant 
rejection require admission and may require treatment with intravenous OKT3 
(Muronab CD3, Murine-derived monoclonal antibodies directed against the CD3 
antigen of human T lymphocytes).
Infection and its management
The following antimicrobial agents are routinely given to all heart transplant 
recipients:
1. Cefuroxime; 1.5 g during induction anaesthesia and 8 hourly after the operation 
for 3 doses.
2. Acyclovir; 200mcg orally 3 times daily for the first 6 weeks after transplantation 
as a prophylaxis for herpes simplex virus.
3. Septrin; 960 mg twice a week continued indefinitely as prophylaxis against 
pneumocystis pneumonii and toxoplasma gondii.
CMV-negative recipients who receive hearts from CMV positive donors receive 
CMV prophylaxis with ganciclovir. This is given by intravenous infusion in a dose 
of 5 mg.kg*1 twice daily for the first post-operative 2 weeks, reduced to 5 mg.kg*1 
once daily for 4 subsequent weeks.
Patients with symptoms or signs of infection (e.g. pyrexia) undergo standard 
screening tests for infection. These include a chest x-ray, specimens of blood and 
urine and a throat swab. Specialised tests such as broncho-alveolar lavage and CT 
scan are also used when indicated. The aim is to identify the causative organism 
before starting any anti-microbial therapy.
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4.3.2 Control Groups
A. Normal subjects
Normal controls were recruited from the medical and laboratory staff of Glasgow 
Royal Infirmary who volunteered to participate in the study.
Inclusion criteria - The inclusion criteria in this group were:
1. Age less than 65 years
2. No history of cardio-pulmonary disease
3. Normal spirometry and lung volumes
B. Patients undergoing coronary artery bypass grafting (CABG)
This group was studied to control for the possible effects of sternotomy and the 
cardio-pulmonary bypass procedure.
Inclusion criteria - The inclusion criteria for this group were:
1. Age less than 65 years
2. No history of primary lung disease
3. No symptoms or clinical signs of heart failure
4. No previous cardiac surgery
5. No co-existing valvular heart disease
Anaesthesia and CPB management: A standard anaesthetic regimen was 
followed. Anaesthesia was induced with midazolam, fentanyl and propofol, and 
intubation was performed after administration of a muscle relaxant (pancuronium or 
Vencuronium). Anaesthesia was maintained with propofol, fentanyl, and the muscle 
relaxant. CPB was performed with roller pump, membrane oxygenator, and arterial 
line filter. The CPB circuit was primed with 2 litres of Hartmann’s solution and
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systemic hypothermia was maintained at 28 C. Myocardial protection was achieved 
using cold potassium cardioplegia ( St. Thomas Solution), and topical cooling with 
iced saline.
Surgical technique and post-operative management: The heart was exposed by 
standard median sternotomy. The left internal mammary artery was used to 
construct one of the coronary artery bypass grafts in all patients with the saphenous 
vein being used for the remainder of the grafts. Post-operatively, all patients were 
transferred to the intensive care unit paralysed and under controlled mandatory 
ventilation. Patients were extubated when haemodynamically stable, usually within 
10 to 12 hours after the operation.
C. Patients undergoing mitral valve surgery
This group was included to control for the effects of pulmonary congestion on 
TLco and its components.
Inclusion criteria - The inclusion criteria for this group were:
1. Age less than 65 years
2. No history of primary lung disease
3. No co-existing coronary artery disease
Anaesthesia, CPB procedure, exposure of the heart, and the post operative 
management of mitral valve replacement patients were similar to that of CABG. 
The mitral valve was exposed through an incision in the left atrium.
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4.4 Study Protocol
4.4.1 Heart transplant patients
A. Pulmonary function Tests
Before the start of this study in October 1993, most heart transplant patients had 
resting pulmonary function tests and cardio-pulmonary exercise as part of their 
routine assessment for possible heart transplantation. From October 1993, all 
transplant patients performed pulmonary function and cardio-pulmonary exercise 
tests according to a protocol specifically designed for the purpose of this study. 
Pulmonary function tests were performed during the assessment for heart 
transplantation and serially after transplantation. In order to include a maximum 
number of heart transplant patients during the period of study and to evaluate both 
the short-term and long term changes in TLco following heart transplantation, 
patients were divided into 2 groups based on the interval between heart 
transplantation and the first post-transplant pulmonary function assessment. The 
early assessment group included all patients who were transplanted since the start 
of the study (October 1993), and in these, resting pulmonary function assessment 
was carried out at 6 weeks, 3 month and 6 months after transplantation, and at 6 
monthly intervals, thereafter, until 2 years after transplantation. Patients who were 
transplanted before October 1993, were previously assessed at 12 monthly intervals 
and this was changed so that they had their first assessment at 12 months after 
transplantation, and at 6 monthly intervals thereafter up to 2 years after 
transplantation. Beyond 2 years after transplantation, pulmonary function
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assessment was performed at yearly intervals for all patients until the end of the 
study period (March 1996).
For the purposes of validation and reproducibility studies, a random sample of heart 
transplant patients performed repeat measurements of TLco and its components 
either on the same day or at the same time on the next day. In addition, pulmonary 
function tests including TLco were repeated in patients awaiting heart 
transplantation for more than one year after their first assessment. The purpose of 
this was to assess the changes in lung function while on the waiting list for 
transplantation.
The appointments for pulmonary function assessment were co-ordinated with the 
transplant co-ordinator and the transplant clinic nurse on weekly basis. The tests 
were performed during patients' routine visit for the out-patient follow-up. The 
tests were performed in patients who were stable, ambulatory and who had not 
suffered from any recent respiratory symptoms. Patients who were admitted for 
treatment of rejection or systemic infection were not tested until at least 2 weeks 
after recovery.
During each assessment the following measurements were performed:
Lung volumes and forced ventilatory flows: These were performed first during 
each visit and included forced vital capacity (FVC), forced expired volume in the 
first second (FEVi), residual volume (RV) and total lung capacity (TLC).
TLco and its components: The TLco measurement was performed after 
spirometry and lung volume measurement. From August 1994, the measurement of
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TLco components (DM and Vc) was introduced as part of the assessment of the 
pulmonary diffusion characteristics to determine the contribution of each 
component to the observed decline in TLCo following transplantation.
B. Cardio-pulmonary exercise:
Cardio-pulmonary exercise tests were performed before transplantation, and at 6 to 
12 months after transplantation.
C. Broncho-alveolar Lavage (BAL) Study
This study was undertaken to determine the role of sub-clinical pulmonary CMV 
infection in the observed decline of TLco following heart transplantation. The study 
was conducted during the period between July 1994 and January 1996, and 
involved serial bronchoscopy with BAL in all consenting heart transplant recipients 
during the first 3 months following transplantation. The procedure was discussed 
with patients towards the end of the first week after transplantation and if they 
agreed to participate the procedure was performed at 2, 6 and 12 weeks after 
transplantation. The protocol was approved by the Ethics Committee of the 
hospital and all patients gave consent before each test. The contra-indications to the 
test in these patients were acute rejection requiring admission for treatment, 
haemodynamic instability, and significant arrhythmias. Specimens obtained from 
BAL along with blood, urine and throat swabs were sent to the Regional Virology 
Laboratory at Ruchill Hospital for tests of CMV activity. In addition, one BAL 
specimen was sent the Department of Cytology in the Royal Infirmary for 
cytological evidence of CMV infection.
D. Clinical and laboratory data
The case notes of all heart transplant patients were regularly reviewed and the 
relevant data were retrospectively recorded in specifically prepared data sheets.
1. Clinical data: This included the patient characteristics, cardiac diagnosis, 
primary indication for transplantation, co-existing diagnoses, medications and pre­
operative haemodynamic data. It also included CXR findings, haemoglobin and 
functional status at the time of pulmonary function assessment. Smoking status was 
based on history obtained during the first pulmonary function assessment and 
patients were categorised into current smokers, smokers who had stopped smoking 
(ex-smokers), and those who never smoked (non-smokers). Ex-smokers were 
defined as those who had stopped smoking at least one year before the first 
pulmonary function assessment. The number of pack-years of smoking (average 
daily consumption of cigarettes multiplied by the number of years smoked) for 
current smokers and ex-smokers, and the length of time since stopped smoking for 
ex-smokers were recorded.
2. Peri-operative data: Peri-operative events that might interfere with lung 
function were also recorded. These included the duration of surgery, cardio­
pulmonary bypass, mechanical ventilation, and the donor heart total ischaemic time.
3. Post-operative pulmonary complications: These included any documented 
lower respiratory tract complication occurring within the first 6 weeks after 
transplantation. Analysis was confined to this period because most of pulmonary 
complications after transplantation occur within this interval (42). In addition, and
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as detailed in chapter'J, TLCo decline was evident on the first assessment at 6 
weeks after transplantation. For each episode, the interval after transplantation, 
diagnosis, method of diagnosis, treatment, and the outcome were recorded.
4. Endomyocardial biopsy data: The results of all endomyocardial biopsies were 
reviewed and the grade for each biopsy and its interval were recorded up to one 
year after transplantation. An episode of rejection was defined as grade 2 or 
greater.
5. Cyclosporin levels: These included all routine cyclosporin levels up to one year 
after transplantation. For each measurement, the time from transplantation and 
whole blood trough levels were recorded.
6. Cytomegalovirus data: In addition to the Broncho-alveolar Lavage Study, data 
from surveillance specimens for CMV infection during the first year after 
transplantation were collected for all patients. For each episode of CMV infection, 
the interval, presentation, affected organs, and treatment if required were recorded. 
The pre-operative CMV status of both the donor and the recipients were also 
recorded.
4.4.2 Control groups
A. Normal subjects
All normal subjects performed one base-line measurement of lung function 
including TLco and its sub-divisions and were asked to repeat the measurements at 
variable intervals from the base-line.
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B. Coronary artery bypass and mitral valve surgery
Coronary artery bypass graft and mitral valve replacement patients were recruited 
from the weekly theatre list. They were interviewed on the day before the operation 
and if the inclusion criteria were satisfied and the patients agreed to participate in 
the study, resting lung function tests, including TLco and its sub-divisions, were 
performed on that day and at 6 weeks after the operation (at the routine post­
operative follow-up clinic). In a small number of these patients additional 
measurements were made at one week and 3 months after the operation.
4.5 Data handling and analysis
All data were sampled and analysed using the SPSS statistical package (SPSS for 
Windows, Release 6.0, SPSS Inc. USA). Details of the different statistical methods 
used are presented in the respective chapters. The following statistical methods 
were applied throughout the process of analysis as appropriate:
1. Checks for normality: All relevant data were checked for normality of 
distribution before applying any statistical test based on this assumption. Unless 
otherwise stated, results were presented as mean +/- standard error of the mean 
(Mean +/- SEM).
2. Comparison between means: For normally distributed data, a two 
independent-sample (unpaired) Student’s t-test was used for comparison 
between 2 means for separate groups and a paired Student’s t-test was used for 
comparison between 2 means from the same group (e.g. TLco before and after 
heart transplantation). When there were more than 2 means from separate 
groups, comparisons were made using the one way analysis of variance.
Assessment of the relationship between various factors: The relationship 
between 2 or more variables was assessed using the Pearson’s correlation 
coefficient and stepwise multiple linear regression analysis.
Statistical significance: A level of p < 0.05 was considered significant.
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CHAPTER 5 
LUNG FUNCTION - MATERIALS AND METHODS
5.1 TLco and its components
5.1.1 Equipment and quality control
Between January 1992 and August 1994, TLco measurements were performed 
using a standard single breath transfer test system (Transfer Test, Model B, P.K. 
Morgan, Kent, England). From August 1994 onwards, measurements were made 
using new transfer test equipment (Transflow Test, Model 540, P.K. Morgan, Kent, 
England). The calculations used to determine TLco, Kco, and alveolar volume are 
identical in both systems. In the Transflow model, volume measurements, gas 
analysis, and all calculations were performed automatically using a software system 
which conforms to the recommendation of the British Thoracic Society and the 
Association of Respiratory Technicians and Physiologists (87). In addition, the 
Transflow model has facilities to estimate the individual components of TLCo using 
the classic Roughton and Forster equation (5). Before changing to the Transflow 
model, the concordance between the 2 systems was assessed in a group of patients 
with various cardio-pulmonary disorders (chapter 6).
The Transflow model consists of the main transfer test instruments, video display 
unit, computer keyboard, and pure oxygen administration kit comprising a 6-litre 
anaesthetic bag, controlling tab and connecting tubing. The main transfer test
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instruments consist of the subject breathing valve, a pneumotachograph, gas 
analysers, absorption chamber (soda lime for CO2 absorption, and calcium chloride 
as a desiccant), and metalised bags for inspiratory and expiratory gas samples. The 
breathing valve includes a mouthpiece port for connecting the subject and 4 
additional ports. One of these ports is controlled manually by a ring-sealed plug and 
it is kept occluded during the transfer test. The remaining 3 ports are controlled by 
pneumatic valves which allow rapid switching of the breathing gas to the 
appropriate port. One of these ports opens to room air (or the pure oxygen 
administration set in the case of high oxygen measurement). Of the remaining two 
ports one opens to the bag of inspired gas mixture and the other opens to the bag 
which collects the post-dead space alveolar gas sample. The dead space of the 
breathing valve is 170 ml and this includes 30 ml due to the dead space of the 
disposable filter fitted to the mouthpiece for each subject. Gas analysis was 
established by an infra-red gas analyser for CO, a thermal conductivity meter for 
helium and a polarographic analyser for oxygen.
Gas analysers were calibrated before each measurement with 2 certified gas 
mixtures (BOC Special Gases) by an automatic calibration routine. The 2 gas 
mixtures correspond to the actual mixtures used during the TLco measurements. 
The pneumotachograph was calibrated daily with a 3-litre syringe stroked 10 times 
at variable emptying velocities (from 15 L.s'1 to 0.1 L.s'1). Verification of the 
volume calibration was performed using the same 3-litre syringe. In addition, TLco, 
Kco and the alveolar volume were routinely performed on alternate days by one of
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the laboratory staff to ensure the integrity of the system and the repeatability of 
measurements.
5.1.2 Procedure
A. Standard TLCo measurement:
Before each test was performed, each subject was carefully instructed in all the 
required manoeuvres. The following points were emphasised:
• Rapid inhalation to total lung capacity
• Breath holding at full inspiration without straining
• Rapid exhalation without interruption
After preparing the system, the subject wearing a nose clip was connected to 
breathing valve with a mouthpiece fitted with a filter (Spiroguard, Air Safety, Ltd.). 
After a few tidal breaths, the subject was instructed to breathe out as fully as 
possible, and at full expiration, the subject was connected to the test gas mixture 
and asked to breathe in as fully as possible. He was then encouraged to hold this 
breath for about 10 seconds, without straining, after which he was asked to breathe 
out rapidly without interruption. The contents of the test gas were as recommended 
by the European Respiratory Society, and consisted of CO = 0.28 %, helium (He) = 
14 %, O2 = 18 % with the remainder nitrogen (41). After a pre-set wash out 
volume of 750 ml, the expired air was directed to the expired gas bag with a sample 
collection time of 1.5 seconds. On completing the expiration, the subject was 
disconnected from the breathing valve and gas analysis started automatically 
followed by a display of the test results which were then inspected for acceptability.
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The test was then repeated after a 5 minute interval. The criteria for acceptable 
measurements were:
1. Inspiration should be rapid and the inspired volume should be at least 90 % of 
the previously measured vital capacity (obtained during ventilatory flow 
measurements)
2. Breath holding should be maintained at full inspiration, and the final breath-hold 
time should be between 9 and 12 seconds
3. The values of TLco and Kco in 2 technically acceptable measurements should be 
within 10 % of each other
The means of the 2 technically acceptable and repeatable TLco and Kco values were
reported as the subject’s TLco and Kco-
B. Measurement of TLco components
Duplicate measurements of single breath TLco were made using 2 different test gas 
concentrations. The low oxygen gas mixture was that used for standard TLCo 
measurement described above. The high oxygen gas mixture consisted of CO =
0.28 %, He = 14 %, and 02 = 85.72 %. The sequence of measurements was in the 
following order:
TLco at low oxygen concentration was measured in duplicate as previously 
described. The subject was then allowed 5 minutes of room air breathing followed 
by another 5 minutes of pure oxygen breathing while wearing a nose clip. The 
single breath TLco at high oxygen concentration was then measured using the same 
steps described for the standard TLco measurement, except for the use of the high 
oxygen mixture in the inspired gas mixture. The steps of room air breathing and 
pure oxygen breathing were repeated and a second high oxygen TLco measurement
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was made. Thus, the interval between the sets of low and high oxygen 
measurements and between each of the high oxygen measurements was at least 10 
minutes.
5.1.3 Calculations
A. TLco calculations:
The single breath TLCo was calculated using the basic Krogh’s equation (50) as 
described by Cotes (2) and recommended by the European Respiratory Society 
(41). The tension of CO in the pulmonary blood was assumed to be zero.
TLco (mmol.min^.kPa'1) = V a ,  d t p s  x  b/t x log™ ( F a c o o  / FAcor)
where:
•  V a ,  d t p s  is the effective alveolar volume corrected to body temperature and 
pressure saturated with water vapour,
• b is a composite factor with a value of 53.6 reflecting the conversion from 
natural to decimal logarithm, from seconds to minutes, from millilitres to 
millimoles and from millilitres STPD to litres BTPS,
• t is the effective breath holding time in minutes, and
• Facoo and FAcof are the fractional alveolar concentration of CO, at the start and 
the end respectively of the breath holding period.
It is assumed that helium (He) and CO are uniformly distributed throughout the
lungs so that the initial alveolar concentration of CO ( F a c o o )  can be calculated
from the following relationship:
F a ,COO -  F /  CO X  ( F a i e /F /H e )
where:
• F/co is the known inspired concentration of CO and
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• F£He and Fme are the known fractional concentration of helium in the expired 
and inspired gas samples respectively.
The effective alveolar volume (Va) is calculated as follows:
VA = K x (V! - VDan - Vds) X  ( F/ne / F ^ )
where:
• Vi is the inspired volume at®TPS,
• K is a constant to correct for the change in the concentration of expired helium 
due to absorption of carbon dioxide before analysis with a value of 1.05,
• VDan is the anatomical dead space ( 2.2 x body weight in kilograms) and
• VdS is the instrument dead space.
The transfer coefficient (Kco) was calculated from TLco and Va 
Kco (mmol.min'1.kPa1.L 1) = TLCo/VA
B. Calculation of TLco components:
The means of each of the duplicate values of TLco with their corresponding 0 
values obtained at low and high alveolar oxygen tensions, were used to derive the 
diffusing capacity of the alveolar-capillary membrane (D m) and the pulmonary 
capillary blood volume (Vc) using the classic Roughton and Forster equation (5);
l/TLco=l/DM+l/0Vc
where:
• 0Vc is the “diffusing capacity” of the total mass of the erythrocytes in the
pulmonary capillary blood available for gas exchange at any instant.
• 0 is the standard rate at which one ml of blood takes up the gas CO, and its
value depends on the prevailing alveolar oxygen tension and the concentration 
of haemoglobin in blood (5,58).
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The values of 0 were derived from the original data of Roughton and Forster
o
obtained from in vitro CO uptake in a suspension of human erythrocytes at 37 C 
(5). This parameter was first reported in ml of CO per minute per ml of blood at an 
average haemoglobin of 14.6 g.dL'1. After correction for actual haemoglobin blood 
concentration and conversion to SI units, the values of 0 at different alveolar 
oxygen partial pressures were obtained using the equation described by Cotes (2);
1/0 = (« + 0 x Pco2) /([Hb] x {1- Seco/100})
The various terms and parameters appearing in this equation are described below:
1. a  - is a constant reflecting the diftusion barrier of the erythrocyte and its value 
depends on the value chosen for the partition coefficient between the membrane 
of the red blood cell and its interior (X). Roughton and Forster demonstrated in 
vitro that X has a wide range of values with a range between 1.5 and infinity 
(5). However, most studies using the Roughton and Forster model assume the 
red cell membrane to have infinite permeability (X = infinity), and at this value 
of X, a  = 1.0 min.kPa. ml of blood.mmol.'1 of CO (2).
o
2. ft - is a temperature dependent factor. At temperature of 37 C, p = 0.134 
min.kPa. ml of blood.mmol.’1 of CO.
3. Pc0 2  - is the mean capillary O2 tension assumed to be 0.67 kPa (5 mmHg) less 
than the alveolar oxygen tension (Pao2) (5). Pao2 was derived by analysis of 
post-dead space alveolar sample collected after the breath hold period; PAo2 = 
Feo2 x (PB - Ph2o), where FEo2 is the fractional expired O2 concentration, Pb is 
the atmospheric barometric pressure, and Pmo is the water vapour pressure.
4. [Hb] - is the haemoglobin concentration as a fraction of normal (the standard 
normal haemoglobin was defined as 14.6 g.dL’1). To obtain conventional TLco 
values, not corrected for haemoglobin, it was assumed that all subjects had 
normal haemoglobin concentration (14.6 g.dL'1). Where indicated, the effect of 
haemoglobin variability on TLco values was determined using a version of the
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classic Roughton and Forster equation as described by Cotes and recommended 
by both the European Respiratory Society and the American Thoracic Society 
(41,88);
1/TLco = 1/Dm + l/([Hb] x 0VC) 
where [Hb] is the haemoglobin concentration of the subject as a fraction of 
normal (i.e. actual haemoglobin divided by 14.6).
5. Scco - is the mean percentage saturation of haemoglobin with CO (assumed to 
be 1.5 %) (2).
The process described for TLco measurement at high and low oxygen 
concentrations yields duplicate values for TLco at each of the oxygen 
concentrations. The mean of each of these duplicate values with the means of their 
corresponding 0 values were used for the determination of Dm and Vc by solving 
the Roughton and Forster equation graphically (Figure 5.1). A plot of 1/TLco 
against 1/0 yields a straight line which intersects the ordinate 1/ TLco at point A. 
At this point, the value of 1/0 equals zero and therefore the value of 1/ TLCo at 
point A equals 1/Dm- The triangular area above the intersection represents a plot of 
l/0Vc against 1/0. Vecan therefore be obtained by dividing l/0Vcby 1/0 (i.e., 1/Vc 
= BC/AB), which is the slope of the line AC. In short, the intersect of the plotted 
line with 1/TLco ordinate equals 1/Dm and its slope equals 1/Vc.
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Figure 5.1 The graphical derivation of TLco components (D m and Vc) using the 
Ruoghton and Forster method
VTLco=1/Dm + 1/0Vc
l /T L Co
High 0 2 mixture ^
1 C
Standard 0 2 mixture
~0~~0 \ N C = BC/AB 1 i/0v(
A Tl
i
Vc = AB/BC 1
B
1/0
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5.1.4 Normal values
Results of the diffusion parameters were expressed in absolute values and as 
percentage of predicted. Predicted normal values for TLco and Kco were 
determined using the European Community for Steel and Coal equations (ECSC) 
which were recommended by the European Respiratory Society (41) and endorsed 
by both the British Thoracic Society (BTS) and the Association of Respiratory 
Technicians and Physiologists (87). The predicted values of DM and Vc were taken 
from Cotes (49). The lower limit of normal was defined by the lower 5th percentile 
of the reference population. Mathematically, this was obtained as follows:
Lower limit of normal = Predicted value - 1.64 x RSD, where RSD is the residual 
standard deviation of the prediction equation and 1.64 RSD represents the limit at 
90 % confidence interval (41,87).
5.2 Static and dynamic lung volumes
5.2.1 Equipment and procedures
Standard spirometry and lung volumes were measured using a body 
plethysmograph (PK. Morgan Ltd, Kent, UK). Measured variables included vital 
capacity (VC), forced vital capacity (FVC), force expiratory volume in one second 
(FEVi), FEVi/FVC ratio, residual volume (RV), and total lung capacity (TLC). 
Quality control and procedures of testing were performed according to formal 
guidelines established by the European Respiratory Society (ERS) (169) and 
recommended by the British Thoracic Society (BTS) and the Association of 
Respiratory Technicians and Physiologists (87). Results of at least 3 satisfactory
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manoeuvres were analysed and the reported values were the highest value for FEVi 
and FVC and the mean of the 3 results for each of the remaining indices.
5.2.2 Calculations and normal values
Static and dynamic lung volumes were compared with normal predicted values of 
ECSC which were recommended by the ERS and BTS (87,169), and results were 
expressed as a percentage of predicted. The lower limit of normal for each index of 
lung function was defined as described for TLco (87).
5.3 Cardio-pulmonary exercise
5.3.1 Equipment
Symptom-limited exercise tests were performed using an electrically braked bicycle 
ergometer with the patient breathing through a low dead space, low resistance 
valve box. The valve box incorporates a flexible pneumotachograph on the inspired 
limb for the measurement of inspired minute ventilation (Flexiflow, PK Morgan 
Ltd, Kent, UK). The expired limb is fed through a mixing chamber from which 
samples of expired air are analysed for the fractional concentrations of carbon 
dioxide and oxygen by an infra red spectrometer and zirconium cell analyser, 
respectively (Benchmark System, PK Morgan, Kent, UK). Gas analysers were 
calibrated with certified gas mixtures, and the pneumatograph system was 
calibrated and verified using a 3-litre calibration syringe before each exercise test.
Arterial blood gas values were monitored throughout exercise testing using a
o
transcutaneous system (TCM3, Radiometer Ltd, Copenhagen) heated to 45 C with 
the electrode attached to the flexor aspect of the forearm (170). The use of the
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transcutaneous system during exercise in patients with dyspnoea due to various 
cardio-pulmonary disorders has been previously validated in our laboratory 
(171,172).
5.3.2 Procedure
Before each test, subjects were seated in a comfortable chair and a brief history 
was taken aimed at identifying any recent respiratory illnesses or cardiac 
decompensation and estimating the functional status at the time of assessment. 
After explaining the procedure, a transcutaneous electrode was attached to the 
flexor surface of the forearm and standard continuous 12-lead electrocardiogram 
monitoring was started. Following a period of an in-vivo calibration using a sample 
of arterial or arterialised ear lobe capillary blood, subjects were initially monitored 
for 2 minutes at rest whilst seated on the bicycle ergometer with a nose clip in 
place. They were then instructed to cycle with no additional load for 2 minutes. 
Then the work-load was automatically increased by increments of 25 watts every 2 
minutes until a symptom limited-maximum and the primary symptom limiting 
exercise was recorded. Blood pressure was measured using standard cuff 
sphygmomanometer at the end of each stage. In addition, Borg scale scores were 
recorded for both dyspnoea and leg fatigue. The criteria for terminating the 
exercise before patients reached a maximum symptom-limited point were: 
ischaemic changes on ECG, ventricular arrhythmia, systemic hypotension (resting 
systolic BP < 90 mm Hg or falling BP during exercise), or severe systemic 
hypertension (systolic BP > 220 mm Hg).
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5.3.3 Calculations and normal values
Throughout each test, minute ventilation (Ve), oxygen consumption (VO2 ), and 
carbon dioxide production (VCO2 ) were measured by on line ventilation and 
expired gas analysis (PK Morgan Ltd, Kent, UK) using standard equations (173).
The ventilatory anaerobic threshold on exertion was calculated by the curve fitting 
method, using a plot of oxygen consumption against carbon dioxide production 
(174).
The transcutaneous values of oxygen (tcPC^) and carbon dioxide (tcPCC>2 )
tension were used to calculate alveolar-arterial oxygen gradient (P^a-slP j ) and
dead space to tidal volume ratio (V d/V t ) using standard equations (173). The 
following cardio-respiratory responses to exercise were also derived (175):
Maximum voluntary ventilation (M W ) = 37 x FEVi.
Ventilatory response at maximum exercise = the change in minute ventilation 
(AVe) divided by the change in carbon dioxide output (AVCo2)-
Heart rate response (beats.L*1) = the change in heart rate (AHR) divided by the 
change in oxygen uptake in litres (AV02).
Oxygen pulse (ml.beats1) at maximum exercise = V02 in millilitres at maximum 
exercise divided by the maximal heart rate.
Maximal exercise values were compared to the predicted normal values of Jones 
and Campbell (175).
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5.4 Broncho-alveolar lavage (BAL) study
5.4.1 Procedure
On the day of the BAL, consenting patients were asked to take a light breakfast no 
later than 8 o’clock in the morning, after which they take nothing orally until at 
least 3 hours after the procedure. They were admitted as day cases to the heart 
transplant ward. During admission a written consent was obtained and the required 
specimens were taken. These included:
• 10 ml of clotted venous blood
• 10 ml of heparinised venous blood
• A urine specimen in a universal container
• A throat swap placed in a standard viral transport medium
BAL was performed as part of the routine Tuesday afternoon bronchoscopy list 
starting at 13:30 hours with the study patients placed first on the list. The 
procedures of bronchoscopy and BAL were performed using standard techniques 
(176,177). During the procedure, all patients were given oxygen (2 L. min‘l), and 
oxygen saturation and heart rate were monitored using continuous pulse oximetry. 
Patients were pre-medicated with intravenous atropine (600 meg) and diazepam (5- 
10 mg) with or without fentanyl (25-100 meg) just before the procedure. Local 
anaesthesia was initiated using 4 % topical lignocaine spray applied to the nose and 
throat. Fibreoptic bronchoscopy was performed with an Olympus T10 
bronchoscope. After lubricating its tip with lignocaine gel, the bronchoscope was 
inserted via the transnasal route. Additional local anaesthesia was obtained by 
instilling 2 ml aliquots of 4 % lignocaine through the bronchoscope channel on to
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the vocal cords and the bronchial tree as necessary, keeping the total dose of 
lignocaine below 800 mg. BAL was performed by wedging the tip of the 
bronchoscope in a segment of the right middle lobe, and 5 to 6 30-ml aliquots of 
sterile warm normal saline were instilled. Each aliquot was immediately aspirated 
by gentle suction, and BAL was directly received into 3 sealed sterile universal 
containers (15 - 20 ml each) numbered sequentially. The first BAL aliquot was 
considered contaminated with lignocaine and was not used, and the remaining 2 
aliquots were used for viral diagnostic tests of CMV activity. After the procedure, 
all patients were reviewed in the ward, and they were discharged when completely 
alert and had had a light meal.
5.4.2 Specimens and diagnostic tests
Specimen were sent to the virololgy laboratories within one hour of their collection 
and were processed in the same day.
1. Serology
CMV IgM and complement fixation tests were performed on 10 ml clotted blood.
2. Direct Early Antigen Fluorescent Foci Test (DEAFF)
DEAFF is used as a rapid test for detection of CMV in various types of clinical 
specimens. In conventional tissue cultures, the detection of virus depends on the 
identification of a specific cytopathic effect in the infected cell, and this takes about 
6 to 8 weeks to produce a definitive result (178). DEAFF can detect CMV in shell- 
vial cultures before the development of the cytopathic effect (CPE) with sensitivity 
and specificity approaching that of the conventional CMV cultures (179). In this
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test, immediate early proteins of CMV can be detected in the nuclei of MRC-5 cells 
by immunofluorescence within 24 to 48 hours of CMV infection, well before CPE 
becomes apparent. DEAFF was performed on BAL specimens, throat swab, urine, 
and buffy coat cells. Buffy coats (leukocyte suspensions) were prepared by gradient 
density centrifugation using 10 ml heparinised blood layered onto a polysucrose 
solution.
3. CMV cultures:
Conventional CMV cultures on human fibroblast cells were also routinely 
performed on BAL, throat swabs, and the buffy coats.
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CHAPTER 6 
VALIDATION AND REPRODUCIBILITY STUDIES
6.1 Introduction
In contrast to standard single breath TLco measurement, there are no specific 
guidelines for the measurement of its components (41,65). Although many aspects 
are covered by the guidelines for the standardisation of single breath TLco, several 
technical questions remain to be answered. These include the effect of CO back 
pressure at high alveolar oxygen tensions, the sequence of oxygen mixtures used 
and the time interval between repeated attempts of measurements at each of the 
inspired oxygen concentrations. As noted in chapter 2, repeated measurements of 
TLco can increase the level of carboxyhaemoglobin, but this is usually not 
significant especially if the number of TLco measurements is limited to a maximum 
of 5 per session (41,59). In heavy smokers, especially when using high inspired 
oxygen concentration, the effects of CO back pressure and carboxyhaemoglobin 
(CO-Hb) may be significant and a correction for these effects is recommended 
(41).
In order to minimise the effects of CO back pressure and CO-Hb during the 
measurement of TLco components, Cotes recommended starting with the high 
oxygen mixture and allowing at least 30 minutes between each measurement (2). 
Since at least 4 measurements (2 at each of the inspired oxygen mixtures) are 
required for reproducible results, a single test will take at least 2 hours. This 
recommendation is based on theoretical considerations and has not been evaluated
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against shorter time intervals. In addition, investigations involving the measurement 
of TLco components rarely state the sequence of measurement steps or the time 
interval between repeat measurements. In the few studies which provide 
information, measurement was started with the standard oxygen mixture and the 
time interval between measurements was 5 to 10 minutes (32,70,93).
As a result of these uncertainties, it was necessary to perform some preliminary 
studies on the measurement of TLco components. The general purpose of these 
studies was to validate the methods, check the reproducibility of the results and 
compare results obtained in normal subjects with published predicted normal 
values.
6.2 Study 1: Validation of the Transflow model against the Transfer test 
model B
Between January 1992 and August 1994, TLco measurements were performed 
using a standard single breath transfer test system (Transfer Test, Model B, P.K. 
Morgan, Kent, England). From August 1994 onwards, measurements were made 
using new transfer test equipment (Transflow Test, Model 540, P.K. Morgan, Kent, 
England).
Aim:
To validate the use of the Transflow Test by comparing its performance with the 
Transfer Test, Model B.
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Subjects and Methods:
In July 1994, 42 consecutive patients referred from respiratory and general medical 
clinics for pulmonary function tests were studied. The group consisted of patients 
with a range of cardio-pulmonary disorders of varying degrees of severity and 
included heart transplant patients.
TLco and Kco values were obtained for each patient using the 2 systems in 2 
separate sessions. The 2 sessions were allocated randomly and were separated by at 
least 30 minutes during which spirometry and lung volume measurement were 
performed. The technique of measurements and calculations were identical in both 
systems and were as described in chapter 5.
The degree of agreement between results obtained by the 2 systems was assessed 
using Bland and Altman statistical analysis (180).
Results:
Table 6.1 shows the results of TLco and Kco using the 2 transfer test systems. 
Using Model B, mean TLco and Kco were 7.54 and 1.43 mmol.min.'1kPa'1 
respectively, with a wide range of values for each, reflecting the wide spectrum of 
patients. The corresponding values using the Transflow Model were almost 
identical. In addition, For each individual, the difference between the duplicate 
values of both TLco and Kco were within 10 % of their mean.
135
Table 6.1: Summary statistics of TLco and Kco using the 2 transfer test systems
Mean SD SEM Range
TLco Model B 7.54 3.21 0.49 1.9-14.7
Transflow 7.49 3.17 0.49 o1
Kco Model B 1.43 0.41 0.06 0.44-2.21
Transflow 1.42 0.40 0.06 0.41-2.11
Figure 6.1 is a scatterplot of individual TLco values as measured by the 2 systems. 
TLco values obtained by the 2 systems were highly correlated (r = 0.99, p<0.001) 
with similar results for Kco values (Figure 6.2).
Figure 6.1: Scatterplot of TLco values obtained by the 2 transfer test systems 
(Transflow Model and Transfer test, Model B)
O ^ 4 2
r = 0.99, pO.OOl
TLco by Trasnfer Test Model B (mmol.min.-1 kPa'1)
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Figure 6.2: Scatterplot of Kco values obtained by the 2 transfer test systems 
(Transflow Model and Transfer test, Model B)
O ^ 4 2
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Trasks
TLco by TraiSfer Test Model B (mmol.min.*1 kPa'1)
Figure 6.3 is a plot of the difference between the TLco results obtained by the 2 
systems against their mean. There was a excellent agreement between the values 
obtained by the 2 systems. The mean difference was 0.05 mmol.min.^kPa'1 with 
very small limits of agreement (- 0.03 and 0.13). For Kco (figure 6.4), the mean 
difference was 0.01 mmol.min.^kPa'1, and limits of agreement were 0.00 to 0.02.
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Figure 6.3: Plot of the difference between TLco values obtained by the 2 transfer 
test systems against their mean
3.0 n
2 .5 «
2.0 .
<D ^
- mean +2SD
meaij, □ m
0 .0 1:
mean - 2SDP Q
- 2 .0 1
- 3.0
Mean TLco (mmoLmin.1 kP a1)
Figure 6.4: Plot of the difference between Kco values obtained by the 2 transfer 
test systems against their mean
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Comments
The results show good agreements between TLco and Kco results obtained by the 2 
systems across a wide range of values in both parameters. In addition, the 
difference between values obtained by the 2 systems in individual patients is 
comparable to the expected intra-individual variability of repeated measurements 
using the same system in one session (41). It can, therefore, be concluded that the 
Transflow system gives similar results to those obtained by the Transfer Test Model
B.
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6.3 Study 2: The sequence of inspired oxygen mixtures
As mentioned previously, the usual sequence of inspired oxygen mixtures used in 
the determination of TLco components starts with the standard oxygen mixture 
followed by a high oxygen mixture. However, the use of high inspired oxygen 
concentration shortly after exposure to CO in the standard oxygen mixture, can 
potentially increase both CO tension in the pulmonary capillaries and the 
concentration of carboxyhaemoglobin (CO-Hb) in blood. As both CO back 
pressure and CO-Hb are assumed to be negligible in the calculations of TLCo and its 
components, a significant increase in either of them could result in underestimation 
of TLco (41,59). If this effect were significant, a protocol starting with standard 
oxygen mixture would consistently yield results lower than that of a protocol 
starting with the high oxygen mixture.
Aim
The aim of this study was to determine the effect of the sequence of inspired 
oxygen mixtures on the results of TLco and its components.
Subjects and Methods
Ten randomly selected heart transplant recipients were studied. All patients 
performed 2 sets of TLco and components determinations. Three patients were life­
long non-smokers and 7 were ex-smokers ( stopped smoking for more than one 
year). For each patient, the 2 sets of measurements were separated by at least one 
hour and were performed in random order. One set was started with the standard
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inspired oxygen concentration and the other with the high oxygen concentration. 
Apart from this difference, the procedures and timing of the different stages of 
measurements were identical and were as described previously (chapter 5).
The degree of agreement between results obtained by the 2 protocols was assessed 
using Bland and Altman statistical analysis (180).
Results
Table 6.2 shows that the 2 sequences of measurements yielded results with virtually 
identical means.
Table 6.2: Mean values of TLCo and its components obtained by the 2 ‘sequence’ 
protocols
High O2 first
Mean (SD) 
Standard 0 2 first ; Difference
TLco (mmol.min.1kPa‘1) 5.14(1.12) 5.13(1.15) 0.01 (0.29)
Dm (mmol.min^kPa’1) 13.02 (3.99) 13.18(3.72) -0.16(0.59)
Vc (ml.) 42.62 (16.89) 42.22 (16.65) j 0.40(1.47)
Figure 6.5 displays plots of the difference between the duplicate values of TLco and 
its components obtained by the 2 protocols against their means. Using Bland and 
Altman analysis, the limits of agreement between duplicate results were: - 0.57 and
0.59 mmol.min.^kPa"1 for TLco, - 134 and 1.02 mmol.min.'1kPa'1 for DM, and - 
2.54 and 3.34 ml. for Vc. Inspection of individual results on the graphs, shows that
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the means of difference between duplicate measurements are nearly zero with 
similar scatter above and below the mean for all parameters.
Figure 6.5: Plots of the difference between duplicate values of TLCo and its 
components obtained by the 2 ‘sequence’ protocols against their mean
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Comments
The results of this study suggest that in non-smokers and ex-smokers there is no 
advantage of starting with high inspired O2 mixture compared to starting with the 
standard mixture. The lack of any significant difference between results of the 2 
protocols, under the conditions of measurement, indicates that there is no 
differential effect of the sequence of oxygen mixtures on CO back pressure and 
CO-Hb. However, an equally significant effect of both methods on CO back 
pressure and CO-Hb cannot be ruled out.
6.4 Study 3: The time interval between measurements 
Aim
To compare the time interval between measurements used in the studies of this 
thesis during the estimation of TLco components (short interval protocol) with that 
recommended by Cotes (long interval protocol).
Subjects and Methods
Ten normal volunteers performed TLCo measurement at high and standard inspired 
oxygen concentrations using 2 different time protocols, in random order. In the 
short protocol, the time intervals between measurements within the same session 
were:
• 5 minutes between each of the measurements at standard O2,
• 10 minutes between the sets of measurements at standard and high O2 and
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• 10 minutes between each measurement at high O2 concentration.
The corresponding time intervals for the long protocol were: 5 minutes, 30 minutes 
and 30 minutes. The total duration of a session was about 30 minutes for the short 
protocol and about 70 minutes for the long protocol. The 2 sessions were 
performed on the same day, but separated by at least one hour. All subjects were 
non-smokers and had no history of any cardio-respiratory disease. The degree of 
agreement between results obtained by the 2 protocols was assessed using Bland 
and Altman statistical analysis (180).
Results
Table 6.3 shows the summary statistics of TLCo and its components obtained by the 
2 protocols. The mean values of duplicate measurements were identical for TLco 
and Dm and nearly identical for Vc. Figure 6.6 displays scatterplots of the results of 
individual subjects using the 2 protocols. The values obtained using the 2 timing 
protocols were strongly correlated for all parameters with all points being close to 
their regression line.
Table 6.3: Mean values of TLco and its components obtained by the 2 ‘interval’ 
protocols
Mean (SEM)
Short interval Long interval Difference
TLco (mmol.min.^kPa'1) 8.0 8.0 0.0
Dm (mmol.min.'1kPa'1) 18.4 18.4 0.0
Vc (ml.) 61.8 61.7 0.1
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Figure 6.6: Scatterplots of duplicate results from individual subjects obtained by 
the 2 ‘interval’ protocols
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Figure 6.7 shows plots of Bland and Altman analysis. There was good agreement 
between the values obtained by the 2 protocols for all parameters. The limits of 
agreement between duplicate results were: - 0.5 to 0.5 mmol.min'VkPa'1 for TLCo, 
-1.1 to 1.1 mmol.mmVkPa*1 for DM and -3.2 to 3.5 ml for Vc. There was no 
systematic difference between duplicate results of individual subjects (equal points 
above and below the line of mean difference which was zero for TLco and DM and
0.1ml for Vc).
Comments
Under the conditions of measurement described in chapter 5, the use of 10 minute 
intervals between successive manoeuvres during the estimation of TLco and its 
components is practical and provides results similar to those obtained when longer 
intervals are used.
Figure 6.7: Plots of the difference between duplicate values of TLco and its 
components obtained by the 2 ‘interval5 protocols against their mean
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6.5 Study 4: Reproducibility of the measurements of TLco and its 
components
Aim
To determine the reproducibility of results of TLco and its components as measured 
by the method applied in the studies of this thesis
Subjects and Methods
As part of routine quality control assurance, TLco and its components were 
routinely measured in one of the laboratory staff on alternate days (biological 
control). Repeat measurements of these parameters were also performed by a 
randomly selected group of subjects on 2 consecutive days. The group consisted of 
9 heart transplant recipients and 5 normal volunteers.
Methods of measurement were as described in chapter 5. Variability in 
measurement in each of the diffusion parameters was assessed in percentage terms 
as the coefficient of variation (C V), where:
• For multiple measurements in one subject
CV = 100 x SD of results / mean of largest and smallest values
• For 2 measurements in several subjects
CV = 100 x SD of the difference / mean of both measurement means
Results
Figure 6.8 displays plots of results of 12 measurements of TLco and its components 
performed by one subject on alternate days over a period of month. All values were 
within 10% of their means and there was no evidence of drift with time. The
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coefficients of variation of these measurements were 2.5%, 2.7%, 3.0% and 2.9% 
for TLco, Kco, Dm and Vc, respectively.
Figure 6.8: Variability of TLco and its components over 12 measurements 
performed by one subject on alternate days
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Sequential number of measurements
Table 6.4 shows summary statistics of the duplicate measurements performed in the 
14 subjects. The coefficients of variation were 5.6, 6.6, 8.7 and 8.9 for TLco, Kco, 
Dm and Vc, respectively. The variability of individual values is shown in figure 6.9. 
There is no obvious difference in the variability between heart transplant recipients 
and normal subjects.
149
Table 6.4: Summary statistics of reproducibility results of TLcoand its components 
in 14 subjects ( 9 heart transplant recipients and 5 normal subjects)
Means of absolute values SD Coefficient
first I second both j difference of difference of variation
TLco 6.48 | 6.46 6.47 j 0.02 0.36 5.6% •
Kco 1.21 | 1.21 1.21 | 0.00 0.08 6.6%
Dm 15.73 ! 15.20 15.47 j 0.53 1.35 8.7%
Vc 46.46 j 46.18 46.32 | 0.28 4.07 8.8%
Figure 6.9: Variability of duplicate measurements of TLco and its components ( 9 
heart transplant recipients and 5 normal subjects)
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Comments
The reproducibility of results of TLCo and its components as measured by the 
method used in this thesis is good and similar to published results (79,181). In 18 
patients receiving bleomycin treatment for testicular tumours, the coefficients of 
variation of DM and Vc from duplicate measurement within one session were 7.1% 
and 8.9%, respectively (181).
6.6 Study 5: Normal values of TLco components 
Aim
To compare values of TLco components obtained using the method outlined in 
chapter 5 of this thesis with the reference values of Cotes (49).
Subjects and Methods
Thirty one normal subjects recruited as volunteers from the general population 
were studied (22 males and 9 females). Their mean age was 48.6 years (range 27 to 
65 years) and the mean height was 173.4 cm (range 165 to 187) for men and 161.1 
cm (149 to 172) for women. They all had normal resting pulmonary function and 
none had a history of cardio-pulmonary disease. Seven subjects were former 
smokers and 24 were lifelong non-smokers.
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The relationship between actual values obtained in this study and reference values 
(49) was assessed by calculating the % of predicted for each subjects and by linear 
regression of the measured absolute values against their predicted values.
Results
The mean of measured Dm was 98.7 % of predicted (range; 87% to 111%), and 
that of Vc was 102.1% of predicted (range; 81% to 112%). Figures 6.10 and 6.11 
display regression plots of Dm and Vc against their reference values. There is a high 
correlation between measured and reference values for both parameters.
Figure 6.10: Scatterplot comparing measured values of Dm against their reference 
values by Cotes.
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Figure 6.11: Scatterplot comparing of measured values of Vc against their 
reference values by Cotes.
100
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Comments
The results of Dm and Vc in normal subjects obtained by the method used in this 
thesis are comparable with established reference values
6.7 Summary and conclusions
The results of studies comprising this chapter shows that:
1. Under identical conditions, The Transflow Model (PK Morgan, Kent, UK) and 
the Transfer Test Model B (PK Morgan, Kent, UK) yield identical results.
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2. The method used to estimate TLco and its components using the Transflow 
Model gives reproducible results in both normal subjects and heart transplant 
patients and these results and the results in normal subjects are comparable with 
established reference values
3. Under the condition of measurement in these studies, the chosen time intervals 
between the different stages of measurement give similar results to those obtained 
using the time intervals recommended by Cotes (2). In addition, the sequence of O2 
mixtures appears to have no influence on the values of TLco and its components.
The results of these studies allowed the production of a standard protocol for the 
estimation of TLco components. The details of this protocol have been described in 
chapter 5. The short duration of the test ( about 30 minutes) is suitable for clinical 
use without compromising precision or reproducibility. The measurement of TLco 
components using this protocol was used as part of the investigation of the 
mechanisms underlying TLco decline following heart transplantation.
154
PART 3
LUNG FUNCTION STUDIES IN HEART 
TRANSPLANT PATIENTS
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CHAPTER 7
LUNG FUNCTION CHANGES FOLLOWING HEART 
TRANSPLANTATION
7.1 Introduction
As noted previously, heart transplantation has been shown to restore lung volumes 
and airway function towards normal (14). In contrast, TLco and Kco have been 
persistently shown either to deteriorate or remain sub-normal following heart 
transplantation (15-21,182). Since most of these studies were retrospective and 
based on cross-sectional analysis of patients assessed at different intervals following 
transplantation (15,17-21), there are little data on the time course of TLco changes 
after heart transplantation (16,182). At the time of starting the present study, there 
was only one report on longitudinal changes in TLco following heart transplantation 
(16). In this study, Greon and associates (16) assessed 34 patients before and at 
one year after heart transplantation and 27 of them had repeat assessments at 2 
years, with a third assessment in 21 patients at 3 years after transplantation. In the 
first post-operative year, static and dynamic lung volumes (TLC, VC, and FEVi) 
tended to normalise. In contrast, Kco decreased by a mean of 12%. In the following 
2 years, Kco tended to improve, but remained below its base-line pre-operative 
value. Most of the potential causes of TLco decline in the setting of heart 
transplantation occur during the first post-transplant year (42). These include the
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effects of surgery including sternotomy and cardio-pulmonary bypass, pulmonary 
infections, drug toxicity and cardiac allograft rejection and dysfunction (42,183). It 
is therefore important to define the longitudinal changes in TLco during the first 
post-transplant year. In 1995, while the present study was in progress, Bussieres et 
al. (182) reported the only available longitudinal study of lung function changes 
during the first year after heart transplantation. In this study, lung function changes 
before and at 1, 3 and 12 months after transplantation were reported in 14 patients. 
Before transplantation, TLco and lung volumes were reduced, and despite 
significant improvement of lung volumes and indices of airway function by 3 
months after transplantation, TLco decreased further soon after transplantation and 
did not improve afterwards. The findings of this small study suggest that the 
aetiology of TLco decline occurs within the first few weeks after heart 
transplantation.
Aim
To determine the longitudinal changes in pulmonary function during the first 3 
years after heart transplantation.
7.2 Methods
7.2.1 Study population
Between January 1992 and February 1996, 98 patients underwent orthotopic heart 
transplantation at the Scottish Cardio-pulmonary Transplantation Unit. The
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longitudinal nature of the study resulted in a number of patients with incomplete 
pulmonary function results. This was due to one of the following reasons:
1. Transplantation without referral for pre-transplant pulmonary function 
assessment.
2. Completion of the follow-up period of the study before recent recipients had 
full post-transplant assessment.
3. Early post-transplant death.
For the purpose of this study patients were included in the analysis if they fulfilled 
one or both of the following criteria:
1. Complete pre-transplant pulmonary function assessment and at least one further 
assessment following transplantation.
2. At least 4 sequential pulmonary function assessments following transplantation.
Figure 7.1 shows that these criteria were met by 81 of the 98 heart transplant 
recipients and of these: 57 patients had pre-transplant and at least one post- 
transplant pulmonary function assessment (Group 1), 61 patients had at least 4 
post-transplant assessments (Group 2) and 37 patients had both pre-transplant and 
at least 4 assessments following transplantation (Group 3). The results of these 3 
groups were analysed separately.
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Figure 7.1: Heart transplant recipients categorised according to the number of 
repeat pulmonary function assessments performed
Pre- & at least one post-tx 
assessment (n = 57)
pre- & 4 post-tx assessments 
(n = 37)
4 post-tx assessments (n = 61)
20 +
Total number of patients = 81 + 17 = 98
The findings in heart transplant patients were compared with data from 28 (23 
males) normal subjects recruited as volunteers from the general population in whom 
there was no evidence of cardio-pulmonary disease. Their mean age was 40.4 years 
(range, 19-61), and 16 of them were life-long non-smokers, 9 former smokers and 
3 were current smokers.
7.2.2 Protocol
The protocol of serial lung function assessment has been described in chapter 4. In 
brief, patients were assessed before transplantation and at 6 weeks, 3, 6 and 12 
months following transplantation (early assessment). Patients who were
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transplanted before the start of the study were assessed at 12,18, 24 and 36 months 
after transplantation (late assessment).
7.2.3 Pulmonary function tests
Methods of lung function testing were as described in chapter 5. Measured and 
calculated variables included FEVi, FVC, FEVi/FVC ratio, RV, TLC, TLco and 
Kco-
7.2.4 Data presentation and analysis
All lung function results were expressed as percentages of predicted (41). Unless 
stated otherwise, values are expressed as mean +/- one standard error of the mean 
(SEM). Mean changes in lung function parameters following heart transplantation 
were calculated as the mean of % predicted values after transplantation minus the 
mean of % predicted before transplantation. Comparisons between results before 
and after transplantation were performed using the paired samples Student’s t-test 
and comparisons between heart transplant recipients and normal controls were 
performed using the independent samples Student’s t-test. A p value of <0.05 was 
considered significant.
7.3 Results
7.3.1 Comparisons between pre- and post-transplant results (Group 1)
1. Clinical characteristics
Table 7.1 shows the clinical characteristics of the 57 heart transplant recipients who 
had pulmonary function assessment before and at least once after transplantation.
Before transplantation, they all had severe congestive heart failure with mean left 
ventricular ejection fraction (LVEF) of 13.4%. After transplantation, mean LVEF 
increased to 47.1% (lower limit of normal = 40%). Thirty two of these patients had 
their first post-transplant assessment at 6 weeks (early) and the remaining 25 
patients at one year following transplantation (late). The mean time between pre­
transplant pulmonary function assessment and transplantation was 6.2 months 
(range; 1 week to 14 months) for the entire group, 7.0 months for the early group 
and 5.1 months for the late group. There was no significant difference between the 
2 sub-groups in any of the listed variables.
Table 7.1: Clinical characteristics of 57 (Group 1) recipients with lung function
results before and after heart transplantation
All Early Late
Number of subjects 57 32 25
Age; mean in years (range) 49.1 (19-61) 48.2 (34-60) 50.4 (39-59)
Sex
male 46 (81%) 26 (81%) 25 (80%)
female 11 (19%) 6 (19%) 5 (20%)
Smoking status
non-smokers 13 (23%) 8 (25%) 5 (20%)
ex-smokers 44 (77%) 24 (75%) 20 (80%)
Diagnosis
ischaemic heart disease 34 (60%) 18 (56%) 16 (64%)
dilated cardiomyopathy 20 (35%) 12 (38%) 8 (32%)
others 3 (5%) 2 (6%) 1 (4%)
Pre-transplant LVEF, mean (SD) 13.4 (5.8) 13.0 (5.7) 13.8 (6.0)
post-transplant LVEF, mean (SD) 47.1 (8.3) 46.3 (9.3) 48.2 (8.0)
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2. Lung function before transplantation
Table 7.2 shows lung function in heart transplant patients compared to normal 
controls. Before transplantation, mean values of FEVi, FVC, FEVi/FVC and TLC 
were slightly reduced. Although above 80% of predicted, they were all significantly 
lower than the values in normal controls (P<0.05). RV was slightly elevated, but 
this was not significantly different from that of normal controls. The greatest 
impairment, however, was in TLco at 72.1% of predicted compared to 98.6% of 
predicted in normal subjects (p <0.001). Although Kco was relatively preserved 
before transplantation, it was significantly lower than that of controls (90.1% and 
105.3% of predicted respectively, P<0.05).
Table 7.2: Resting pulmonary function results in 57 heart transplant recipients 
(Group 1) compared to normal controls
mean % predicted (SEM)
normal
controls
heart transplant patients
before after
FEVj 107.2 (3.9)* 86.0(2.0) 88.6(2.1)
FVC 110.9(2.1)* 93.3 (2.0) 94.6(2.3)
FEVi/FVC 98.6(1.8)* 91.7(1.6) 91.0(1.5)
RV 101.9(3.3) 104.9(5.0) j 103.2(3.7)
TLC 100.2 (3.3)* 92.7 (2.2) 93.3 (2.3)
TLco 98.6(1.3)* 72.1(2.1) j 54.2(1.7)**
Kco 105.3 (2.2)* 90.1 (2.7) | 64.0(2.0)**
* = significant difference between normal controls and patients before and after
transplantation, ** = significant difference between pre- and post-transplant values
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3. Effect of heart transplantation
Table 7.2 also shows that there was no significant change in any of the mean values 
of static and dynamic lung volumes after transplantation. In contrast, mean TLco 
declined significantly following transplantation (from 72.1% to 54.2% of predicted, 
p <0.001), and the decline in Kco was even greater (from 90.1% to 64.0% of 
predicted, p <0.001).
Figures 7.2 and 7.3 show that the lack of any significant change in the mean values 
of static and dynamic lung volumes in the entire group following transplantation 
was a composite of different changes in the 2 sub-groups. At 6 weeks following 
transplantation, there was a reduction in all lung volumes and flow rates, but these 
changes were not statistically significant. In the late assessment group (one year), 
there was evidence of improvement in these parameters (FEVi, FVC and TLC 
increased and RV decreased), but again these changes were not significant. The 
decline in TLco and Kco were similar in the 2 sub-groups.
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Figure 7.2: Means of changes in % predicted values of lung function parameters in 
57 patients (Group 1) following heart transplantation
F V C F E V . / F V C  R V
Figure 7.3: Comparison between changes in lung function in 2 sub-groups of heart 
transplant recipients (Group 1); six weeks vs. one year post-transplantation
i FEV./FVC|  -25
Early (six weeks) Late (one year)
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Figures 7.4 to 7.8 display the changes in static and dynamic lung volumes following 
heart transplantation in individual patients. The upper plot of each figure represents 
the entire group whereas the lower 2 plots show the individual changes in the early 
and late assessment groups separately. Inspection of these graphs reveals marked 
individual variability in the changes in these parameters following transplantation. 
The individual changes in the % predicted values ranged from -38 to 36 for FEVi, - 
40 to 39 for FVC, -22 to 18 for FEVi/FVC, -62 to 65 for RV and from -38 to 32 
for TLC. For the entire group, approximately 50% of patients had changes less than 
10% of predicted values of FEVi, FVC and TLC and the remaining 50% who had 
changes greater than 10% of predicted were equally divided into those who had 
improvement and those who had deterioration. On the other hand more than 75% 
of patients had no change (< 10% of predicted) in their FEVi/FVC or RV with the 
remaining equally distributed between those who improved and those who 
deteriorated. Comparisons between early and late assessment sub-groups revealed 
similar pattern of individual variability for all of these parameters with 2 notable 
differences:
1. In the early assessment group, the proportion of patients with decline was 
greater than those with improvement for all static and dynamic lung volumes 
and the opposite was true in the late group.
2. The magnitude of change in any of these indices was greater in the early 
compared to the late assessment group.
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In contrast, almost all patients had reductions in TLco and Kco with the majority 
deteriorating by more than 10% of predicted with no difference between the 2 sub­
groups (Figures 7.9 and 7.10).
Figure 7.4: Individual changes in % predicted FEVi following heart transplantation 
(Group 1)
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Figure 7.5: Individual changes in % predicted FVC following heart transplantation 
(Group 1)
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Figure 7.6: Individual changes in % predicted EYC/TEVi following heart 
transplantation (Group 1)
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Figure 7.7: Individual changes in % predicted RV following heart transplantation
(Group 1)
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Figure 7.8: Individual changes in % predicted TLC following heart transplantation
(Group 1)
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Figure 7.9: Individual changes in % predicted TLCo following heart transplantation
(Group 1)
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Figure 7.10: Individual changes in % predicted Kco following heart transplantation
(Group 1)
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7.3.2 Longitudinal changes following heart transplantation (Group 2)
1. Clinical characteristics
Table 7.3 shows the clinical characteristics of the 61 patients who had 4 sequential 
pulmonary function assessments following transplantation sub-divided into early 
(34 patients) and late (27 patients) assessment groups. There was no significant 
difference between the 2 sub-groups in any of the listed parameters.
Table 7.3: Clinical characteristics of 61 recipients (Group 2) with serial lung 
function results after heart transplantation
A ll Early Late
Number of subjects 61 34 27
Age; mean in years (range) 48.2 (19-61) 47.1 (19-61) 49.7 (39-59)
Sex
male
female
50 (83%) 
11 (17%)
28 (82%) 
6 (18%)
22 (81%) 
5 (19%)
Smoking status
non-smokers
ex-smokers
16 (26%) 
45 (74%)
8 (24%) 
26 (76%)
8 (30%) 
19 (70%)
Diagnosis
ischaemic heart disease 
dilated cardiomyopathy 
others
37 (61%) 
20 (33%) 
4 (6%)
20 (59%) 
12 (35%) 
2 (6%)
17 (63%) 
8 (30%) 
2 (7%)
Pre-transplant LVEF, mean (SD) 
post-transplant LVEF, mean (SD)
14.3 (6.3) 
50.5 (9.2)
14.1 (6.0) 
49.9 (8.4)
15.1 (6.2) 
51.3 (10.4)
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2. Lung function
Using the first post-transplant pulmonary function assessment as a base-line for 
subsequent results, figure 7.11 shows that in the entire group FEVi, FVC and TLC 
increased slightly in the second assessment with no further changes later. Sub­
group plots show that the initial low values for these parameters in the entire group 
were due to the lower values in the early assessment group (i.e. at 6 weeks after 
transplantation). In contrast, there was no change in either TLco or Kco from the 
first post-transplant assessment (Figure 7.12). Although sub-group plots show a 
small decline in both parameters during the last 2 measurements in the late group 
(i.e. at 24 and 36 months following transplantation), this was not statistically 
significant.
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Figure 7.11: Post-transplant longitudinal changes in lung volumes and expiratory 
flow rate in 61 recipients (Group 2)
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Figure 7.12: Post-transplant longitudinal changes in TLCo and Kco in 61 recipients 
(Group 2)
iFirst 
1Second
iFourth
176
Thirty seven of the 81 heart transplant recipients studied, had both full pulmonary 
function assessment before and serially after transplantation (Group 3). Table 7.4 
shows that their clinical characteristics were similar to the entire group of heart 
transplant recipients (Tables 7.1 and 7.3). The first pulmonary assessment after 
transplantation was at 6 weeks in 26 patients (early) and at 12 months in 11 
patients (late). Apart from the difference in the number of patients in each sub­
group, there was no significant difference between them in any of the listed 
parameters (Table 7.4).
Table 7.4: Clinical characteristics of 37 recipients (Group 3) with lung function 
results before and serially after transplantation
A ll Early Late
Number of subjects 37 26 11
Age; mean in years (range) 49.2 (19-61) 47.8 (19-61) 50.0 (44-58)
Sex
male 31 (84%) 21 (81%) 10 (91%)
female 6 (16%) 5 (19%) 1 (9%)
Smoking status 
non-smokers 10 (27%) 9 (35%) 1 (9%)
ex-smokers 27 (73%) 17 (65%) 10 (91%)
Diagnosis
ischaemic heart disease 20 (54%) 14 (54%) 6 (55%)
dilated cardiomyopathy 15 (41%) 10 (38%) 5 (45%)
others 2 (5%) 2 (8%) 0
Pre-transplant LVEF, mean (SD) 13.2 (5.6) 13.3 (5.9) 13.0 (5.0)
post-transplant LVEF, mean (SD) 50.3 (8.3) 49.0 (8.7) 53.7 (6.3)
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Figures 7.13 to 7.15 show that the changes in lung function in these patients were 
similar to what would be expected from the results in the previous 2 groups. 
Although there was a tendency for FEVi, FVC and TLC to improve with time, this 
was not statistically significant. Sub-group plots show that FVC and TLC were 
lower than their pre-transplant values at 6 weeks after transplantation, but both 
exceeded their pre-transplant baseline in the subsequent interval. There were no 
consistent changes in RV or FEVi/FVC.
Figure 11.15 shows that the decline in TLco and Kco was evident at 6 weeks after 
transplantation with no further changes afterwards.
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Figure 7.13: Longitudinal changes in FEVi, FVC and FEVj/FVC in 37 recipients
(Group 3) with full results before and serially after transplantation
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Figure 7.14: Longitudinal changes in RV and TLC in 37 recipients (Group 3) with
full results before and after transplantation
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Figure 7.15: Longitudinal changes in TLco and Kco in 37 recipients (Group 3) with
full results before and serially after transplantation
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7.4 Discussion
7.4.1 Summary of results
The findings of the studies comprising this chapter may be summarised as follows:
Despite the wide individual variability and the lack of significant change in any of 
the static and dynamic lung volumes following heart transplantation, this study 
demonstrated a consistent trend of change in the mean values of these parameters. 
Before transplantation there was a mild impairment of static and dynamic lung 
volumes. At 6 weeks after transplantation, there was a further reduction in FEVi, 
FVC, RV and TLC, but all of these increased in the subsequent measurements to 
exceed their pre-transplant values at about one year after transplantation. However, 
all of these parameters were still significantly lower than in normal controls. TLco 
and Kco decline was evident at 6 weeks after transplantation with no changes 
afterwards. In contrast to the wide variability in static and dynamic lung volumes, 
TLco and Kco decline occurred in almost all patients with no significant difference 
between the early and the late assessment sub-groups.
7.4.2 Static and dynamic lung volumes
The changes in static and dynamic lung volumes demonstrated in this study were in 
agreement with previous reports (14,16,20). In 17 patients studied before and 15 
+/- 10 months (mean +/- SD), Hosenpud and associates reported a significant 
improvement in FEVi and FVC following transplantation, but there was no change 
observed in FEVi/FVC. Despite an overall improvement in lung volumes in this
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small group of patients, those with smoking history continued to have sub-normal 
results. Plots of changes in individual patients demonstrated a wide variability 
similar to that of our study. Most patients had no change and most of the 
improvement in the mean values in FEVi and FVC appeared to be due to marked 
improvement in 4 patients.
In the longitudinal study of Groen et al. (16), FEVi, FVC and TLC were all 
reduced before transplantation and all demonstrated significant improvement at one 
year after transplantation with no further changes in the subsequent 2 years. In 
contrast, FEVi/FVC was normal before transplantation and did not change 
afterwards. In 100 heart transplant patients studied before and at different intervals 
(I month to 10 years) after transplantation, Degre et al. (20) reported persistence 
of the pre-transplant restrictive ventilatory defect in patients assessed at one month 
after transplantation, but this was absent in those assessed at one year or thereafter.
To date there have been no reports on the changes in the residual volume (RV) in 
heart transplant patients. In patients with chronic heart failure, RV is usually 
preserved and may even be elevated despite decreases in other lung volumes 
(28,184). In the present study, mean pre-transplant RV was normal (104% of 
predicted). After transplantation, there was a tendency for RV to decrease, but this 
was not statistically significant. This may, in part, explain the lack of complete 
normalisation of TLC following transplantation in our patients.
The early changes in static and dynamic lung volumes reported in the present study 
are similar to those reported in patients following coronary artery bypass grafting
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(CABG) (141,146) and valve replacement surgery (38). The decline in these 
parameters has been suggested to result from the adverse effects of sternotomy and 
cardio-pulmonary bypass (CPB) procedure on lung mechanics. In heart transplant 
recipients, these effects would tend to counteract the expected improvement in lung 
mechanics resulting from the relief of pulmonary congestion. After CABG, lung 
volumes and airway function abnormalities have been shown to resolve within 3 to 
6 months (141,146). In our patients, the improvement in lung volumes and indices 
of airway function beyond this time to values higher than their pre-transplant may 
be due to the resolution of the pulmonary complications of chronic congestive heart 
failure following transplantation (e.g. pulmonary congestion and interstitial oedema, 
cardiomegaly and pleural effusions). However, the lack of complete normalisation 
of these parameters during 3 years of follow-up suggests residual sub-clinical 
pulmonary dysfunction in heart transplant recipients.
7.4.3 TLco changes
TLco changes during the first year after transplantation in the present study are in 
agreement with those recently reported by Bussieres et al. (182). In addition to 
confirming the findings of Bussieres and associates in a larger number of patients, 
the present study showed that the early decline in TLco and Kco persisted during 3 
years of follow-up. In the cross-sectional study of Degre et al. (20), TLco decline 
was observed in patients assessed at one month after transplantation and the 
magnitude of decline was similar to that found in patients assessed as late as 10 
years after transplantation. Since the earliest post-transplant assessment in the 
present study was at 6 weeks, it is possible that the TLco decline occurred well
184
before this time, perhaps immediately after transplantation (e.g. intra-operatively or 
during the first few days). In patients undergoing conventional cardiac surgery 
including CABG, pulmonary dysfunction including TLco decline has been reported 
to be maximal within the first few hours after surgery (123,145). In addition, 
measurement of lung function before and one week after percutaneous transvenous 
mitral commissurotomy demonstrated TLco decline despite improvement of static 
and dynamic lung volumes (116).
The cause and the underlying mechanisms of TLco decline following heart 
transplantation have not been determined and these are the topics of the next 2 
chapters of this thesis. The importance of the findings in this chapter lies in that 
they focus attention on the early post-transplant period as the time during which the 
potential causes of TLCo decline should be sought. These include sternotomy and 
CPB, early post-operative pulmonary complications and the changes in pulmonary 
vascular pressures following transplantation. In CABG patients, sternotomy and 
CPB have been shown to be associated with early post-operative decline in TLco, 
but this usually resolves within 3 to 6 months after surgery (141,146). It is possible 
that the adverse effects of sternotomy and CPB are greater and or last longer in 
patients with long standing heart failure as compared to those undergoing CABG 
who usually have normal lungs.
In patients with congenital and valvular heart disease, TLco changes have been 
shown to be related to the changes in the pulmonary vascular pressures (30) and 
surgery for these disorders has been reported to be associated with reductions in 
both pulmonary vascular pressures and TLco (23,115). Cyclosporin pulmonary
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toxicity (15,16) and CMV infection (21) have also been suggested as causes for 
TLco decline after heart transplantation. The possible roles of all of these factors 
are investigated in chapter 9.
7.5 Conclusions
From the findings of this study and from data in the literature on TLco changes 
following various forms of cardiac surgery, the following points may be made 
regarding TLco decline following heart transplantation:
1. The isolated decline in TLco in the face of improving lung volumes and airway 
function following transplantation is consistent with pulmonary vascular 
dysfunction.
2. The early and non-progressive nature of TLco decline suggest an aetiology 
occurring early after transplantation.
3. The resulting reduction in pulmonary haemodynamics immediately after 
transplantation appears to be a plausible cause. Before transplantation, the long­
standing pulmonary congestion and the associated chronic pulmonary vascular 
and parenchymal changes would be expected to lead to TLco impairment by 
reducing both of its components (DM and Vc). The reduction in pulmonary 
haemodynamics following heart transplantation, would be expected to decrease 
Vc and, therefore, may contribute to TLCo decline after heart transplantation. 
This concept may be tested by the measurement of the TLco components in 
heart transplant patients (chapter 8).
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CHAPTER 8
MECHANISMS OF TLco REDUCTION IN HEART 
TRANSPLANT RECIPIENTS
8.1 Introduction
Although TLco reduction in heart transplant recipients is well documented, the 
causes and mechanisms of this reduction remain unknown (15-21). It has been 
suggested that it might be due to a reduction in the diffusing capacity of the 
alveolar-capillary membrane (DM) secondary to new insults to the membrane after 
heart transplantation (16,21). However, TLco components have not been 
determined in heart transplant recipients.
As has been noted in chapters 3 and 5, Roughton and Forster showed that the 
measurement of TLco at different alveolar oxygen tensions allows the estimation of 
the diffusing capacity of the alveolar-capillary membrane (D m) and the 
instantaneous pulmonary capillary blood volume available for gas transfer (Vc) (5). 
According to Roughton and Forster, the relationship between TLco and its 
components is described by the following equation:
1/TLco = 1/Dm + l/0Vc
where 1/TLco is reciprocal of the transfer factor for the entire lung and represents 
the total resistance of the lung to CO transfer, and by analogy 1/Dm represents the 
resistance of the alveolar-capillary membrane, and 0Vc represents the resistance of 
the total mass of the erythrocytes in the capillary blood (intra-capillary resistance),
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where, 0 is the standard rate of at which one millilitre of whole blood takes up CO 
and this is dependent on the prevailing alveolar oxygen tension and haemoglobin 
concentration. In the conventional calculation of TLco, haemoglobin concentration 
is assumed to be normal (14.6 g.dL'1) (41). The effect of haemoglobin variability 
on TLco values can be determined using a version of the classic Roughton and 
Forster equation as described by Cotes and recommended by both the European 
Respiratory Society and the American Thoracic Society (41,88);
1/TLco = 1/Dm + l/([Hb] X0VC)
where [Hb] is the haemoglobin concentration as a fraction of normal (i.e. actual 
haemoglobin divided by 14.6). Thus, the application of Roughton and Forster 
model, permits the determination of the relative contribution of Dm, V c, and blood 
haemoglobin to TLCo changes. The findings in chapter 7 showed that TLCo decline 
occurs early after heart transplantation. It was suggested that this may be due to a 
reduction in Vc secondary to normalisation of the pulmonary vascular pressures 
following heart transplantation.
Aim
The aim of the studies comprising this chapter was, therefore, to determine the 
mechanism of TLco reduction in heart transplant recipients in terms of the relative 
contribution of each of its individual components.
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8.2 Methods
8.2.1 Study population
TLco and its components were determined in 75 heart transplant recipients at 6 
weeks to 36 months after transplantation. The findings in heart transplant recipients 
were compared with data from 38 patients with severe chronic heart failure 
awaiting heart transplantation (candidates) and 26 normal subjects recruited as 
volunteers from the general population in whom there was no evidence of cardio­
pulmonary disease. Table 8.1 shows the clinical characteristics of the 3 study 
groups.
Table 8.1 Clinical characteristics of heart transplant recipients compared to heart
transplant candidates and normal controls
Recipients Candidates Normal
Number of subjects 75 38 26
Age; mean in years (range) 47.7 (19-61) 50.6 (34-61) 47.3 (27-62)
Sex
male 61 (81%) 30 (79%) 20 (77%)
female 14 (19%) 8 (21%) 6 (23%)
Smoking status 
non-smokers 17 (23%) 10 (26%) 21 (81%)
ex-smokers 58 (77%) 28 (74%) 5 (19%)
Diagnosis
ischaemic heart disease 44 (59%) 25 (66%)
dilated cardiomyopathy 27 (36%) 10 (26%)
valvular heart disease 3 (5%) 3 (8%)
Haemoglobin, g.dL'1, mean (SD) 12.1 (1.4) 14.0(1.7) assumed 14.6
LVEF, mean (SD) 47.2 (10.4) 12.8 (6.3)
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Nine of the 75 heart transplant recipients had TLco and its components measured 
before and at six weeks after transplantation. The pre- and post-transplant findings 
in these patients were compared with results from 7 patients with mitral stenosis 
studied one day before and 6 weeks after mitral valve replacement (MVR). Table
8.2 show the clinical characteristics of these patients.
Table 8.2 Clinical characteristics of 9 heart transplant recipients with TLCo 
components measured before and after transplantation compared to 7 mitral valve
replacement patients (MVR)
Transplant MVR
Number of subjects 9 1
Age; mean in years (range) 49.7 (34-61) 53.7(31-65)
Sex
male 9 (100%) 3 (43%)
female 0 4 (57%)
Smoking status
non-smokers 3 (33%) 3 (43%)
ex-smokers 6 (67%) 4 (57%)
Haemoglobin, g.dL'1, mean (SD)
before surgery 13.3 (1.3) 13.7 (0.8)
after surgery 11.6(1.7) 12.2 (0.7)
8.2.2 Measurement of TLco and its components
TLco and its components were measured as described in chapter 5. The influence of 
haemoglobin concentration was estimated by comparing TLco results before and 
after correction for actual haemoglobin. Haemoglobin concentration in patients was
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determined on the same day of TLco measurement using venous blood samples. 
Normal subjects were assumed to have normal haemoglobin concentration (i.e. 
14.6 g.dL'1).
8.2.3 Data presentation and analysis
TLco and its components were expressed as percentages of predicted using the 
European Community for Steel and Coal equations for TLco (41) and the reference 
values of Cotes for Dm and Vc (49). The total resistance to CO transfer (1/TLco) 
and its components (1/D m and 1/0Vc) were expressed in absolute values 
(Pa.min1.mmol'1). Unless stated otherwise, values were presented as mean +/- 
standard error of the mean (SEM). Comparisons between groups were performed 
using one-way analysis of variance (ANOVA), whereas comparisons within groups 
(e.g. TLco results before and after correction for haemoglobin in heart transplant 
recipients and candidates, and TLco and its components before and after surgery in 
heart transplant and mitral valve replacement groups) were performed using the 
paired samples Student’s t-test. A p value of <0.05 was considered significant.
8.3 Results
8.3.1 TLco and its components in recipients compared to candidates and 
normal controls
Figure 8.1 shows TLco and its components in heart transplant recipients compared 
to candidates and normal controls. Mean TLco was significantly reduced in heart 
transplant recipients compared to heart transplant candidates (56.9 +/- 1.4% and
69.9 +/- 2.0% of predicted respectively, p<0.001) and in both it was significantly 
lower than that o f normal controls (97.7 + /-  1.6% o f predicted, p<0.001). Similarly, 
Vc was reduced in recipients compared to candidates (52.8 +/- 2.0% vs. 80.2 +/- 
4.2% of predicted, p<0.001). In contrast, DM was similar in heart transplant 
recipients and candidates (77.7 +/- 2.5% and 81.4 +/- 5.4% o f predicted 
respectively, p = 0.48) and in both it was significantly lower than that o f  normal 
subjects (100.0 +/- 1.3% o f predicted, p<0.001).
Figure 8.1 TLco and its components in recipients compared to candidates and 
normal controls
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M
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Figure 8.2 shows that the change in the TLco and its components following heart 
transplantation is independent of the time between transplantation and assessment.
Figure 8.2 Scatterplots of individual results of TLco and its components at 
different intervals after heart transplantation
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Figure 8.3 displays the diffusion parameters in terms of their reciprocals (i.e. 
resistance to diffusion) in the 3 study groups. The total resistance to CO transfer 
(1/TLco) was higher in heart transplant recipients compared to candidates (212.9 
+/- 7.8 vs. 176.1 +/- 8.6 Pa.min1.mmol'1., p<0.001) and in both it was higher than 
that of normal controls (113.9 +/- 3.8 Pa-min1.mmol’1., p<0.001). The increase in 
1/TLco in heart transplant candidates was due to a proportionate increase in both 
the alveolar-capillary membrane resistance (1/D m) and the intra-capillary resistance
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(l/0Vc), being 88.4 +/- 6.3 and 87.7 +/- 5.0 Pa.min'1.mmol'1., respectively 
compared to 59.0 +/- 1.0 and 54.9 +/-  3.8 Pa.min"1.mmol'1., in normal subjects. The 
increase in l/TLCo in heart transplant recipients above that o f candidates was 
entirely due to the marked increase in l/0Vc (127.4 +/- 5.3 vs. 87.7 +/-5.0 Pa.min' 
l.mmol'1, p<0.001) with 1/DM being similar in both groups (85.5 +/- 4.0 and 88.4 
+/- 6.3 Pa.min"1.mmol1, respectively, p = 0.69).
Figure 8.3 The total resistance to CO transfer (l/TLCo) and its components (1/DM 
and l/0Vc) in recipients compared to candidates and normal controls
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Figure 8.4 is a 100% stacked bar chart showing the relative contribution o f the 
alveolar-capillary membrane resistance (1/DM) and the intra-capillary resistance
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(l/0Vc) to the total resistance to CO transfer (1/TLco) in heart transplant recipients 
compared to candidates and normal controls. 1/DM and l/0Vc contributed equally 
to 1/TLco (approximately 50% each) in both normal subjects and heart transplant 
candidates. In contrast, 1/0Vc provided the main resistance to CO transfer in heart 
transplant recipients (60% o f 1/TLco).
Figure 8.4 100% stacked bar chart showing the relative contribution o f  1/DM and 
1/0 Vc to 1/TLco in recipients compared to candidates and normal controls
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8.3.2 The influence of haemoglobin concentration
Figure 8.5 displays scatter plots of % predicted TLco against haemoglobin 
concentration in heart transplant recipients and candidates. Mean haemoglobin 
concentration in recipients was reduced compared to candidates (12.1 vs. 14.0 
g.dL-1, p<0.001). There was a weak but significant correlation between % 
predicted TLco and haemoglobin concentration in recipients (r = 0.27, p<0.05), but 
there was no significant correlation between the two variables in candidates (r =
0.16, p = 0.33).
Figure 8.5 Scatter plots of % predicted TLCo against haemoglobin concentration 
in heart transplant recipients and candidates
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Figure 8.6 compares TLCo as percentage o f predicted before and after correction 
for actual haemoglobin concentration in the study groups. Correction for 
haemoglobin in heart transplant candidates produced no significant effect (69.9 +/- 
3.0% vs. 71.1 +/- 3.1% o f predicted, p = 0.09). In contrast, TLCo in heart 
transplant recipients increased from 56.9 +/-1.4% to 63.5 +/- 1.5% o f predicted 
(p<0.001), but this was still lower than that o f candidates (p<0.05).
Figure 8.6 TLco in heart transplant recipients and candidates before and after 
correction for haemoglobin
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In terms o f resistance to CO transfer, the correction for actual haemoglobin 
concentration in heart transplant recipients reduced l/TLCo (from 212.9 +/- 7.8 to
190.0 +/- 7.0 Pa.min.'1mmor1., <0.001) by reducing l/0Vc (from, 127.4 +/- 5.3 to
104.5 +/- 4.4 Pa.min.^mmof1, p<0.001), but this was still significantly higher than 
that o f heart transplant candidates (84.3 +/- 5.0 Pa.min*1.mmol'1 , p<0.01) and 
normal subjects (54.9 +/- 3.8 Pa.min.*1 mmol*1, p<0.001), both in absolute (Figure 
8.7) and relative terms (Figure 8.8).
Figure 8.7 The total resistance to CO transfer (l/TLCo) and its components (1/DM 
and 1/0Vc) after correction for actual haemoglobin
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Figure 8.8 100% stacked bar chart showing the relative contributions o f 1/DM and 
1/0Vc to 1/TLco in the 3 study groups after correction for haemoglobin
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8.3.3 Comparison between heart transplant recipients and mitral valve 
replacement (MVR)
Table 8.3 shows the mean values o f  TLco and its components (% predicted) in 9 
heart transplant recipients and 7 MVR patients before and at 6 weeks after surgery. 
Before surgery, TLCo and DM were similarly reduced in both groups o f patients. Vc 
was also reduced in both groups, but it was significantly lower in MVR patients 
compared to heart transplant patients (p<0.05). Although, TLCo and its components 
all declined in both groups after surgery, the decline in DM was not statistically 
significant.
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Table 8.3: Mean values of TLco and its components in heart transplant recipients 
compared to mitral valve replacement patients before and 6 weeks after surgery
Recipients MVR
Before After Before After
TLco 70.0 (8.6) | 53.7 (4.6)* 75.2(6.6) | 64.1(5.8)*
Dm 84.2(12.1) 1 75.7(6.4) 83.0(5.4) j 80.4(7.3)
Vc 89.2 (9.6) | 56.2 (8.7)* 75.3 (6.7)** | 58.4 (6.7)*
* = significant difference between results before and after surgery in the same 
group, ** = significant difference between the two groups
Figure 8.9 shows that changes in diffusion parameters were also similar in the two 
groups. Although the magnitude of decline in TLco and Vc was higher in recipients 
compared to MVR patients, this difference was not statistically significant. The 
decline in Dm was small in both groups, and it was significantly greater in recipients 
compared to MVR patients.
201
Figure 8.9 Mean changes in TLCo and its components in heart transplant recipients 
and mitral valve replacement patients 6 weeks after surgery
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Figure 8.10 displays the results o f TLco and its components in individual patients 
before and after surgery in the 2 study groups. Despite the wide range o f values, all 
heart transplant recipients and mitral valve replacement patients had declines in 
TLco and Vc at 6 weeks after surgery. In contrast, there was no consistent trend in 
the changes in Dm in either o f the 2 groups.
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Figure 8.10 Changes in TLco and its components in individual patients 6 weeks
after heart transplantation compared to mitral valve replacement
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8.4 Discussion
8.4.1 Summary of results
The main findings of this study may be summarised in 4 points:
1. TLco reduction in patients with severe chronic heart failure (heart transplant 
candidates) was found to be due to a proportionate reduction in both of its 
components (D m and Vc).
2. TLco reduction in heart transplant recipients beyond that of heart transplant 
candidates was due to an increase in the intra-capillary resistance (l/0Vc) with 
1/Dm being similarly elevated in both recipients and candidates
3. The increase in 1/0 Vc in heart transplant recipients was shown to be due to a 
combination of anaemia and reduced Vc.
4. The changes in TLco and its components after heart transplantation were similar 
to the changes following mitral valve replacements six weeks after surgery
8.4.2 TLco and its components in heart transplant candidates
The results of this study represent the first report on the changes in TLco 
components in heart transplant candidates. In addition to confirming TLco 
reduction in these patients, it was shown that this reduction was due to a 
proportionate reduction in both of its components (D m and Vc). The lack of any 
effect for haemoglobin concentrations on TLco values is a reflection of their 
relatively normal haemoglobin concentration. In the only study of TLco 
components in patients with chronic congestive heart failure, Puri and associates
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(9) reported that TLco reduction was common in this condition and was primarily 
due to a reduction in Dm with Vc being normal. The apparent discrepancy between 
these results and ours is probably due to the difference in severity of heart failure. 
In the study of Puri et al., patients had mild to moderately severe chronic heart 
failure with NYHA classes II and III and mean left ventricular ejection fraction 
(LVEF) of 33% whereas our patients, who were awaiting heart transplantation, had 
severe long-standing heart failure (mean LVEF = 12.8%). In patients with mitral 
stenosis Dm has been shown to decline progressively with increasing severity of the 
disease (32). In contrast, Vc has a biphasic relationship with disease severity (32). 
In mild to moderately severe mitral stenosis, Vc is usually normal and may even be 
elevated whereas in severe cases, it is reduced. The reduction in Vc has been 
suggested to be secondary to fibrosis and obliteration of the pulmonary vascular 
bed which are common in severe mitral stenosis (30,89). The finding of equally 
reduced Dm and Vc in our heart transplant candidates is similar to those of patients 
with severe mitral stenosis suggesting that these patients have significant pulmonary 
parenchymal and vascular abnormalities.
8.4.3 TLco and its components in heart transplant recipients
In addition to confirming previous reports of TLco reduction in heart transplant 
recipients (15-21), the present study identified the increase in the intra-capillary 
resistance (l/0Vc) as the underlying mechanism. The increase in 1/0Vc was shown 
to be due to a combination of anaemia and reduced Vc. Contrary to what has been 
suggested by previous investigators (16), Dm in heart transplant recipients was 
similar to that of candidates.
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The finding of anaemia in heart transplant recipients was not unexpected (185,186). 
Possible cause include bone marrow suppression caused by immunosuppressive 
therapy, blood loss during surgery and repeated venous blood sampling. Although 
the effect of haemoglobin concentration on TLco measurement is well documented 
and correction for its effect when outside the normal range is recommended (41), 
this study is the first report on the relative contribution of anaemia to TLco 
reduction in heart transplant recipients. Mean TLco was lower in heart transplant 
recipients than heart transplant candidates by 13% of predicted and this difference 
was reduced to 8% of predicted after correction for haemoglobin. Thus, the 
difference in haemoglobin levels between recipients and candidates accounted for 
approximately 40% of the total difference in TLco. As Dm was similar in the 2 
groups and Vc was significantly reduced in recipients compared to candidates, it 
appears reasonable to assume that the remaining difference (60% of the total 
difference) in TLCo was due to the reduction in Vc in heart transplant recipients.
8.4.4 The mechanisms of Vc reduction in heart transplant recipients
The volume of the pulmonary capillary blood at any instant (Vc) depends on the 
number and dimensions of functioning pulmonary capillaries (89). The mechanisms 
by which the size of the pulmonary capillary bed is increased are not fully 
understood, but experimental and clinical studies suggest that it is caused by 
increases in pulmonary blood flow or pulmonary capillary transmural pressure, with 
the transmural capillary pressure appearing more important than the pulmonary 
blood flow (59). These haemodynamic factors are believed to increase the size and 
uniformity of the pulmonary capillary bed by vascular recruitment and distension
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uniformity of the pulmonary capillary bed by vascular recruitment and distension 
(59). Therefore in any condition where pulmonary capillary transmural pressure or 
the pulmonary blood flow is increased (e.g. exercise, congenital heart disease with 
left to right shunts and early stages of mitral stenosis and congestive heart failure), 
Vc would be expected to be higher than normal (89). Under these circumstances, a 
normal or reduced Vc would suggest derangement of the pulmonary vascular bed 
(89).
The present study did not investigate the direct relationship between TLco 
components and the pulmonary haemodynamics in heart transplant patients. 
However, previous reports on the relationship between TLCo in general and Vc in 
particular and pulmonary haemodynamics in patients with congenital and valvular 
heart diseases suggest an important role for the changes in pulmonary 
haemodynamics in the decline of Vc and TLco following heart transplantation. 
Congenital heart diseases which result in pulmonary vascular congestion and 
increased pulmonary blood flow without significant pulmonary arterial hypertension 
are associated with increased values of TLco and its components with Vc increasing 
relatively more than Dm (22,23). However, if pulmonary arterial hypertension or 
pulmonary vascular resistance is severe, these parameters are usually normal or 
reduced (22). Surgical correction of the congenital defects results in restoration of 
the pulmonary haemodynamics towards normal and this is associated with 
reduction in TLco and its components (23).
TLco in mitral valve disease has been shown to be related to the severity of 
pulmonary haemodynamics (30). In moderately severe mitral stenosis, the increase
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in pulmonary venous pressure would be expected to increase Vc by expanding and 
increasing the uniformity of the pulmonary vascular bed. However, Vc is usually 
normal or even reduced in these cases (32). This was explained by an opposite 
force which counterbalances the augmenting effect of pulmonary congestion; 
namely, the obliteration of the pulmonary vascular bed by progressive fibrosis and 
repeated pulmonary emboli which are common in severe mitral stenosis (30,54). It 
follows therefore, that the relief of pulmonary congestion without concomitant 
restoration of the structural changes in the pulmonary vascular bed would be 
expected to reduce Vc. In keeping with this, mitral valve surgery has been shown to 
result in further decline in TLco (116-118) and this was found to be due to 
reduction in Vc with Dm remaining unchanged (118). The results of our MVR 
patients were in agreement with these reports.
Heart transplant and mitral valve patients have very similar haemodynamic profiles 
both before and after surgery (13,29). The fact that the changes in TLco and its 
components before and after transplantation were also very similar to those of 
patients undergoing mitral valve surgery suggests that TLco reduction has a 
common mechanism in both conditions. Like patients with mitral valve disease, Vc 
in patients with severe chronic heart failure awaiting heart transplantation is 
determined by two factors acting in opposite directions; the increased pulmonary 
venous pressure tending to increase it and the pulmonary fibrosis and destruction of 
the pulmonary vascular bed tending to decrease it. The finding of reduced Vc 
before transplantation indicates that these patients have significant structural 
pulmonary vascular abnormalities and the lack of any improvement in Dm after
208
volumes suggests that these structural abnormalities persist after transplantation. 
Thus, the reduction in the pulmonary vascular pressures without resolution of the 
pulmonary vascular abnormalities after heart transplantation may be the cause of Vc 
reduction which in addition to anaemia leads to TLco decline following heart 
transplantation.
Although the changes in pulmonary haemodynamics and anaemia appear to explain 
TLco reduction in heart transplant recipients, other factors may also have some 
influence. Cyclosporin pulmonary toxicity (15,16) and CMV infection have been 
proposed as possible factors (21). Other potential factors include sternotomy and 
cardio-pulmonary bypass procedure, post-operative pulmonary complications and 
cardiac allograft rejection.
8.5 Conclusions
The findings of this study suggest that TLco reduction in heart transplant recipients 
results from an increase in the intra-capillary resistance to CO transfer which is due 
to a combination of anaemia and reduction in the pulmonary capillary blood volume 
(Vc). Although the reduction in pulmonary vascular pressures after transplantation, 
in the face of persisting pulmonary vascular abnormalities of the pre-transplant 
severe chronic heart failure appears, a plausible explanation for the decline in Vc 
and therefore haemoglobin-corrected TLCo, other potential contributory factors 
need to be evaluated.
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CHAPTER 9
DETERMINANTS OF TLco DECLINE AFTER HEART 
TRANSPLANTATION
9.1 Introduction
In the preceding chapter, TLco decline after heart transplantation was shown to be 
due to a combination of anaemia and reduction in the pulmonary capillary blood 
volume (Vc). It was suggested that the reduction in Vc and, therefore, TLco was 
secondary to the reduction in pulmonary vascular pressures after heart 
transplantation. However, there are several other factors that potentially can be 
responsible for TLco decline after heart transplantation. These include: pre­
transplant cardiac and lung function (10,11), cardio-pulmonary bypass (141), post­
transplant pulmonary complications (42), CMV infection (21), cardiac allograft 
rejection (42), and cyclosporin pulmonary toxicity (15).
Aim
The aim of the studies comprising this chapter was to determine the responsible 
factors for TLco decline after heart transplantation.
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9.2 Subjects and Methods
9.2.1 Subjects
A. Heart transplant patients
The influence of potential factors on TLCo changes after heart transplantation was 
analysed in 57 patients who had pulmonary function assessment before and after 
transplantation. Thirty-two patients had their first post-transplant assessment at 6 
weeks and the remaining 25 at one year following transplantation. The clinical 
characteristics of these patients have already been described in chapter 7 (Table 
7.1).
B. Coronary artery bypass graft patients
The potential effects of cardio-pulmonary bypass on TLco were assessed by 
comparing the results in heart transplant patients with data from 15 (14 male) 
patients who had lung function tests before and at 6 weeks after coronary artery 
bypass graft surgery. The inclusion criteria of coronary artery surgery patients were 
as out-lined in chapter 4 (section 4.3.2). Their mean age was 54.7 years (range; 41- 
65 years). Three were life-long non-smokers, and 12 were ex-smokers.
9.2.2 TLco and other lung function tests
Methods of lung function tests were as previously described. Measured TLco was 
corrected for actual haemoglobin concentration using the equation of Dinakara and 
associates (187):
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Haemoglobin-corrected TLco = Observed TLco / (0.06965 x Hb);
where Hb is the patient’s actual haemoglobin and 0.06965 is a correction factor to 
a standard haemoglobin concentration of 14.4 g.dL'1. This equation was derived 
from TLco measurement in 50 patients with haemoglobin concentrations ranging 
from 6.7 to 16.8 g.dL'1 and is one of recommended equations by the American 
Thoracic Society (65). It was chosen in preference to the more commonly used 
equation of Cotes and associates (41,65);
Haemoglobin-corrected TLco = Observed TLco ([10.22 + Hb]/1.7 xHb)
This equation is based on the classic Roughton and Forster equation (41) and the 
assumption of a constant D m/V c ratio (D m/V c = 0.7 in traditional units). This 
assumption is not valid in heart transplant recipients due to a disproportionate 
reduction in Vc (in the 75 heart transplant recipients analysed in chapter 7, Dm/Vc 
ratio was 1.2).
Kco was corrected for haemoglobin concentration from the following relationship: 
corrected TLco /corrected Kco = observed TLco /observed Kco, hence: 
Hb-corrected Kco = Hb-corrected TLco x observed Kco /observed TLco
9.2.3 Potential determinants of TLco decline after heart transplantation
A. Pre-transplant lung function
All patients had complete pre-transplant lung function tests as previously out-lined 
at an average of 22 weeks before transplantation (range; 1-54 weeks).
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B. Pre-transplant cardiac status
The severity of heart failure was assessed by left ventricular ejection fraction 
(LVEF) duration of exertional dyspnoea and New York Heart Association 
(NYHA) functional status. LVEF was measured by radionuclide imaging at the 
time of lung function assessment. Pulmonary haemodynamics were measured by the 
referring cardiologists at various centres as part of routine assessment for possible 
heart transplantation. They were all performed within 3 months (range 1-13 weeks) 
of pre-transplant lung function assessment and included mean pulmonary artery 
pressure (mPAP), mean pulmonary capillary wedge pressure (mPCWP) and the 
transpulmonary gradient (TPG). Data on cardiac output and pulmonary vascular 
resistance were incomplete and were therefore, not included in this analysis.
C. Post-transplant pulmonary complications
For the purpose of this study, a pulmonary complication after heart transplantation 
was defined by symptoms and signs occurring during the period between 
transplantation and lung function assessment, which were directly attributable to 
lower respiratory tract involvement and required specific respiratory treatment, 
other than routine post-operative chest physiotherapy. Lower respiratory tract 
involvement was often confirmed by microbiological studies, imaging, or both. 
Pneumonia was diagnosed if a specific organism was identified in the sputum or 
broncho-alveolar lavage fluid analysis in a patient with new pulmonary infiltrates on 
the chest radiograph. Radiographic infiltrates and respiratory symptoms which were
213
not associated with a definable organism or any specific histopathology were 
classified according to the working diagnosis documented in patients’ case notes.
D. Cytomegalovirus (CMV) infection
CMV infection was accepted if there was laboratory evidence of viral replication in 
the surveillance specimens and CMV disease was defined as the combination of 
CMV infection with a compatible clinical picture and laboratory evidence of organ 
dysfunction in absence of other causes (188). In addition to data from surveillance 
specimens, the incidence of asymptomatic pulmonary CMV infection was 
prospectively evaluated by serial bronchoalveolar lavage (BAL) fluid analysis 
during the first three months after transplantation. The protocol and procedure of 
BAL were as out-lined in chapter 5 (section 5.4).
E. Cardiac allograft rejection
The diagnosis, grading and treatment of cardiac allograft rejection in our centre 
have been described in chapter 4. In this analysis, the number of rejection episodes 
refers to the number of rejections with histological grades 2 or higher occurring 
during the period between transplantation and post-transplant lung function 
measurement.
F. Cyclosporin blood levels
Cyclosporin whole blood trough levels were routinely determined in all heart 
transplant recipients according to the following protocol:
♦ 0-4 weeks - twice a week
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♦ 4-6 weeks - weekly
♦ 6-12 weeks - fortnightly
♦ 3-6 months - monthly
♦ 6-12 months - 3 monthly
♦ 1-2 years - 6 monthly
♦ >2 years - yearly
For each patient, the level at the time of lung function assessment and the mean 
value of all measurements performed between transplantation and lung function 
assessment were used to determine the influence of cyclosporin on TLco changes 
after heart transplantation.
G. Other factors
The influence of the following factors on TLco changes after heart transplantation 
were also evaluated: sex, smoking status, cardiac diagnosis (ischaemic versus 
dilated cardiomyopathy) and cardio-pulmonary bypass time.
9.2.4 Data presentation and analysis
The change in lung function parameters after heart transplantation was calculated 
by subtracting the % predicted value before transplantation from that after 
transplantation. As a result, positive values represent increases and negative values 
represent reductions after transplantation. The relationship between the change in 
TLco after heart transplantation and continuous variables (e.g. pre-transplant lung 
function and pulmonary haemodynamics) was determined for each factor using the 
Pearson correlation. To determine the relationship between the change in TLCo and 
categorical variables (e.g. sex, presence and absence of pulmonary complications),
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patients were first sub-divided into 2 groups on the basis of the presence and 
absence of each of the factors under study. The difference between the 2 sub­
groups in TLco change for each category was then assessed using the independent 
samples Student’s t-test. The independent effects of factors showing significant 
association (p<0.05) with the change in TLco were determined by stepwise multiple 
regression analysis.
9.3 Results
9.3.1 Comparison between heart transplant recipients and coronary artery 
bypass graft (CABG) patients
Table 9.1 shows lung function results in 15 patients before and at 6 weeks after 
CABG. Before surgery, static and dynamic lung volumes were all above 90% of 
predicted. Six weeks after surgery, there was a significant reduction in FVC, FEVi 
and TLC with no significant change in either RV or FEVi/FVC. TLco was slightly 
reduced before surgery and decreased further after surgery. Pre-operative Kco was 
normal and did not change after surgery. Mean haemoglobin concentration 
decreased from 14.9 +/- 0.3 before surgery to 13.0 +/- 0.2 afterwards. Correction 
of the observed TLco and Kco for haemoglobin concentrations before and after 
surgery showed that the apparent decrease in TLco at 6 weeks after CABG was 
entirely due to the reduction in haemoglobin (Hb-corrected TLco increased from 
84.3% to 87.9% of predicted). Similarly, Hb-corrected Kco increased from 96.7% 
to 106.2% of predicted after surgery.
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Table 9.1: Lung function results in 15 patients before and 6 weeks after coronary 
artery bypass graft
before after P value
FEVi 93.8 (4.8) 81.8(4.4) <0.001
FVC 103.8(3.7) 90.0 (3.5) <0.001
FEVj/FVC 92.4 (2.6) 93.1 (3.1) ns
RV 92.3 (9.8) 89.2 (5.4) ns
TLC 93.1 (3.0) ....... 85,?„.(4;p)....... <0.05
observed TLco 87.8 (3.3) 79.2 (3.0) <0.01
Hb-corrected 84.3 (2.7) 87.9 (3.3) ns
observed Kco 100.8 (4.4) ....... ?5,7.(4;8)....... ns
Hb-corrected Kco 96.7(3.7) 106.2 (5.3) <0.05
Table 9.2 compares lung function results in 32 heart transplant recipients with the 
15 CABG patients before and at 6 weeks after surgery. Before surgery, FEVi, FVC 
and observed TLco were significantly reduced in recipients compared to CABG 
patients. Although Hb-corrected TLCo and Kco (mean pre-transplant haemoglobin 
concentration was 13.9 +/- 0.2 decreasing to 12.1 +/- 0.2 after transplantation) 
were lower in recipients compared to CABG patients, the difference was not 
statistically significant. Six weeks after surgery, the pre-operative difference 
between the two groups in FEVi and FVC disappeared due to a greater reduction 
in these two parameters after CABG. In contrast, the difference between the 2 
groups in TLco and Kco widened, especially after correction for haemoglobin.
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Table 9.2: Pulmonary function results in 32 heart transplant recipients compared to 
15 coronary artery bypass graft patients before and 6 weeks after surgery
Before surgery 6 weeks ajler surgery
Recipients ! CABG 1 p  value Recipients ! CABG 1 P value
FEVi 80.9(2.3) I 93.8(4.8) 1 <0.01 80.4(2.4) j 81.8(4.4) j ns
FVC 94.0 (2.6) 1 103.8 (3.7) j <0.05 93.4(3.0) | 90.0(3.5) j ns
RV 105.2(8.1) | 92.3(9.8) j ns 101.2(5.1) | 89.2(5.4) | ns
TLC 95.0(3.2) 1 93.1 (3.0) j ns 89.8(2.6) | 85.9(4.0) j ns
observed TLCo 71.9(3.2) I 87.8(3.3) j <0.01 52.6(2.2) | 79.2(3.0) j <0.001
Hb-corrected 76.3(3.5) | 84.3(2.7) j ns 64.6(3.0) | 87.9(3.3) j <0.001
observed Kco 88.8 (3.6) | 100.8 (4.4) j ns 62.8(2.6) | 95.7(4.8) j <0.001
Hb-corrected Kco 93.7(4.0) | 96.7(3.7) j ns 77.0 (3.8) j 106.2 (5.3) j <0.001
The changes in lung function parameters in recipients and CABG patients after 
surgery are shown in Table 9.3. At 6 weeks after surgery, there was a reduction in 
all measures of lung volume and airway function in both groups. However, the 
decrease in heart transplant recipients was minimal with almost no change in mean 
FEVi and FVC. The magnitude of reduction in these 2 parameters was significantly 
greater after CABG. The reduction in TLC was also greater after CABG, but the 
difference was not statistically significant. The observed TLco and Kco were also 
reduced after surgery in both groups, but the decline in these indices was 
significantly greater after heart transplantation. Correction for haemoglobin 
concentration reduced the magnitude of change in TLco and Kco after surgery in 
both groups. Hb-corrected TLco and Kco were the only parameters which did not 
decline 6 weeks after CABG.
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Table 9.3: The change (A) in lung function parameters (expressed in % of 
predicted) at 6 weeks after surgery: comparisons between heart transplant 
recipients and coronary artery bypass graft (CABG) patients
Recioients (n=32) CABG (n=15) ! P value
AFEVj ........ -Q,6(2,7)....... ........ ....................... | <0.01
A FVC -0.7 (2.8) -13.8(2.1) <0.01
ARV -3.3 (8.0) ........-2,4(7,0).........1 ns
A TLC -4.9 (2.9) .........:Z,?...(.?,6)........ | ns
A observed TLcq -19.4(2.4) .........:.8:7 (2.5)........1 <0.01
A Hb-corrected TLco -11.8(2.9) +3.6 (2.9) | <0.01
A observed Kco -25.0 (2.8) -5.1(3.20 | <0.001
A Hb-corrected Km -16.1 (3.5) +9.5 (3.3) <0.001
Cardio-pulmonary bypass time was significantly longer in recipients compared to 
CABG patients (136.1 +/- 4.7 and 85.8 +/- 6.1 minutes, respectively, p<0.001), but 
there was no relationship between cardio-pulmonary bypass time and the change in 
TLco in any of the 2 groups.
9.3.2 The incidence and types of CMV complications after heart 
transplantation
Table 9.4 shows the individual results of the BAL-CMV study in 15 consecutive 
heart transplant recipients during the first 3 months after transplantation. A total of 
30 BALs were performed with no complications and all patients were free of 
respiratory symptoms during the period of study. Two patients were matched 
negative for CMV (both donor and recipient were negative for CMV). The
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the 15 patients, only one patient had laboratory evidence of CMV infection. In this 
patient, serum IgM was positive at 2 weeks with the other specimens, including the 
BAL, being negative at this stage. At 6 and 12 weeks after transplantation all 
specimens from this patient showed evidence of CMV infection, but he remained 
asymptomatic. Except for serum IgM, the concordance between BAL and 
conventional surveillance specimen (bufly coats, urine and throat swabs) was 
100%.
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Table 9.4: Individual results of 30 CMV-BAL studies in 15 heart transplant 
recipients
patient BAL CMV status Interval Results
number number Donor Recipients (weeks) BAL IgM Buffy coats Th. swab Urine
1 1 + + 2 - + - - -
2 6 + + + + +
3 12 + + + + +
2 1 - + 2 - - - - -
2 6 - - - - -
3 12 - - - - -
3 1 + + 2 - - - - -
2 6 - - - - -
4 1 + + 2 - - - - -
2 6 - - - - -
5 1 - + 2 - - - - -
2 6 - - - - -
3 12 - - - - -
6 1 + + 2 - - - - -
2 6 - - - - -
7 1 + + 6 - - - - -
8 1 + - 2 - - - - -
9 1 + + 2 - - - - -
2 6 - - - - -
3 12 - - - - -
10 1 + + 6 - - - - -
11 1 - - 2 - - - - -
2 6 - - - - -
3 12 - - - - -
12 1 - + 2 - - - - -
13 1 - - 2 - - - -
14 1 + - 2 - - - - -
15 1 + + 6 - - - - -
221
Table 9.5 shows the incidence and types of CMV complications in heart transplant 
recipients during the period between heart transplantation and lung function 
measurement. In the entire group of 57 patients, only 5 patients (9%) developed 
laboratory evidence of CMV infection during the first 6 weeks (all between 5 to 6 
weeks) after transplantation and only one of these was symptomatic. In the 25 
patients with one year follow up, 15 patients (60%) developed evidence of CMV 
infection with 12 of these becoming symptomatic (9 non-pulmonary and 3 
pulmonary). All of the 3 CMV pneumonias developed beyond 6 weeks (8, 13, and 
18 weeks) after transplantation.
Table 9.5: The incidence and types of CMV complications in the period between 
heart transplantation and lung function assessment (6 weeks in 32 patients and 12 
months in 25 patients)
6 weeks (h=32) | 12 months (n=25) j all (n=57)
CMV infection 3 (9%) 15(60%) 18 (32%)
CMV disease (all types) 1 (3%) | 12 (48%) | 13 (23%)
pulmonaiy 0 1 3 (12%) j 3 (5%)
non-pulmonary 1 (3%) 9 (36%) 10(18%)
9.3.3 Pulmonary complications after heart transplantation
Table 9.6 shows the incidence and types of pulmonary complications in the study 
group during the time between heart transplantation and lung function assessment. 
In the entire group, 20 patients (35%) developed pulmonary complications as 
defined previously at an average of 11.4 weeks after transplantation. Four of the 13
222
complications in the long follow up group were within the first 6 weeks after 
transplantation and therefore, the total number of patients with a pulmonary 
complication during this period was 11 patients (19%).
Table 9.6: The incidence and type of pulmonary complications in the period 
between heart transplantation and lung function assessment^ weeks in 32 patients 
and 12 months in 25 patients)
6 weeks (n=32) | 12 months (n=25)* all (n=57)
Pneumonia ...........3.(9%).......... 8 (32%) 11 (19%)
Acute bronchitis 4 (13%) j 4 (16%) 8 (14%)
pulmonary embolism 0 1 1 (4%) ......L(?%)........
Total 7 (22%) 1 13 (52%) 20 (35%)
Mean interval (weeks) 3.3 (1-6) 15.7(1-44) 11.4(1-44)
* In the long follow-up group, 4 patients (16%) had pulmonary complications 
during the first 6 weeks after transplantation.
9.3.4 Determinants of the change in TLco after heart transplantation
Table 9.7 shows the Pearson correlation coefficients between the change in TLco 
(corrected for haemoglobin) and a selected number of pre- and post-transplant 
factors which could potentially influence TLco in the setting of heart 
transplantation. Of the listed factors, only three pre-transplant variables showed a 
significant correlation with the change in TLco after heart transplantation. These 
were the pre-transplant TLco, Kco and mean PCWP. Figures 9.1-9.3 display the
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scatterplots of these factors against the change in TLco after heart transplantation. 
For each of these variables, the higher the value, the greater the decline in TLco.
Table 9.7: The relationship between the change in TLco after heart transplantation
and selected pre- and post-transplant factors
Variables Mean (SEM) r* value P value
Pre-transplant lung function (% of predicted) 
(57 patients)
FEVi 86.0 (2.0) 0.04 ns
FVC 93.3 (2.0) -0.09 ns
TLC 92.7 (2.2) -0.07 ns
Hb-corrected TLco 75.1 (2.4) -0.55 <0.001
Hb-corrected Kco 93.5 (2.9) -0.30 <0.05
Pre-transplant pulmonary pressures (mmHg) 
(55 patients)
Mean pulmonary artery pressure 28.8 (1.2) -0.22 ns
Mean pulmonary capillary wedge pressure 19.9 (1.0) -0.27 <0.05
Transpulmonary gradient 8.8 (0.4) 0.08 ns
Pre-transplant cardiac status (57 patients)
Duration of dyspnoea (months) 37.7 (4.2) 0.04 ns
NYHA functional class 3.7 (0.4) -0.08 ns
Left ventricular ejection fraction (LVEF) 13.4(0.6) 0.25 ns
Cardio-pulmonary bypass time (minutes) 136.1(4.7) 0.19 ns
Cyclosporin blood level (mcg.L'1) 
Absolute level
At 6 weeks (32 patients) 464.0 (23.4) -0.05 ns
At 12 months (25 patients 302.7 (20.3) 0.19 ns
Mean of total blood levels
At 6 weeks (32 patients) 522.2 (19.4) 0.16 ns
At 12 months (25 patients 482.7 (28.9) -0.06 ns
Number of rejection episodes
At 6 weeks (32 patients) 1.0 (0.2) 0.23 ns
At 12 months (25 patients) 2.7 (0.3) 0.29 ns
Post-transplant LVEF (57 patients) 45.1 (0.8) 0.05 ns
* r ; denotes Pearson correlation coefficient
224
Figure 9.1: Scatterplot of the relationship between the change in TLco after heart 
transplantation and the pre-transplant TLco
Ch
an
ge
 
in 
% 
pr
ed
ic
te
d 
TL
C0
(p
os
t-t
ra
ns
pl
an
t 
- p
re
-tr
an
sp
la
nt
)
1 
1 
1 
1 
1 
1
U)
 
K)
 
m
 
KJ
 
U>
 ^j 
OO
 
O 
d? 
dl?
□ □ r = -0.55, p<0.001 
□ dP □ D
d °o A □ 
aS a
□
40 60 80 100 120 140 
Pre-transplant TLco(% predicted)
Figure 9.2: Scatterplot of the relationship between the change in T L co after heart 
transplantation and the pre-transplant K co
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Figure 9.3: Scatterplot of the relationship between the change in TLCo after heart 
transplantation and the pre-transplant pulmonary capillary wedge pressure
r = -0.27, p<0.05
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Table 9.8 compares the change in T L co after heart transplantation in patients sub­
divided on the basis of the presence and absence of selected categorical factors 
which could potentially influence the change in T L co after heart transplantation. 
The change in T L co after heart transplantation appears to be independent of factors 
such as sex, pre-transplant smoking status, the primary cardiac diagnosis, the time 
of post-transplant T L co measurement, and post-transplant problems such as 
pulmonary complications, CMV infection and episodes of cardiac allograft 
rejection.
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Table 9.8: Comparisons between the changes in T L co (ATLCo) after heart 
transplantation in patients grouped on the basis of selected pre- and post-transplant
categorical factors
no. of 
patients
A TLco 
Mean (SEM)
P value
Sex
Male
Female
46 (81%) 
11 (19%)
-11.0(2.3)
-11.6(4.1) ns
Smoking status 
Non-smoker 
Ex-smoker
1 2  (2 1 %) 
45 (79%)
-11.7(4.9)
-1 1 .2 (2 .2 ) ns
Pre-transplant cardiac diagnosis 
Ischaemic heart disease 
Dilated cardiomyopathy
34 (60%) 
20 (40%)
-11.7(2.3)
-11.3(4.0) ns
Time of post-transplant assessment 
6  weeks 
1 2  months
32 (56%) 
25 (44%)
-11.5(2.9) 
-9.6 (2.6) ns
Pulmonary complication 
Present 
Absent
20 (35%) 
37 (65%)
-12.2 (3.6) 
-10.6 (2.4) ns
CMV infection 
Present 
Absent
18 (32%) 
39 (6 8 %)
-11.0 (3.9) 
-11.2(2.3) ns
CMV disease 
Present 
Absent
13 (23%) 
44 (77%)
-8 . 6  (4.6) 
-11.9(2.2) ns
CMV pneumonia 
Present 
Absent
3 (5%) 
54 (95%)
-8 . 8  (7.6) 
-11.3(2.1) ns
Cardiac allograft rejection 
Present 
Absent
47 (82%) 
1 0  (18%)
-10.8 (1.9) 
-12.9 (7.2) ns
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9.4 Discussion
9.4.1 Summary
The results of the studies in this chapter show that the reduction in haemoglobin- 
corrected T L co after heart transplantation is related to the pre-transplant T L co and 
the pre-transplant PCWP. The change in T L co after heart transplantation was 
shown to be independent of factors such as pre-transplant static and dynamic lung 
volumes, pre-transplant cardiac status, cardio-pulmonary bypass, cyclosporin blood 
levels and post-transplant complications such as pulmonary complications, CMV 
infection, and episodes of cardiac allograft rejection.
9.4.2 Potential determinants of TLco decline after heart transplantation
A. Pre-transplant lung function
As has been noted previously, lung function abnormalities in heart transplant 
candidates are common (10,11). These include restrictive and obstructive 
ventilatory defects and a significant reduction in TLCo. In conventional cardiac 
surgery, patients with greater impairment of pre-operative lung function have been 
shown to be at higher risk of post-operative pulmonary complications (137). 
However, Bussieres and associates (160) did not find any relationship between pre­
transplant lung function and survival in 32 patients during the first year after heart 
transplantation. The influence of pre-transplant pulmonary function on post­
transplant lung function is not well documented. In the study of Groen et al. (16), 
the percentage reduction in Kco after transplantation was greater in patients with
respiratory crackles compared with those without crackles before transplantation. It 
was suggested that patients with clinical evidence of pulmonary oedema experience 
greater reduction in K co after transplantation. In the same study, the percentage 
change in K co was positively correlated with pre-transplant K co (patients with 
higher pre-transplant K co had greater decreases in K co after transplantation), but 
the relationship between the post-transplant decline in K co and other indices of pre­
transplant lung function was not reported. In another study of 22 heart transplant 
patients, Ohar et al. (19) found no relationship between the change in T L co and the 
changes in static and dynamic lung volumes after heart transplantation. The results 
of the present investigation are in agreement with the findings of the above 2  
studies. The change in T L co after transplantation was correlated with the pre- 
transplant T L co and K co, with patients with higher pre-transplant T L Co and K co  
having greater decline in T L co after transplantation. In contrast, there was no 
correlation between the change in T L co and other pre-transplant indices of lung 
function which included F E V j, F V C  and T L C . The lack of any significant 
correlation between the change in T L co and the pre-transplant static and dynamic 
lung volumes may be due to the fact that these were only mildly reduced before 
transplantation. Patients with severe lung function abnormalities and those with 
significant co-existing primary lung disease are usually excluded in the selection 
process of heart transplant candidates. This may also explain the absence of any 
relationship between pre-transplant lung function and outcome after heart 
transplantation reported by Bussieres et al. (160). The relationship between pre­
transplant T L co and its change after transplantation may be due to the known
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relationship between TLCo and pulmonary haemodynamics in states of pulmonary 
venous hypertension (31,32). The link between the changes in TLco and pulmonary 
vascular pressures in our patients is suggested by the finding that the pre-transplant 
mean PCWP predicts the magnitude of TLco decline after heart transplantation.
B. Cardiac function before and after transplantation
By definition, heart transplant candidates have severe end-stage heart disease. The 
majority of these patients have severe long-standing heart failure with LVEF less 
than 20% (42). They are also characterised by mild to moderate pulmonary arterial 
hypertension secondary to chronically elevated end-diastolic left ventricular 
pressure (161), Previous studies have failed to show any relationship between the 
decline in TLco after heart transplantation and any of the indices of pre-transplant 
cardiac function including LVEF, duration of symptoms and cardiomegaly 
(16,19,21). The results in this chapter are in agreement with these findings. There 
was no relationship between the decline in TLco and any of the measures of pre­
transplant cardiac status which included LVEF, duration of dyspnoea, and NYHA 
functional class. The change in TLco was also independent of the pre-transplant 
primary cardiac diagnosis. In addition, the failure to demonstrate any relationship 
between the change in TLco and either the post-transplant LVEF or the number of 
cardiac rejection episodes is consistent with the findings of Egan and associates 
(21).
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C. Sternotomy and cardio-pulmonary bypass
The effects of coronary artery bypass graft (CABG) surgery on lung function are 
well documented and the relevant investigations have been reviewed in chapter 3 
(section 3.3.3). The changes in lung function in our CABG patients were similar to 
previous reports (141,146). Before surgery, there was a minimal reduction in static 
and dynamic lung volumes with a greater reduction in TLco- Six weeks after 
surgery, there was a further reduction in all indices of lung function including the 
measured T L co and K co- However, when T L co and K co were corrected for 
haemoglobin concentration which declined after surgery, the post-operative values 
of these 2 parameters exceeded their pre-operative values. Therefore, the reduction 
in T L co after CABG appears to be due to the post-operative decline in 
haemoglobin concentration which was common in our patients. Previous reports 
did not give any information regarding correction for the effects of haemoglobin on 
the measured TLco- In agreement with previous studies, there was no relationship 
between the length of cardio-pulmonary bypass and the post-operative change in 
T L co.
Another interesting finding in this analysis was that the reduction in static and 
dynamic lung volumes at 6  weeks after surgery was greater in CABG patients than 
in heart transplant recipients. It has been suggested that the reduction in lung 
volumes and indices of airway function after CABG may be secondary to the 
effects of sternotomy and cardio-pulmonary bypass on lung and chest wall 
mechanics (133). The expected decline in static and dynamic lung volumes from the
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effects of sternotomy and cardio-pulmonary bypass in heart transplant recipients 
was probably counterbalanced by the improvement in these parameters resulting 
from the resolution of pulmonary congestion and oedema after heart 
transplantation. Although our CABG patients were not assessed beyond 6  weeks 
after surgery, previous investigators have shown that the early post-operative 
decline in lung function gradually improves with almost complete resolution within 
4 to 6  months after surgery. The persistence of T L co decline after heart 
transplantation together with the lack of any decline in haemoglobin-corrected 
T L co after CABG suggests that the decline in T L co after heart transplantation is 
unlikely to be due to the effects of sternotomy or cardio-pulmonary bypass.
D. Post-transplant pulmonary complications
Pulmonary complications are common after heart transplantation and are due to 
both infectious and non-infectious causes (42,159). Non-infectious pulmonary 
complications include pulmonary atelectasis, pleural effusions and left phrenic nerve 
paralysis resulting in left hemi-diaphragmatic dysfunction in the immediate post­
transplant period (42). These complications are common and similar to those 
reported in other forms of cardiac surgery (132). They usually resolve within the 
first few weeks after transplantation in most patients (42). Pulmonary oedema is 
also common in the immediate post-transplant period and is believed to be related 
to the pre-operative pulmonary congestion together with the effects of cardio­
pulmonary bypass and pre-transplant renal impairment (42). Pulmonary infections 
are the most common infectious complication after heart transplantation occurring
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in 20 to 40% of patients (159,190,191). A wide variety of common and 
opportunistic infections have been reported and the majority of these infections 
occur within the first 4 months after transplantation (159,190,191). Post-transplant 
pulmonary complications are therefore a potential cause for the reported decline in 
TLco after heart transplantation. Although data on pulmonary complications were 
based on a retrospective review of the clinical notes, the incidence^infectious 
complications found in this limited analysis was comparable to previous reports 
(159,190). Post-transplant pulmonary complications as defined in this study appear 
to have no relationship to the decline in TLco after heart transplantation.
E. Cytomegalovirus infection
Cytomegalovirus (CMV), a member of the herpesvirus group, is the most common 
opportunistic pathogen in transplant patients (188). It is estimated that 50 to 80% 
of adults carry this virus, but it is virtually always asymptomatic in the 
immunocompetent host. When the host becomes immunocompromised, either by 
disease or immunosuppressive therapy as in transplant recipients, CMV infection 
can become a serious problem (188). The clinical manifestations of symptomatic 
CMV infection (i.e., CMV disease) are very variable and range from a self-limiting 
febrile illness to severe life-threatening multi-organ disease (188).
Pneumonia is the most serious pulmonary complication of CMV infection in heart 
transplant recipients and has been reported in 15% of patients, and associated with 
high mortality (42,159). The use of ganciclovir has reduced the mortality rate of 
CMV pneumonia in heart transplant patients from 46 - 75% to 15 - 20% (42). In
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bone marrow transplant patients, where CMV pneumonia is much more common 
and serious, sub-clinical CMV infection of the lungs, where the virus is isolated 
from the bronchoalveolar lavage in absence of any respiratory symptoms, has been 
shown to be a major risk factor for the subsequent development of CMV 
pneumonia (42).
Asymptomatic CMV infection has been implicated in the pathogenesis of a variety 
of complications in heart transplant recipients, including increased incidence of 
cardiac allograft rejection and atherosclerosis, increased risk of other infections and 
T L co reduction (21,42). The incidence of sub-clinical pulmonary CMV infection in 
heart transplant recipients has not been determined. The association between 
asymptomatic CMV infection and T L co decline after heart transplantation was 
suggested by Egan et al. (21). Thirteen of their 22 patients had serological evidence 
of CMV infection and despite absence of respiratory symptoms, the mean 
percentage reduction in T L co in this sub-group of patients was greater (31%) than 
in patients who had no evidence of CMV infection (16%), but this difference was 
not statistically significant (p = 0.06). The decline in TL Co did not show any 
correlation with cardiac allograft rejection, cyclosporin levels, or cardio-pulmonary 
haemodynamics. It was suggested that the decline in T L co following heart 
transplantation may represent an additional marker of CMV infection and may 
reflect an infective or immune injury to the lung in these patients. In an earlier 
study, van Son and associates investigated the relationship between CMV infection 
and K co in 24 renal transplant patients who had normal chest radiographs, normal 
arterial blood gas analysis, and no respiratory symptoms (192). T L co was measured
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using the rebreathing method starting in the second week after transplantation and 
once a week thereafter for three months. During the study period, 12 patients 
developed evidence of CMV infection and in these patients mean Kco was 
significantly lower than that of the remaining patients (0.83 and 1.28 mmol.min. '1 
kPa'1, respectively). It was concluded that CMV infection in renal transplant 
patients was the cause of the observed pulmonary dysfunction.
Although the findings of these two studies suggest an association between CMV 
infection and the decline of TLco and KCo in heart and renal transplant recipients, 
this does not necessarily establish a causal relationship. Both studies had a small 
number of patients and the evidence of CMV infection was derived from non- 
pulmonary specimens. In addition, the study of Egan et al. was retrospective, and 
TLco was measured at different post-transplant intervals which would preclude the 
establishment of any temporal association between CMV infection and TLco 
decline after heart transplantation. It is possible that TLco had declined for other 
reasons well before the development of CMV infection.
In the present analysis, the BAL-CMV study represents the first report on the 
incidence of asymptomatic pulmonary CMV infection during the first 3 months 
after heart transplantation. It showed that asymptomatic pulmonary CMV infection 
was uncommon during this period (only one of 15 patients). Perhaps of more 
importance was the finding that when the BAL fluid was positive for evidence of 
CMV infection, all the conventional specimens (urine, buffy coats and throat 
swabs) were also positive. This finding is in keeping with the hypothesis that during 
an episode of CMV viraemia, the virus reaches various organs where it replicates
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causing sub-clinical systemic infection manifested by virus shedding into various 
body secretions (e.g. urine and BAL fluid) (193,194). Because of the frequent 
isolation of CMV in asymptomatic patients, the diagnosis of CMV disease requires 
evidence of organ damage or dysfunction in addition to laboratory evidence of virus 
replication (188).
The overall incidence of CMV infection in our heart transplant recipients is similar 
to previous reports (42). The finding in our patients that a previous history of CMV 
pneumonia was not associated with greater decline in T L co after heart 
transplantation is in agreement with results from Ettinger and associates (195) in 
double-lung transplant patients. In their study, the longitudinal changes (before and 
at 1, 3, 6  and 12 months after transplantation) in lung function in 10 patients with 
documented CMV pneumonia were compared with those of 7 patients who never 
had any evidence of CMV infection or pneumonia (both donors and recipients were 
CMV-negative). There was no significant difference between the 2 groups in the 
changes of lung function parameters including T L co during the period of follow-up. 
The authors concluded that documented CMV pneumonia after double lung 
transplantation was not associated with any adverse effects on lung function.
The findings in the studies of this thesis provide evidence against the implication of 
CMV infection in the aetiology of T L co decline after heart transplantation. First, 
CMV infection was uncommon during the first 6  weeks after transplantation. On 
the other hand, T L co decline was almost universal and evident at 6  weeks after 
transplantation with no further changes afterwards. Second, there was no difference 
in T L co changes in patients with and without evidence of CMV infection and the
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changes in TLco in patients who recovered from documented CMV pneumonia 
were similar to those who did not have this complication. Finally, the similarity 
between heart transplant recipients and patients undergoing mitral valve 
replacement, who are not at any increased risk for CMV infection, is further 
evidence against the implication of CMV infection as a cause of TLco decline after 
heart transplantation.
F. Cyclosporin
Cyclosporin is a lipophilic cyclic peptide of fungal origin (196). It is a strong 
immunosuppressant and represents a major advance in immunosuppressive therapy 
in organ transplantation. However, it is associated with many potentially serious 
side-effects including systemic hypertension, dose-dependent nephrotoxicity, 
neurotoxicity and gastrointestinal upset (196,197). The mechanisms by which 
cyclosporin induces systemic hypertension and renal dysfunction are complex and 
appear to be related to disturbance of vasomotor tone with abnormal reactions to 
physiological vaso-active agents (196). Cyclosporin has been found to cause 
disturbance of many vascular regulatory systems including activation of the 
sympathetic system, change in relative activity of prostacycline and thromboxane 
A2 in the vascular wall, local platelet aggregation with microemboli formation and 
stimulation of contraction and hyperplasia of the small renal arteries (198,199).
In contrast to other systems, cyclosporin pulmonary toxicity appears to be rare with 
only few case reports in the literature linking cyclosporin toxicity to an acute 
respiratory distress similar to adult respiratory distress syndrome (196,197,200).
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However, cyclosporin pulmonary toxicity has been suggested as a possible cause 
for TLco decline after heart transplantation (15,16), but this has not been confirmed 
by subsequent investigators (21,201). In 10 patients studied before and after heart 
transplantation, Casan and associates (15) reported a significant correlation 
between the post-transplant T L co and cyclosporin whole blood levels determined 
within a few days of lung function assessment. In addition to the small number of 
patients and the use of a single cyclosporin blood level to reflect exposure, the 
analysis in this study was made using the post-transplant T L co rather than the 
change in T L co after transplantation. Furthermore, it was stated that one of the 1 0  
patients experienced repeated episodes of severe rejection requiring augmented 
immunosuppression complicated by the development of pneumocystis carinii 
pneumonia. This patient had the highest cyclosporin level and the lowest post­
transplant T L co. The findings of Casan et al. have been reinforced by Greon and 
co-workers (16) who carried out a longitudinal study of 34 heart transplant 
patients. They claimed that the percentage change in K co in the first post-transplant 
year was significantly related to the cyclosporin blood level measured nearest to the 
time of K co measurement. However, this relationship disappeared in the subsequent 
2  years and there was no correlation between cyclosporin levels and the post­
transplant pulmonary vascular resistance. Based on the known adverse effects of 
cyclosporin on the systemic and renal vasculature, it was suggested that cyclosporin 
may reduce K co by causing fibrotic thickening of the alveolar-capillary membrane.
Contrary to the findings of these 2 studies, Egan and associates (21) found in 22 
patients that cyclosporin blood levels (both the absolute level collected at the time
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of lung function measurement and the total mean level for each patient from 
transplantation to the time of lung function measurement) have no relationship to 
the change in T L Co after heart transplantation. In our 57 patients, the results on the 
relationship between cyclosporin and the change in TLco after heart transplantation 
were in agreement with those of Egan and associates. The discrepancy between the 
results of these studies may be due to the differences in numbers of patients and the 
methods of analysis.
Studies from other organ transplants do not support the association between 
cyclosporin and lung dysfunction (201,202). In a study of 95 liver transplant 
patients receiving cyclosporin-based immunosuppression, mean T L co was reduced 
before transplantation (78.0% of predicted) and was unchanged at 9 to 12 months 
after transplantation (78.5% of predicted) (202). Morales and associates (201) also 
showed no relationship between cyclosporin levels and lung function in renal 
transplant recipients. In this longitudinal prospective study, lung function was 
assessed in 21 patients before and at 3, 6  and 12 months after renal transplantation. 
T L co and K co corrected for haemoglobin remained unchanged throughout the 
follow-up period. Based on these findings, the authors concluded that cyclosporin 
is not associated with T L co decline in renal transplant recipients.
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G. Cardio-pulmonary haemodynamics
As stated earlier, heart transplant candidates are characterised by mild to moderate 
pulmonary arterial hypertension with raised pulmonary vascular resistance (167). 
Although many investigators have consistently reported a rapid reduction of 
pulmonary vascular pressures after heart transplantation, they remain at the upper 
limit of normal (13,163,164). In addition pulmonary haemodynamic responses to 
exercise after heart transplantation have been shown to be abnormal and resemble 
those of patients with mild to moderate chronic heart failure (165-167). These 
haemodynamic studies suggest a significant but incomplete resolution of pulmonary 
vascular bed abnormalities. The relationship between the changes in pulmonary 
haemodynamics and the changes in TLco and its components in heart disease is well 
documented and has been out-lined in chapter 3. In the present study, the finding of 
a significant relationship between the pre-transplant PCWP and the change in TLco 
was in keeping with findings of Greon et. al (16).
An important limitation of studies in this thesis is the absence of any reliable 
pulmonary haemodynamic data. The pre-transplant haemodynamic data were 
retrospective and not standardised and there were no post-transplant 
haemodynamic data. The measurement of post-transplant cardio-pulmonary 
haemodynamics was not part of the routine care of our patients because of the 
invasive procedures required. Therefore such data are not available for analysis in 
this thesis. Although the relationship between changes in pulmonary 
haemodynamics and changes in TLco after heart transplantation has not been
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determined, the results of the various studies in the thesis supported by evidence 
from patients with congenital heart disease and mitral valve disease undergoing 
surgery, suggest that the reduction in haemoglobin-corrected T L co after heart 
transplantation is due to a reduction in pulmonary vascular pressures.
9.5 Conclusion
In conclusion the studies comprising this chapter identified pre-transplant T L Co and 
PCWP as the only predictors of T L co change after heart transplantation. The fact 
that these 2  factors tend to reflect the degree of pre-transplant pulmonary vascular 
engorgement and the failure to identify any relationship between the change in 
T L co and the various other factors analysed supports the hypothesis that T L co  
decline after heart transplantation is probably due the associated decline in 
pulmonary vascular pressure after heart transplantation. The reduction in T L co  
together with the incomplete normalisation of pulmonary haemodynamics after 
heart transplantation suggests that the structural abnormalities of the pulmonary 
vascular bed in severe chronic heart failure are only partially reversed by successful 
heart transplantation.
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CHAPTER 10
THE CLINICAL SIGNIFICANCE OF TLco REDUCTION IN 
HEART TRANSPLANT RECIPIENTS
10.1 Introduction
Heart transplantation is an established treatment for end-stage heart failure (203). 
In addition to increased life expectancy, heart transplant recipients report a 
remarkable improvement in symptoms and functional capacity (157). However, 
exercise performance following heart transplantation remains impaired, even in the 
absence of exertional symptoms (167). The maximum symptom-limited oxygen 
uptake and the ventilatory anaerobic threshold are in the range of 50% to 70% of 
predicted (204). These values are comparable to those of patients with severe heart 
failure (left ventricular ejection fraction less than 2 0 %) managed with tailored 
medical therapy (205). The cause of exercise intolerance in heart transplant 
recipients is not clear, but there is increasing evidence that it is multifactorial and is 
related to cardiac, neurohormonal, vascular, muscle and pulmonary changes
(167,183). The denervated heart has a reduced heart rate reserve due to the 
elevated resting heart rate and its blunted response to exercise (183). Heart 
compliance is also reduced resulting in left ventricular diastolic dysfunction with 
relatively preserved systolic function (167). Several factors have been identified as 
contributing to myocardial stiffness following heart transplantation including: 
myocardial ischaemia due to prolonged donor heart ischaemic time and ischaemia
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sustained during the operation, cyclosporin-induced systemic hypertension, 
cyclosporin myocardial toxicity and recurrent minor episodes of rejection
(167,183). Persistent peripheral abnormalities which could contribute to exercise 
limitation in these patients include abnormal neuro-hormonal responses to exercise 
(206), deconditioning (207) and peripheral circulatory dysfunction (208).
Efficient pulmonary gas exchange is an essential part of the complex process of 
exercise (209). Pulmonary dysfunction following heart transplantation is therefore a 
potential cause of exercise intolerance in heart transplant recipients (183). Although 
central haemodynamic and peripheral circulatory changes have been extensively 
evaluated in heart transplant recipients (167), there is little information on the 
possible effects of lung dysfunction on exercise performance (2 1 0 -2 1 2 ).
TLco impairment has been suggested as a possible contributory factor to exercise 
limitation following heart transplantation (210,211). In a study of 11 patients 
evaluated before and after transplantation, arterial blood gases and pH were 
significantly lower in recipients with T L co below 70% of predicted compared to 
those with higher T L co at similar work loads (2 1 0 ). In another post-transplant 
study, T L co per unit alveolar volume (K co) was found to be significantly correlated 
with heart rate, oxygenation and lactate levels at maximum exercise (2 1 1 ). 
However, both studies had important limitations; the first was limited by the small 
number of patients, and the second by the lack of pre-transplant data. In addition, 
the maximum symptom-limited oxygen uptake and it relationship to T L co were not 
reported.
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Aim
The aim of this chapter was to determine the impact of TLco reduction on exercise 
capacity in heart transplant recipients.
10.2 Methods
10.2.1 Study population
The study population consisted of three groups: heart transplant recipients, heart 
transplant candidates and normal volunteers.
A. Heart transplant recipients
Between January 1992 and January 1995, 67 patients underwent orthotopic heart 
transplantation at the Scottish Cardio-pulmonary Transplantation Unit. As part of 
routine post-transplantation assessment, 53 of these patients performed resting 
pulmonary function tests and cardio-pulmonary exercise test at 6  to 1 2  months 
following transplantation. Twenty six of the 53 patients had also performed these 
tests as part of their pre-transplant assessment. The remaining 27 patients were 
transplanted before the combined pulmonary function tests and cardio-pulmonary 
exercise test became part of routine assessment for possible heart transplantation. 
Assessment was performed in stable patients who had not suffered from any 
respiratory illness during the preceding 2 weeks. Patients who received treatment 
for rejection or systemic infection were not tested until at least 2  weeks after 
completing treatment. All patients were on standard triple immunosupression 
(cyclosporin, azathioprine and prednisolone).
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B. Heart transplant candidates
This group consisted of 53 heart transplant candidates selected randomly from 
patients who had complete pulmonary function and cardio-pulmonary exercise 
during assessment for possible heart transplantation. They all complained of 
breathlessness on exertion due to left ventricular dysfunction. Anti-failure 
medication consisted of diuretics (all patients), ACE inhibitors (41 patients), 
digoxin (32 patients) and other vasodilators (21 patients). All patients were stable 
at the time of assessment and none had a history of primary lung disease.
C. Normal subjects
The findings in heart transplant patients were compared with data from 28 normal 
subjects recruited as volunteers from the general population in whom there was no 
evidence of cardio-pulmonary disease.
10.2.2 Pulmonary function and cardio-pulmonary exercise tests
Methods of lung function tests and cardio-pulmonary exercise testing were as 
described in chapter 5. Measured T L co was corrected for actual haemoglobin 
concentration using the equation of Dinakara and associates (187).
10.2.3 Data presentation and analysis
Unless stated otherwise, values are expressed as mean +/- one standard error of the 
mean (SEM). Lung function and cardio-pulmonary exercise data in heart transplant 
recipients were compared to those of candidates and normal subjects using the one 
way analysis of variance (ANOVA). Comparisons within the heart transplant
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recipients group were performed using Student’s t-test (the paired samples t-test 
for comparing data from the 26 recipients with pre and post-transplant results and 
the independent samples t-test for comparing recipients with normal and abnormal 
resting lung function). The relationship between haemoglobin-corrected TLco and 
exercise parameters was assessed using the Pearson correlation and linear 
regression analysis. A p value of <0.05 was considered significant.
10.3 Results
10.3.1 Subject characteristics
Subject characteristics are summarised in table 10.1. All groups had similar age and 
sex distribution. All patients were either life-long non-smokers or former smokers 
with no significant difference in the smoking status between recipients and 
candidates. There was no difference in the underlying cardiac diagnosis in the 2 
groups. Before transplantation, LVEF and NYHA functional class in recipients 
were similar to those of the candidates. After transplantation, there was a 
significant improvement in both LVEF and the functional status. Mean 
haemoglobin concentration was significantly reduced in recipients compared with 
candidates.
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Table 10.1: Characteristics of the study groups
Recipients Candidates Normal
Number of subjects 53 53 28
Age; mean in years (range) 48.1 (19-61) 4 9 . 4  (34-60) 40.4 (19-61)
Sex
Male 42 (79%) 42 (79%) 23 (82%)
Female 1 1  (2 1 %) 1 1  (2 1 %) 5 (18%)
Smoking status 
Non-smokers 13 (25%) 8  (15%) 16 (57%)
Ex-smokers 40 (75%) 45 (85%) 9 (32%)
Current smokers 0 0 3(11%)
Diagnosis
Ischaemic heart disease 31 (58%) 31 (58%)
Dilated cardiomyopathy 19 (36%) 20 (38% -
Others 3 (6 %) 2 (4%) -
Pre-transplant LVEF, mean (SD) 13.4 (5.4) 12.3 (4.5) -
Post-transplant LVEF, mean (SD) 44.3 (11.2) - -
Pre-transplant transpulmonary 
Mean (SD) 9.2 (4.8) 8.7 (3.4)
-
Pre-transplant functional class 
NYHAin 17 (32%) 20 (38%)
NYHAIV 36 (6 8 %) 33 (62%) -
Mean (SD) 3.7 (0.5) 3.6 (0.5) -
Post-transplant functional class 
NYHAI 17 (32%)
NYHAII 35 (6 6 %) - -
NYHAHI 1 (2 %) - -
Mean (SD) 1.7 (0.3) - -
Haemoglobin, g.dL*1; mean (SD) 1 2 .2 ( 1 .2 ) 14.1 (1.5) assumed 14.6
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10.3.2 Resting pulmonary function
Table 10.2 compares the resting pulmonary function results in the study groups. 
TLC, FEVi and FEVi/FVC were slightly reduced in heart transplant recipients and 
candidates compared to normal subjects. Although, TLC was greater in recipients 
compared to candidates, this did not reach statistical significance. In contrast TLco 
and Kco (before and after correction for haemoglobin) were significantly lower in 
recipients compared to candidates in whom these parameters were significantly 
lower than normal subjects.
Table 10.2: Resting pulmonary function results (as percentages of predicted) in 
recipients compared to candidates and normal controls
1 Recipients Candidates Normal
FEVi 90.1 (2.3) 8 8 . 0  (2 .2 ) 107.2 (3.9)*
FEVi/FVC 93.1 (1.4) 91.1 (1.4)** 98.6(1.8)**
TLC 96.3 (2.3) 90.4(1.9)** 100.2 (3.3)**
TLco 57.5(2.0)* 71.7(2.1) 98.6(1.3)
TLco (Hb-corrected) 62.3(2.1) 72.9 (2.0) -
Kco 65.9(2.4)* 82.7 (2.7) 105.3 (2.2)
Kco (Hb-corrected) 71.4(2.5)** 84.1 (2.7)** -
Significant difference between the marked group and each of the other 2 
groups
Significant difference between the 2 marked groups 
Significant difference between all groups
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10.3.3 Cardio-pulmonary responses to exercise
Table 10.3 shows the results of resting cardio-respiratory data in heart transplant 
recipients compared to heart transplant candidates and normal subjects. There was 
no significant difference in resting oxygen uptake across the study groups. Resting 
heart rate was significantly higher in recipients than in candidates and normal 
subjects. The pulmonary dead space to tidal volume ratio (V d/V t) at rest was 
similar in heart transplant recipients and candidates, and in both it was significantly 
higher than in normal controls. The alveolar-arterial oxygen pressure gradient 
(P(A-a)Sh) was significantly higher in candidates compared with recipients and 
normal subjects. Although P(a-& )& 2  was higher in recipients than in normal 
subjects, the difference was not significant.
Table 10.3: Resting cardio-respiratory data in the study groups
Recipients Candidates Normal
VO2 L.min' 1 0.26 0.25 0.25
HRbeats.min' 1 91.0(2.0)** 83.0 (2) 79.0 (2.0)**
V d/V t 0.40 (0.01) 0.44 (0.01) 0.30 (0.01)*
P(A-a), 0 2 kPa 1.9 (0.1) 2.9 (0.1)* 1 . 6  (0 .1)
Significant difference between the marked group and each of the other 2 
groups
Significant difference between the 2 marked groups
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Table 10.4 displays the cardio-respiratory responses to symptom-limited exercise in 
heart transplant recipients compared with heart transplant candidates and normal 
controls. Maximum symptom-limited oxygen uptake (FO2) as a percentage of 
predicted was significantly higher in recipients than in-controls (46.0% vs. 39.8% of 
predicted, p<0.05), and both were substantially lower than normal controls (92.9% 
of predicted, p<0.001). Although the ventilatory anaerobic threshold was higher in 
recipients compared to candidates, the difference was not statistically significant 
and in both groups it was markedly reduced compared to controls. The ventilatory 
and gas exchange responses to exercise (Fe/FCo2, V d/V t and P(a-*),0?) were 
significantly lower in recipients than in candidates, but they were all higher than in 
normal controls. The heart rate response was reduced in recipients compared with 
normal controls, but it was markedly elevated in candidates. The oxygen pulse at 
maximum symptom-limited exercise was higher in recipients than in candidates and 
in both it was significantly lower than in normal subjects.
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Table 10.4: Cardio-respiratory responses to symptom-limited exercise in the study
groups
Recipients Candidates Normal
VO2 % pred. 46.0(1.9)# 39.8(1.5) 92.9 (2.5)
VO2 , AT % M 32.6(1.1) 30.4 (0.9) 52.6(1.9)*
FEL.min' 1 46.4(1.6) 45.6 (2.0) 72.4 (4.2)*
Ve % pred. 45.6(1.8) 43.9(1.8) 57.9 (2.1)
Ve IVcoi 35.6(1.0)* 46.6 (2.8) 24.3 (0.06)
Vd/V t 0.30(0.01)* 0.36 (0.01) 0.19(0.01)
PfA-a), 0 2 kPa 2.4 (0.2) 3.5 (0.2)* 1 . 8  (0 .1)
Heart rate (HR) % pred. 67.9(1.4)* 91.3 (1.7) 86.4(1.9)
HR response beats.L' 1 26.8 (2 .0 ) 70.6 (4.5)* 35.7 (2.0)
O2 pulse, ml.beats' 1 1 0 . 6  (0 .6 )* 7.4 (0.3) 16.5 (0.6)
The ventilatory anaerobic threshold as a percentage of predicted maximal
V02
Significant difference between the marked group and each of the other 2 
groups,
Significant difference between the 2 marked groups,
Significant difference between all groups
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10.3.4 The relationship between haemoglobin-corrected TLco and exercise 
parameters
Since measured TL Co is directly influenced by haemoglobin concentration, analysis 
of the relationship between T L co and exercise parameters was made on 
haemoglobin-corrected T L Co- Figure 1 0 . 1  shows regression plots of % predicted 
T L co at rest against % predicted maximal V02 in the three study groups. There was 
a significant positive correlation between T L Co and V02 in heart transplant 
recipients (r = 0.62, p<0.001). In contrast, there was no correlation between the 2 
variables in either heart transplant candidates or normal controls. The relationship 
between T L Co and V02 in recipients persisted even after correction for lung 
volumes (the correlation between K co and VO2 was 0.38, p<0 .0 0 1 ). There was no 
relationship between % predicted VO2 and any of the other indices of lung function 
in any of the studied groups. T L co was also positively correlated with the anaerobic 
threshold in recipients, but not in candidates or normal subjects (Table 10.5). T L co  
was also inversely related to the ventilatory response (Fe/F ok ), V d/V t and 
P(A-a),02 in heart transplant recipients, but there was no relationship between T L co  
and any of these parameters in the other 2  groups.
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Figure 10.1 - Regression plots of % predicted TLco (haemoglobin-corrected) 
against % predicted maximum symptom-limited V02 in heart transplant recipients 
compared with heart transplant candidates and normal controls.
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Table 10.5: The relationship between % predicted TLco (haemoglobin-corrected) 
and maximum symptom-limited exercise variables
Correlation with % predicted TLCo
Recipients Candidates Normal
r* P r p r P
V02 % pred. 0.60 I <0 .0 0 1 0.13 | 0.34 0.03 j 0.90
V02, AT % 0.54 j <0.001 0.04 | 0.79 0.27 ! 0.17
Ve /V co2 -0.43 j <0.001 - 0.06 j 0.67 - 0 . 1 0  | 0.60
V d/V t -0.29 | <0.05 - 0.27 I 0.05 -0.14 j 0.48
P(A-a), 0 2 kPa -0.38 j <0.01 - 0.24 | 0.07 0.23 ; 0.14
* Pearson correlation coefficient
Mean haemoglobin concentration was significantly lower in recipients than in 
candidates (12.2 and 14.1 g.dL' 1 respectively, p<0.001), but there was no 
correlation between haemoglobin and % predicted maximum symptom-limited VO2 
in either groups.
Forty of the 53 heart transplant recipients had haemoglobin-corrected TLco below 
70% of predicted, and in these maximum symptom-limited V02 was significantly 
reduced compared with the remaining 13 patients with higher TLco (42.9% vs. 
55.7% of predicted, p<0.001).
The possible influence of static and dynamic lung volumes on the cardio-respiratory 
responses to exercise in heart transplant recipients was evaluated by dividing them 
into 2 groups based on the results of static and dynamic lung volumes. The lower
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limit of normality for all indices of lung function was defined as the predicted value 
minus 1.64 standard deviations of the reference regression equation (41). Using this 
definition, 32 recipients had normal results whereas 21 had at least one abnormal 
results. Table 10.6 shows that there was no significant difference between these 2 
sub-groups in any of the cardio-respiratory responses to exercise.
Table 10.6: Maximum symptom-limited exercise responses in heart transplant
recipients with normal and abnormal spirometric results
Normal (32) Abnormal (21) P value
V02 % pred. 47.5 (2.0) 43.8(1.9) 0 .2 1
V02 , AT % 32.2(1.7) 33.2(1.1) 0.65
Ve IVcm 35.0(1.4) 1 36.5(1.6) ! 0.47
Vd/V t 0.29 (0.01) | 0.32 (0.02) 0.29
P(A-a),02 kPa 2.3 (0.3) 2.5 (0.3 | 0.55
HR % pred. 68.5(2.1) 66.9(1.6) 0.58
HR response beats.L*1 29.2 (2.7) 22.9 (2.8) 0.13
O2 pulse, ml.beats' 1 1 1 .2  (1 .0 ) 9.7 (0.5) 0.24
Twenty six of the heart transplant recipients had complete lung function and cardio­
pulmonary exercise data before and after transplantation. Table 10.7 shows that the 
clinical characteristics of these patients are similar to those who had no pre- 
transplant data. They also had similar resting pulmonary function and cardio­
pulmonary responses to exercise following transplantation (Table 10.8).
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Table 10.7: Clinical characteristics and resting cardiorespiratory parameters in 
heart transplant recipients: patients with data before and after transplantation
(Group 1) compared to those with post-transplant data only (Group 2)
Group 1 Group 2
Number of subjects 26 27
Age; mean in years (range) 48.6 (19-59) 47.6(32-61)
Sex
Male 2 1  (81%) 23 (79%)
Female 5 (19%) 6  (2 1 %)
Diagnosis
Ischaemic heart disease 16(61%) 17 (59%)
Dilated cardiomyopathy 9 (23%) 10 (34%)
Valvular heart disease 1 (4%) 2 (7%)
Pre-transplant LVEF, mean (SD) 13.8(5.4) 13.6 (6 .6 )
Post-transplant LVEF, mean (SD) 42.7(11.1) 45.2(11.2)
Table 10.8: Resting pulmonary function and maximum symptom-limited exercise 
results in heart transplant recipients with data before and after transplantation
(Group 1) compared to those who had post-transplant data only (Group 2 )
Group 1 Group 2 p  value
FEVi* 88.7 (3.0) 91.1 (3.5) 0.61
FEVi/FVC* 90.7 (2.0) 92.4(1.8) 0.50
TLC* 96.6 (2.7) 92.3 (2.4) 0.24
TLco* (Hb-corrected) 61.5(2.3) 63.7(2.5) 0.44
Kco * (Hb-corrected) 70.9 (3.0) 72.2 (3.1) 0.69
V02* 48.6(1.7) 45.0 (2.0) 0.15
V02, AT % 34.6(1.2) 32.3(1.1) 0.27
Ve IVq.02 34.1 (1.3) 37.6 (2.1) 0.16
Vd/Vt 0.31(0.01) 0.30 (0.01) 0.78
.Z/A^k.Q2..!iPa................ 2.4 (0.3) 2.4 (0.3) 0.84
Heart rate (HR)* 70.5 (1.7) 67.1 (2.3) 0.25
HR response, beats.L' 1 24.2 (2.5) 27.8 (2.9) 0.35
0 2 pulse, ml.beats1 10.4 (0.6) 10.0 (0.5) 0.64
* Results expressed as percentage of predicted
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Table 10.9 shows maximum symptom-limited exercise responses in 26 heart 
transplant recipients before and after transplantation and figure 1 0 . 2  compares the 
relationship between % predicted TLCo and % predicted V02 in these patients. The 
trend and magnitude of changes in all parameters are similar to those obtained by 
the cross-sectional comparisons between heart transplant recipients and candidates 
(Table 10.4 and Figure 10.1).
Table 10.9: Maximum symptom-limited exercise responses in 26 heart transplant
recipients before and after transplantation
pre-trcmsplcmt post-transplant P value
VO2 % pred. 41.3 (2.2) 48.6(1.7) <0 .0 1
V02, AT % 31.5(1.1) 35.6(1.0) <0.05
Ve IVcm 45.6(2.5) 34.1(1.3) <0 . 0 0 1
Ve/Vt 0.35 (0.02) 0.31 (0.01) <0.05
P(A-a) & 2  kPa 3.4 (0.3) 2.4 (0.3) <0 .0 1
Heart rate (HR) % pred. 82.2 (2 .6 ) 70.5(1.7) <0 . 0 0 1
HR response, beats.L' 1 72.1 (6.5) 24.2 (2.5) <0 . 0 0 1
O2 pulse, ml.beats' 1 7.7 (0.4) 10.4 (0.4) <0 . 0 0 1
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Figure 1 0 .2 : The relationship between % predicted TLco (haemoglobin-corrected) 
and maximum symptom-limited VO2 (% predicted) in 26 patients before and after 
transplantation
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TLco components were measured in 47 of the 53 heart transplant recipients. As in 
the entire group, TLco was positively correlated with maximal V02 (r = 0.42, 
p<0 .0 1 ). Figure 10.3 shows that VO2 was also positively correlated with both Vc 
and Dm.
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Figure 10.3: Regression plots of % predicted VO2 against each of the diffusion 
parameters in 48 heart transplant recipients
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10.4 Discussion
10.4.1 Summary of main results
In addition to confirming previous reports on exercise intolerance in heart 
transplant recipients, this study demonstrated three new findings. First, these data 
demonstrated that haemoglobin-corrected TLco is significantly correlated with 
maximum symptom-limited oxygen uptake in heart transplant recipients, so that 
even in presence of normal arterial oxygenation, patients with the lowest TLco had 
the lowest exercise capacity. Second, TLco was also inversely related to the 
ventilatory and pulmonary gas exchange responses to exercise following 
transplantation ( F e / F Co 2,  V d / V t  and / Jf A -a ) ,0 2) .  Third, the effect of TLco 
impairment on exercise performance in heart transplant recipients was independent 
of resting lung function tests which were relatively normal and had no influence on 
exercise capacity in these patients.
10.4.2 Resting pulmonary function
The results of resting pulmonary function tests in this study are in agreement with 
previous reports (15-18,20,21), and have been described in the previous chapters of 
this thesis.
10.4.3 Cardio-pulmonary responses to exercise
In agreement with previous reports (165), the results of this study show that 
despite substantial improvement of subjective functional capacity, heart transplant 
recipients continue to have limited exercise performance as assessed by incremental 
cardio-pulmonary exercise testing. The ventilatory response to exercise in our
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patients was similar to that reported by Marzo and associates (213). Before 
transplantation, V )^VCo2 was elevated and decreased significantly following 
transplantation, but remained higher than normal. In addition, the present study 
showed that despite significant improvement in Vd/Vt after transplantation, it 
remained higher than normal. It is not known why ventilatory and gas exchange 
abnormalities on exercise fail to resolve completely after heart transplantation. One 
possible explanation is that long-standing pre-transplant heart failure leads to 
irreversible structural lung damage. Alternatively, these abnormal pulmonary 
responses may be functional in origin, resulting from a sub-optimal cardiac output 
response to exercise. Heart failure is characterised by excessive ventilatory 
response to exercise (214). Patients with chronic heart failure also have increased 
’’wasted ventilation” as assessed by Vd/V t (214). We and others have previously 
shown that the ventilatory response and Vd/V t in heart failure are positively 
correlated and suggested that they be causally linked (170,215). It was postulated 
that failure to increase cardiac output to match ventilation during exercise increases 
the proportion of lung units with high ventilation-perfiision ratio thereby increasing 
the V d/V t and consequently leading to an excessive ventilatory response to exercise 
(170,215). Although cardiac output is markedly improved after heart 
transplantation, its response to exercise remains sub-normal (216) and this may 
explain the residual abnormalities of ventilatory and gas exchange responses to 
exercise following transplantation.
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10.4.4 TLco and exercise capacity
Exercise intolerance in heart transplant recipients is well documented (167). 
Although the underlying pathophysiology not fully understood, the complex nature 
of exercise process favours multiple causes (167). Factors identified as contributory 
to exercise intolerance following transplantation include: inotropic and
chronotropic incompetence of the denervated heart (165,216), abnormal peripheral 
circulation (208), abnormal neuro-hormonal responses (206), persistent skeletal 
muscle abnormalities (207) and pulmonary dysfunction (210,211).
In this study, we showed that TLco impairment which was very common in heart 
transplant recipients was associated with exercise intolerance. The correlation 
between haemoglobin-corrected TLco and exercise performance was independent 
of lung volumes and airway function both of which were normal in most patients 
and had no influence on exercise capacity. The lack of any correlation between 
TLco and exercise capacity in heart transplant candidates and normal subjects 
suggests that TLco becomes a limiting factor in exercise performance when 
impairment is severe. In patients with chronic obstructive pulmonary disease, TLco 
below 70% of predicted is associated with frequent gas exchange abnormalities on 
exercise, whereas above 70% of predicted, these abnormalities are uncommon (44). 
In addition TLco impairment has been shown to predict pulmonary gas exchange 
abnormalities and exercise intolerance in patients with mild to moderately severe 
heart failure (153,217,218). In a recent study, Puri et al. (153) reported a positive 
correlation between TLco and exercise capacity in patients with mild to moderately
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severe congestive heart failure (NYHA, grades II and III) and showed that it was 
primarily due to impairment of the diffusing capacity of the alveolar-capillary 
membrane (DM). Unlike these reports, there was no relationship between V02 and 
any of the diffusion parameters in heart transplant candidates. The difference 
between our findings and the others may be due to the severity of heart failure in 
heart transplant candidates. Heart transplant candidates may stop exercising 
because of severe cardiac insufficiency before any TLco impairment becomes 
important.
The mechanism by which TLco impairment causes exercise intolerance is not clear. 
Gas exchange in the lungs depends on several interdependent processes. These 
include ventilation, perfusion, ventilation-perfusion matching and diffusion (28). 
The measured TLco is affected by disturbance in any of these processes and 
therefore, can be considered as a composite index of the integrity of the pulmonary 
gas exchanging unit, rather than being specifically determined by the process of 
diffusion (43). In addition, isolated impairment of diffusion is very rare and because 
of the large physiological reserve, diffusion impairment is not considered an 
important limiting factor in the transfer of oxygen to the arterial blood even in 
patients with severe lung disease (43). The relationship between TLco and exercise 
performance in heart transplant recipients is therefore likely to represent a general 
dysfunction of pulmonary gas exchange rather than an isolated diffusion defect. 
This is supported by the lack of complete resolution of the ventilatory and 
pulmonary gas exchange responses (Vr/Vcoi, Vd/Vt and P(A-a),02) to exercise, and 
by the significant inverse relationship between TLco and each of these parameters.
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10.4.5 Study limitations
This study is limited by the fact that measurements of resting pulmonary function 
were related to variability in the cardio-respiratory responses to exercise. 
Measurement of TLco during exercise may have a stronger relationship to exercise 
capacity. In addition, other potential contributory factors to exercise limitation such 
as cardio-pulmonary haemodynamics, skeletal muscle function and peripheral 
circulatory responses were not assessed. These factors have been previously 
evaluated (165,206,207,216) and the aim of this chapter was primarily to evaluate 
the effect of TLco impairment on exercise capacity. It is also important to 
emphasise that the correlation between TLco and the various responses to exercise 
noted above represent associations and do not necessarily imply causative 
relationship.
10.5 Conclusion
TLco impairment in heart transplant recipients is associated with abnormal 
ventilatory and pulmonary gas exchange responses to exercise. Pulmonary 
dysfunction as reflected by TLco impairment appears to contribute to exercise 
intolerance after heart transplantation.
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CHAPTER 11 
CONCLUSIONS
Heart transplantation is now an established therapeutic option in the management 
of end-stage heart disease (156). Severe chronic heart failure, the primary 
indication for heart transplantation is characterised by chronic pulmonary 
congestion and associated with a variety of pulmonary function abnormalities ( 1 0 ). 
The transplanted heart would be expected to improve lung function abnormalities 
specifically related to heart failure. However, the procedure of heart transplantation 
and its associated complications may lead to new pulmonary function abnormalities. 
It has been suggested that the decline in TLco after heart transplantation is 
secondary to the adverse effects of heart transplantation on the lungs (15,21). The 
studies comprising this thesis were carried out to answer specific questions about 
the reported reduction in TLco after heart transplantation. This chapter summarises 
and brings together the results of the various studies presented in the previous 
chapters. On the basis of these findings and evidence from the literature, a theory is 
proposed to explain TLco decline after heart transplantation.
11.1 Summary of results
The main findings of the studies comprising this thesis were as follows:
1 . lung function in heart transplant candidates is characterised by a mild restrictive 
ventilatory defect with a greater reduction in TLco and the latter occurs because 
of a proportionate reduction in both of its components (Dm and Vc).
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2. Heart transplantation is associated with a further reduction in the mean values 
of static and dynamic lung volumes at 6  weeks after transplantation with 
gradual improvement in the subsequent measurements, exceeding their pre­
transplant values at one year after transplantation. There was marked variability 
in the individual responses.
3. T L co and K co declined significantly in almost all patients at 6  weeks after 
transplantation with no further changes up to 3 years after transplantation. T L co  
reduction in heart transplant recipients was due to an increase in the intra­
capillary resistance ( l / 0 V c )  caused by a combination of post-transplant anaemia 
and reduced V c. Correction of T L co for the effect of anaemia reduced the 
magnitude of T L co decline after heart transplantation by about 50%. Dm was 
unchanged by transplantation being similarly reduced in both candidates and 
recipients.
4. The reduction in haemoglobin-corrected T L co after heart transplantation is 
related to the pre-transplant T L co and P C W P . The change in T L co after heart 
transplantation was shown to be independent of factors such as pre-transplant 
static and dynamic lung volumes, pre-transplant cardiac status, cardio­
pulmonary bypass, cyclosporin blood levels and post-transplant problems 
including pulmonary complications, C M V  infection and episodes of cardiac 
allograft rejection.
5. T L co in heart transplant recipients was found to be positively correlated with 
maximum symptom-limited oxygen uptake, so that patients with lowest T L co
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had the lowest exercise capacity. TLco was also inversely related to the 
ventilatory and pulmonary gas exchange responses to exercise following 
transplantation (V^JVcoi? Vd/Vt and P(A-a>02). These associations were 
independent of the other resting lung function parameters which were relatively 
normal and had no influence on exercise capacity.
6 . In addition these studies have demonstrated that:
a) The changes in TLco and its components after heart transplantation were similar 
to the changes following mitral valve replacement six weeks after surgery.
b) The reduction in TLco after coronary artery bypass graft surgery was due to the 
reduction in haemoglobin after surgery.
7. A protocol was also described for the estimation of TLco components using the 
Roughton and Forster method. The validation studies presented in this thesis 
showed that the described procedure yields reproducible estimation of TLco 
components comparable with previous reports (49).
11.2 The pulmonary consequences of chronic pulmonary venous hypertension 
with particular reference to TLco decline after heart transplantation
The interpretation of the above results and their relationship to previous work have 
been discussed in the previous chapters. The following account is an attempt to 
explain the mechanism of TLco reduction after heart transplantation using mitral 
stenosis as a model for the pulmonary consequences of chronic pulmonary venous 
hypertension.
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Figure 11.1 illustrates the pulmonary consequences of chronic pulmonary venous 
hypertension and the impact of heart transplantation on these changes in terms of 
the changes in pulmonary haemodynamics, TLco and its components. Any cause of 
chronic heart failure including coronary artery disease, valvular heart disease and 
the various forms of cardiomyopathy can potentially cause pulmonary arterial 
hypertension with structural vascular and parenchymal changes in the lungs (1 2 ). 
Mildly elevated pulmonary venous pressure is associated with a corresponding 
increase in pulmonary artery pressure to maintain a normal gradient across the 
pulmonary capillary bed (94). The increase in pulmonary vascular pressures in 
absence of significant structural changes in the pulmonary vasculature leads to an 
increase in the functioning pulmonary capillaries by opening collapsed vessels 
(vascular recruitment) and distending open ones (vascular distension) (27). These 
functional changes act to maintain a normal pulmonary vascular resistance (27). In 
addition, they result in an increase in both the total pulmonary blood volume and 
the pulmonary capillary blood volume (Vc) (32). TLco at this stage may be greater 
than predicted, mainly due to the increase in Vc, but Dm is also increased because 
of the increase in the effective surface area available for gas exchange resulting 
from improved matching between ventilation and perfusion (31,60). However, the 
augmenting effects of vascular recruitment and distension on TLco and its 
components may be offset by co-existing pulmonary interstitial oedema (7).
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Progression of the disease process leads to structural vascular and parenchymal 
changes in the lungs. In severe mitral stenosis, these include intimal and medial 
hyperplasia of the small pulmonary arteries and veins together with pulmonary 
interstitial fibrosis resulting in thickened alveolar-capillary membranes and 
destruction of the pulmonary vascular bed (27,107). Pathophysiologically, these 
structural changes are reflected by disproportionate increase in pulmonary arterial 
pressure in relation to the increase in pulmonary venous pressure indicating the 
development of established pulmonary arterial hypertension with increased 
pulmonary vascular resistance. TLco is also reduced due to reductions in both of its 
components.
There are no data on the pulmonary structural abnormalities in heart transplant 
candidates. However, the finding of moderate reduction in TLco with proportional 
reduction in Dm and Vc in heart transplant candidates in the studies of this thesis 
suggests that these patients have significant pulmonary parenchymal and vascular 
abnormalities. This is also suggested by the well documented pulmonary 
haemodynamic profile of these patients (161). Heart transplantation has been 
shown to relieve the pulmonary congestion and oedema of heart failure and to 
restore resting pulmonary haemodynamics towards normal (13), but there are no 
data on its effects on the pulmonary structural abnormalities. The reduction in 
pulmonary vascular pressures would be expected to eliminate the augmenting 
effects of vascular recruitment and distension on TLco and its components. If this 
was not accompanied by improvement in the pulmonary structural changes of heart 
failure, TLco and its components would be expected to decline after heart
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transplantation. The finding of TLco and Vc decline after heart transplantation 
suggests that the pulmonary structural abnormalities are not reversed by heart 
transplantation. The lack of any change in Dm after heart transplantation may be 
due to opposing effects of the relief of pulmonary oedema and the elimination of 
pulmonary vascular recruitment. The persistence of pulmonary vascular dysfunction 
after heart transplantation is also suggested by the incomplete normalisation of 
resting pulmonary haemodynamics (13,163,164) and by the abnormal pulmonary 
haemodynamic responses to exercise, resembling that of mild to moderate heart 
failure (167). The relationship between TLco and gas exchange abnormalities on 
exercise in heart transplant recipients demonstrated in this thesis is in keeping with 
a contribution from pulmonary parenchymal and vascular dysfunction to exercise 
limitation. At the time of concluding this thesis, Egan and associates (219) 
described the bronchoalveolar lavage (BAL) and transbronchial lung biopsy 
findings in 2 0  heart transplant recipients studied at a mean of 152 days (range 62- 
331 days) after heart transplantation. Four of these patients had histological 
evidence of CMV pneumonitis and 3 had evidence of Pneumocystis carinii 
pneumonia. Light microscopy demonstrated focal pulmonary fibrosis in 12 patients 
and of these only one had evidence of CMV pneumonitis. The BAL differential cell 
counts were normal, but 11 of the 18 patients had high haemosiderin scores in BAL 
macrophages. It was suggested that these changes may underlie the fall in TLco 
after heart transplantation. Although the authors suggested CMV infection or 
cyclosporin toxicity as possible causes, the described changes are consistent with 
those found in patients with mitral stenosis (27).
271
In summary, based on the results of the studies in this thesis and previous 
knowledge on the pulmonary consequences of chronic pulmonary venous 
hypertension, the decline in TLco after heart transplantation appears to be 
secondary to reduction in the pulmonary vascular pressures in the absence of any 
significant reversibility in the structural abnormalities of the pulmonary bed. Thus, 
the fall in TLco after heart transplantation is probably a marker of persistent 
pulmonary dysfunction associated with previous heart failure rather than being due 
to new damage to the lungs caused by heart transplantation or its complications.
The evidence adduced to implicate changes in pulmonary haemodynamics as a 
cause of TLco decline after heart transplantation was indirect and further research is 
required to define the precise relationship between changes in TLco and its 
components with pulmonary haemodynamics both before and after transplantation. 
This will require simultaneous measurement of these indices under standardised 
conditions before and serially after transplantation. Definite proof of persisting 
pulmonary vascular and parenchymal structural abnormalities resulting from pre­
transplant heart failure would require demonstration of similar histopathology in the 
pulmonary vascular bed before and after heart transplantation. This would entail the 
performance of small lung biopsies at the time of heart transplantation and serially, 
perhaps by the transbronchial route, after transplantation. Although taking small 
lung biopsies at the time of operation is feasible and has been performed during 
mitral valve replacement without any added risks (30), the performance of serial 
post-transplant transbronchial lung biopsies would be difficult to justify because of 
the risk of significant complications (haemorrhage and pneumothorax) and the
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possibility^sampling errors due to the patchy nature of pulmonary abnormalities in 
pulmonary venous hypertension (30).
Finally, it is important to emphasise some points of clinical relevance in the use of 
TLco measurement in heart transplant patients. First, TLco may be normal despite 
definite abnormalities of the pulmonary vascular bed resulting in abnormal, but 
opposite changes in TLco components. Second, the longitudinal studies of lung 
function in this thesis have shown that lung function including TLco does not 
decline after the first post-transplantation assessment in asymptomatic patients. 
Therefore, a significant decline in lung function from the first post-transplant values 
would suggest a new pulmonary complication. Third, in conditions associated with 
significant changes in haemoglobin (e.g. cardiac surgery and heart transplantation) 
it is important to correct for the effect of haemoglobin concentration on the 
measured TLco.
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